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Abstract 
 
Abstract 
 In the last recent decades, stress has become an inevitable part plaguing the daily 
lives. Psychological stress has a negative impact over physical, mental and social well-
being of a person. It has been suggested to play an important role in causation or 
precipitation of multitude of medical and dental problems ranging from serious heart 
diseases, cancers, gastrointestinal diseases, to common headaches, migraine, recurrent 
oral ulcerations, burning and dry mouth.  
In order to better understand the role of stress, valid and reliable measurement of 
stress is of utmost importance. Since, most of methods used for the diagnosis of stress are 
questionnaires form (subjective methods) which depend on person and there is many inter 
individual variation between subjects, thus there is increased need of biological stress 
markers to provide an objective, reliable and authentic evidence of stress.  Self-reporting 
subjective questionnaire forms in stress evaluation and as psychological diagnostic mean 
provide highly inconsistent results according to patient’s mood and attitude. And this is 
because many individuals suffering from stress related problems have a tendency to either 
negate or exaggerate the real condition; which may lead to a deviation in the study and 
discompose the results. Thus there is a high need for studying the changes caused by stress 
in the human body to evaluate the usefulness of the bio physiological indicators or 
biomarkers to provide a reliable objective evaluation and assessment of a stress and 
psychologically related conditions. Salivary biomarkers are one of most widely researched 
area of interest because it might to provide a reliable, noninvasive and objective 
measurements of the response of the body, also because of easy and rapid collection of 
samples compared to the blood and urine samples thereby increasing the patient 
compliance. Many biomarkers have been used in determination of stress such as cortisol 
levels, immunoglobulins, cardiovascular parameters. Studies showed there is an evidence 
of sensitivity of SAA levels in response to different stressful conditions, physically and 
psychologically. 
Changes in SAA is thought to have implications for health. And consider a 
promising role of salivary alpha amylase as a possible biological stress marker. The 
release of salivary alpha amylase enzyme was reported to react to physiological and 
psychological stressors thus it might be a biomarker of stress which consider very 
important and valuable biological markers in psychophysiological research and clinical 
practice.   
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It’s very difficult to describe the situation in IRAQ and there is no accurate 
statistics in all fields especially in health sector which has been affected thoroughly by 
the war and the number of subjects need psychological health care has been increased due 
to the increased stress, violence due to the post war conflicts. For these reasons its 
necessary to find simple and economical method to detect subjects under stress to help in 
the prevention of deterioration of their mental state and progress to a more serious 
condition. This will be the prime objective of this study. 
In this study, in view of the shortage of data in IRAQ especially from 2003 and 
with increased susceptible of people to violence and stress and increase susceptibility to 
psychiatric disorders and increase need for drug treatments. This study was to record type 
of psychiatric disorders in sample of different patients as an example that may reflect the 
population, adverse effects of most widely used fluoxetine therapy in our population as a 
goal to reach maintenance of optimal functioning and well-being and as try to achieve 
“keep people healthy” as opposed to “how well it cures diseases and the consequence of 
adverse drug therapy”, as a part, encourage the patients to concern with oral hygiene and 
maintain their oral health as a part of the general health and to report any dental problems 
including adverse effects of drugs to the psychiatrist. 
Drug use is associated with significant detrimental, psychological, nutritional, and 
social changes, any of which can affect the general and oral health. Fluoxetine was the 
first SSRIs approved to treat depression in humans and is one of the most widely 
prescribed antidepressant drugs. Many general and oral adverse effects have been 
reported with fluoxetine therapy. Some of its observed secondary effects are related to an 
alteration in the salivary secretion and composition. Despite that fluoxetine was approved 
by the United States Food and Drug Administration's (FDA) in 1987 for the treatment of 
depression and then for the treatment of a number of psychiatric disorders in adults and 
children, it was used in the psychiatric treatment in IRAQ in the ultimate years and there 
is shortage of data that record efficacy, adverse effects and other about drug due to the 
non-recognition of the psychiatric disorders and mainly depression by the majority of the 
society. Most of the people in middle east does not accept the concept of (pharmacological 
treatment) for the psychiatric disorders especially depression because of some religious 
believes and social aspects. This study was the first pharmacological study done in Mosul 
and Iraq on the psychological patients to see the effects of the drug (fluoxetine) on the 
patients and encourage both the psychiatrist and the patients to detects the adverse effects 
of the drug and try to avoid it as possible. 
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Saliva is one of the most important factors in regulating oral health, with flow rate 
and composition changing throughout development and during disease and treatment with 
different type of medications like SSRIs. Fluoxetine is one of the class termed SSRIs 
which is a serotonin agonist. Many general and oral adverse effects have been reported 
with fluoxetine therapy. 
 
The aims of the present study were to measure the effects of psychiatric diseases and 
their treatment with SSRIs (fluoxetine) on the salivary flow rate and contents (salivary 
alpha amylase, sodium, and potassium).  Also, to evaluate the adverse effects (general 
and orofacial) of fluoxetine therapy and its relationship with the dose and duration of the 
treatment.  
The specific aims of the study were to investigate: 
1. The usefulness of salivary alpha amylase (SAA) as a good biological marker of 
stress in psychological patients and check the possibility to use it to detect person 
on stress like a psychological patient. 
2. Salivary sodium and potassium, as markers of stress and check the possibility to 
use them to detect person on stress in conjunction to SAA to detect patients. 
3. The biochemical changes in saliva including sodium, potassium and salivary 
alpha amylase concentrations, and changes in salivary flow rate associated with 
fluoxetine therapy in psychiatric patients. 
4. The effects of psychiatric diseases on the composition of saliva (salivary alpha 
amylase, sodium and potassium) and salivary flow rate. 
5. Objective and subjective measurement of xerostomia and determination of its 
grades as a result of disease process and fluoxetine therapy. 
6. The adverse effects associated with fluoxetine therapy in our population including 
both general adverse effects on the body at whole and oral adverse effects and 
their relation with dose and duration of therapy. 
7. Fluoxetine concentrations in serum by high performance liquid chromatography 
(HPLC) and their relation to SAA, Na+, K+ concentrations and adverse effects of 
fluoxetine administration. 
 
Materials and Methods: The study including eighty individuals divided in to two major 
groups of study: 
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1. The study group (Patients): consisted of (60) patients with age range was between 
(15-56) years which divided into two subgroups to investigate the effects of fluoxetine 
therapy in the patients in short (acute) and long durations (chronic) and as follows:  
1.1. The Acute group consisted of (39) patients with different psychological diseases 
(23 males, 16 females) which have been provided with fluoxetine capsules and starting 
fluoxetine therapy after two weeks wash out period and have been followed for (2 
months). Their average age was (35.4±10.7) years.  
1.2. The Chronic group 21 patients with different psychological diseases (7 males, 
14 females); their average age was (33.95±10.7) years. These patients were already on 
fluoxetine therapy for different doses and different durations. 
 
2. The Control group: included twenty nonsmoker healthy subjects (10 males, 10 
females) their average age (35.6+13.9) range (17–59years). 
 
Saliva and blood samples and standard questionnaire form including visual 
analogue scale (VAS) were obtained from each individuals in each visit (one visit for 
chronic group and three for acute group (pre, post 4weeks and post 8weeks of treatments). 
Salivary (alpha amylase, sodium ion, potassium ion, fluoxetine concentration by HPLC 
and flow rate) were analyzed. Also the symptoms and adverse effects of fluoxetine 
reported in the clinical reports of the patients have been recorded and analyzed in each 
visit. 
 
Results and Discussion:  
Salivary alpha amylase activity in patients showed statistically significant higher 
values when compared to control healthy group at (p=0.0001). Also when comparing the 
SAA activity of the patients with the healthy levels, we notice that SAA had the ability to 
distinguish 76.9% of the patients at pretreated level and 85.7% of the patients in the 
chronic group and this percent was increased by using the SAA, Na+ and K+ concentration 
measurements together to detect psychological patients which can be considered as a good 
high percent of detection and might indicate that they are a promising good biomarkers of 
stress in psychological conditions. 
Depending on the physiological response to stress, we can explain the increment 
in the SAA activity. Psychosocial stress is known to induce various responses of 
physiologic systems with particular increasing activities in the hypothalamus-pituitary-
Abstract 
 
adrenal axis (HPA) reflected by cortisol secretion as well as in the sympathetic-adrenal-
medullary (SAM) system reflected by salivary alpha amylase level. Many studies study 
the salivary activity after acute stressor physical or psychological such as (Granger et al., 
2006; Nater et al., 2006   Malamud and Rodriguez-Chavez, 2011).  Granger et al. in the 
study done in 2007 said “An increase in SNS activity leads to higher levels of alpha-
amylase production, which can be measured by examining saliva samples “. Multiple 
studies have examined the relationship between norepinephrine and SAA because both 
are associated with SNS activation. However, the results have been inconsistent such as 
(Chatterton et al., 1996;  Nater et al., 2006).  
Allwood et al., (2011) found results suggesting that SAA is more reactive to 
laboratory stressors (performance or peer rejection tasks) than cortisol. This is the first 
study that examines the SAA activity in acute and chronic state and in psychological 
patients with different psychological situations and compare it with other salivary 
electrolytes and with the adverse effects reported in the patients. Our sample size was less 
to represent the general population, but it gives an idea about the salivary changes that 
accompanying the stress and psychological conditions and thus more studies was needed 
with large numbers to confirm our findings. 
The salivary changes reported in groups in this study were as follows: 
In the disease condition comparing with the healthy control, this study showed 
significant higher levels of SAA and Na+, while significant lower K+ level in the disease 
condition than in the healthy control at p<0.05. Also reported significant lower FR and 
significant higher VAS than the healthy control at p<0.05. Significant nervousness, 
headache, insomnia, change appetite, xerostomia, and dysgeusia than the healthy control 
at p<0.05 have been reported in this study.  
Release of SAA is regulated by autonomic innervations (Bagan-Sabastain, 2004) 
and usually higher level of SAA produced by increased sympathetic activity (Granger et 
al., 2006; 2007). SAA activity increased as a normal response of the body to stress and 
this mediated by sympathetic adreno medullary system, in which SAA level considered 
as a good biomarker to its activity (Friedlander and Mahler, 2001). While significant 
higher Na+ and significant lower K+ level reported in the disease condition than in the 
healthy control at p<0.05 this may be due to that most of the patients in this study were 
depressed and even suffer from other psychiatric disorders might have been associated 
with depression. The explanation would depend on this to explain our finding. Depression 
known to be associated with increased level of aldosterone which lead to increase Na+ re 
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absorption and exchange of K+ this will explain the increased level of Na+ and decreased 
level of K+ in the disease condition when compare with healthy individuals (Zanatta et 
al.,2001). 
In the study group (chronic patients), the SAA level showed significant 
decrease with fluoxetine therapy at p<0.05. While, Na+ and K+ reported significant 
differences with the disease pre level. The concentration of Na+ was low, while K+ was 
high than in the disease condition. Significant changes in the salivary flow rate and VAS 
between the chronic group and the pretreated level. 
 In the study group (acute or follow up patients for two month of fluoxetine 
therapy), significant differences have been reported between different readings (pre, 
post1, post2) of the acute group in the SAA output. Although, the level showed decliner 
with the treatment, but it still higher than the healthy level.  In this study, it was found that 
the SAA output was significantly higher in the disease condition (represented by acute and 
the chronic group in this study) compared with the healthy control condition. Significant 
differences were found between the base line pretreated level (19.87u/min) which was 
higher than the treated post1 (12.86 u/min) and post2 (11.43 u/min) measures which 
indicated the efficacy of the treatment to reduce psychological stress associated with the 
psychological conditions. This is in agreement with (Noto et al., 2005) were they found 
that salivary alpha amylase is a useful indicator of psychological stress. The changes in 
SAA levels may be related to the activation of the β-adrenergic system and reflects the 
psychological stress in depression and other psychiatric disorders. However, the results of 
Kivlighan and Granger (2006) and Inagaki et al. (2010) which indicated a predominant 
role of the sympathetic nervous system in the secretion of SAA together with 
parasympathetic withdrawal, under psychosocial stress, support our suggestion that 
psychological factors (like stress) effects SAA secretions and concentrations. Thus, as a 
result to body response to fluoxetine therapy and efficacy in treating depression and 
psychological disorders and improved in mood due to the increased 5-HT level and reduce 
the effect of stress on the patients. This will have appeared in the decliner in SAA secretion 
which reflect the decrease in sympathetic activity.  
Na+ reported significant changes between pre and post treated level in the acute 
group, while K+ showed no significant changes. The pattern of changes was decrement in 
Na+ and increment in K+ with fluoxetine therapy. The pretreated level was significantly 
higher than the post treatment level with fluoxetine at p<0.05. Published studies do not 
offer any explanations for dramatic changes in K+ and Na+ concentration in the psychiatric 
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patients on fluoxetine therapy. It is interesting that many of patients in this study showed 
salivary changes such as significant changes reported between the disease condition 
(patients chronic and acute groups which was on fluoxetine therapy) when compared with 
the healthy control subjects. Based on published studies on non-psychiatric patients, it is 
attempted to supply some explanations. As the salivary flow rate increases, the 
concentrations of total protein, Na+, calcium, chloride, and bicarbonate, as well as the pH 
increases to various levels (Edgar, 1992; Tenovuo et al., 1994) which may explain these 
findings that the Na+ showed a pattern of decliner with the treatment and it reached to the 
healthy control level in the post 2 level. This may be as a result of the decreased in salivary 
flow that have been reported with treatment and this was also in agreement with (Höld et 
al., 1999) which propose direct relation of Na+ secretion with the salivary flow rate. This 
also may explain the pattern of increment with treatment that have been reported with 
fluoxetine therapy which may be due to the indirect relation of K+ secretion with FR as 
mentioned by Höld et al., (1999). Another explanation to the decrease and increase in Na+ 
and K+ conc. respectively was that the composition of saliva is subject to hormonal 
modulation (Wotman et al., 1973; Kakmoto et al., 1988) which act directly to increase 
Na+ reabsortion and K+ secretion. Also this supported by the finding of (Zanatta et al., 
2001) which found that fluoxetine was increase the Na-K ATPase activity by 27% than 
the control which might lead to increase Na+ re absorption and K+ excretion. 
According to all of the above, and by comparison of the concentrations of Na+ and 
K+ with the concentrations mentioned in other studies we can notice the higher 
concentrations of these parameters in our sample compared with others, which may be a 
serious or even dangerous indicator to the severe and continuous stress that our population 
live in. This exciting finding may give rise to many studies that should be done to 
investigate the effect of such acute and continuous stress on the performance and wellbeing 
in our population and its effect on cognitive functions and memory. Also, on the ability to 
make a decision.  According to this point of view, that needs more studies to measure the 
effect of acute and chronic stress and anxiety in our population, not only to study it, but to 
try to find some solutions or methods to compensate or deal with it. 
Assessment of safety and tolerability showed that 16 patients (41.02%) out of 39 
patients were withdrawn from our study, 8 patients (20.51%) due to the adverse effects 
(G.I.T, insomnia, sexual adverse effects, and TMJ problems) and 8 (20.51%) due to lack 
of efficacy and non-complaint. The main adverse effects caused by fluoxetine therapy 
were breathing difficulties, abnormal dreams, drowsiness, insomnia, headache, weight 
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loss, change in appetite, tremor, myalgia, anorexia, nausea, diarrhea, anxiety, taste 
changes (dysgeusia), xerostomia, and TMJ problems. 
The effect of gender on parameters showed that from all salivary parameters: Only 
Na+ concentration was significantly high in females than males in the chronic group. 
While general adverse effects including (anxiety, headache, nervousness) were 
significantly higher in males than females in the chronic group while anxiety, 
constipation, palpitation were significantly higher in males than females in the acute 
group. Only dysgeusia was significantly high in males than females in the chronic group 
while TMJ problems was significantly high in males than females in the acute group.  
In relation to dose, Na+  and nervousness showed a significant increase level with 
dose 40 mg/d of fluoxetine in the chronic group at (p=0.04 and p=0.034 respectively), 
and only anxiety in the acute group showed significant higher incidence with dose 60mg/d 
at p=0.035.  
The FR decreased with the duration while the VAS showed high score with long 
term treatment. Weight loss, myalgia, constipation, palpitation, breathing difficulties, 
nervousness, anxiety, insomnia, nausea, taste changes, xerostomia, TMJ problems and 
black hairy tongue showed significant increase with the increased duration of therapy at 
p<0.05. 
All patients being treated with antidepressants for any indication should be 
monitored appropriately and observed closely for clinical worsening, suicidality, and 
unusual changes in behavior, especially during the initial few months of a course of drug 
therapy, or at times of dose changes, either increases or decreases. And for that purpose 
HPLC is the most commonly used mean for quantitative serum measurements of a 
medications. Many factors might influence the measured plasma drug concentrations, 
including variations in absorption, distribution, and metabolic clearance rates that are 
influenced by genetic and other differences among individuals. Determination of the 
relationship between fluoxetine concentrations and clinical response remains a 
questionable and also the relations between fluoxetine conc. and the adverse effects 
reported by patients. 
In this study, a wide range of fluoxetine concentration has been reported in relation 
to dose.  All was within the reported therapeutic levels.  
In general, the mean concentration reported in this study was higher in females than 
males in the chronic and acute groups (Ferguson, 2006; Blazquez et al., 2014). Amsterdam 
et al. had found in his study in (1997) that males had lower fluoxetine and norfluoxetine 
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serum levels while Pato et al. in his study (1991) said that sex and age of the patient did 
not impact metabolism and drug concentrations of fluoxetine. Also in this study, no clear 
relation noticed between drug concentration and a patients’ withdrawal from the study but 
these patients reported a higher range of fluoxetine concentration in the previous reading 
comparing with other patients. Amsterdam et al. (1997) reported that decreased clinical 
response at higher plasma concentrations and Altamura et al. 1994 was find that 
Concentrations of fluoxetine plus norfluoxetine above 500 mg/L appear to be associated 
with a poorer clinical response than lower concentrations.  
No significant relation has been found between fluoxetine concentration and 
general adverse effects in this study and this is in agreement with Beasley study in 1990 
which discuses “fluoxetine: relationships among dose, response, adverse events, and 
plasma concentrations in the treatment of depression” and found adverse events were not 
related to plasma concentrations. While Altamura et al. reported the increase in incidence 
of nausea and vomiting with the increase in fluoxetine dose.  
Direct relation was found between the concentration and oral adverse effects 
(xerostomia); the incidence of xerostomia was increased in the higher drug concentrations 
in our study. Also salivary flow rate showed decrement with the higher fluoxetine 
concentrations. 
This symptom may be the result of both diminished salivary secretion and an 
alteration in saliva composition (Patrícia et al., 2012). The subjective dry mouth sensation 
may occur even in the presence of a normal salivary flow that is, not necessarily being 
associated with a diminution in the amount of saliva (Närhi, 1994). 
The antidepressants inhibit the cholinergic signals in the salivary tissues and thus 
diminish the excretion of fluids by the glands, and interferences in central pathways 
(serotoninergics and dopaminergics) may also alter salivary composition (Atkinson and 
Baum, 2001). 
It is important to emphasize that the dry mouth sensation and alteration in salivary 
composition may occur during periods of stress and/or acute anxiety, frequently present in 
depressive disorders, due to predominant stimulation of the sympathetic system, 
irrespective of the use of anxiolytic and/or antidepressant medication (Guggenheimer and 
Moore, 2003). Therefore, it may be difficult to determine whether these side effects and 
their intensity arise from the medical condition that led to the treatment or from the 
medication prescribed for it (Smith and Burtner, 1994), it probably is as a result of both 
(Patrícia et al., 2012). 
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Conclusions: 
SAA is a good biomarker of stress in psychological patients with a high 
percentage of detection comparing with the healthy levels. With the possibility of using 
Na+ and K+ level as a biomarker with SAA. The SAA level was higher in men than 
women.   
VAS showed good correlation with the changes in the salivary flow and 
considered as a good subjective tool of mouth dryness. Females were more sensitive to 
mouth dryness than males which can be seen in the higher VAS scores reported by 
females. Also females were more compliant than males which can be seen from the higher 
percentage of male’s withdrawal from the study. Higher females mean fluoxetine 
concentration reported in this study than males in the chronic and acute groups. 
The concentration of fluoxetine in serum have no clear relations with the salivary 
biomarkers or with the adverse effects reported in the patient thus it cannot be used to make 
a decision and evaluation of the therapy and psychological situation of the patients. 
Direct relation was found between the concentration and oral adverse effects 
(xerostomia); the incidence of xerostomia was increased in the higher drug concentrations 
in our study. Also salivary flow rate showed decrement with the higher fluoxetine 
concentrations. 
  Fluoxetine therapy cause significant decline in SAA output level. And significant 
declinement of Na+ level with treatment. In addition, there was a direct correlation of Na+ 
with the salivary flow. Fluoxetine therapy causes significant changes in VAS score and 
salivary flow rate when compared with pre-therapy level. 
By comparison of the concentrations of Na+ and K+ with the concentrations 
mentioned in other studies we can notice the higher concentrations of these parameters in 
our sample compared with others, which may be a serious or even dangerous indicator to 
the severe and continuous stress that our population live in. This exciting finding may give 
rise to many studies that should be done to investigate the effect of such acute and 
continuous stress on the performance and wellbeing in our population and its effect on 
cognitive functions and memory. Also, on the ability to make a decision of treatment.  
According to this point of view, that needs more studies to measure the effect of acute and 
chronic stress and anxiety in our population, not only to study it, but to try to find some 
solutions or methods to compensate or deal with it. 
This is a preliminary study, limited by its sample size, but the design, findings, 
and inclusion of physiological measures present a contributory role in the essential line 
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of research. More expanded studies and researches are needed, including larger number 
of patients to measure the effects of continuous stress and increased levels of stress 
biomarker on the individuals and on cognitions and other activities in children and 
especially after our finding of higher levels of salivary electrolytes reported in this study. 
Also to measure the effects of violence, wars and post war conflicts on individuals. 
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Resumen 
En las últimas décadas, el estrés se ha convertido en un problema, en cierta forma 
inevitable, que afecta de forma negativa a la vida cotidiana. El estrés psicológico tiene un 
impacto negativo sobre el bienestar físico, mental y social de una persona. Se ha sugerido 
que puede desempeñar un papel importante en la causalidad o precipitación de multitud 
de problemas médicos y odontológicos que van desde graves enfermedades del corazón, 
cáncer, enfermedades gastrointestinales, dolores de cabeza, migrañas, ulceraciones orales 
recurrentes, sequedad de boca, etc.  
Para entender mejor el papel del estrés en la vida de los ciudadanos y proceder a 
su control, es necesario disponer de métodos de medida fiables y objetivos. En la 
actualidad, la mayoría de los métodos de diagnóstico psicológicos utilizados consisten en 
cuestionarios, que por lo general recogen la percepción de los síntomas del estrés por el 
propio paciente. Por tanto, al tratarse de una evaluación subjetiva, proporcionan resultados 
muy inconsistentes, ya que los datos obtenidos dependen del estado de ánimo y la actitud 
de los propios pacientes. Son numerosas las personas con estrés que tienen tendencia a 
negar o exagerar su condición real, lo que puede conducir a una desviación en el estudio 
y a un error en los resultados obtenidos. 
Parece clara por tanto la necesidad de encontrar indicadores biofisiológicos o 
biormarcadores que sean fiables, representativos y objetivos de los cambios ocurridos en 
el organismo como consecuencia del estado de estrés y que permitan además el 
seguimiento de su tratamiento.  
Entre ellos, los biomarcadores salivales han sido ampliamente investigados al 
consistir en una medida no invasiva y sencilla, que permite una fácil recogida de muestras, 
si se compara con otras como la de sangre u orina. Su facilidad contribuye de manera 
decisiva al cumplimiento por parte de los pacientes. 
En la detección del estado de estrés se han empleado como biomarcadores el 
cortisol, diferentes inmunoglobulinas y determinados parámetros que miden la función 
cardiovascular. No obstante, en diferentes estudios se ha demostrado que  la medida de 
las concentraciones de alfa amilasa salival (SAA) muestra una elevada sensibilidad frente 
a los cambios en las condiciones de estrés, tanto físicos como psicológicos, por lo que 
podría ser considerada como un marcador prometedor en la detección y evaluación del 
estrés biológico y por tanto de gran valor para la investigación psicofisiológica y para la 
práctica clínica.   
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Resulta difícil describir la situación de la población en Irak ya que no hay 
estadísticas precisas, especialmente en el sector de la salud, afectado dramáticamente por 
la guerra.  El número de sujetos que necesitan en la actualidad y necesitarán en el futuro 
un tratamiento psicológico se ha visto incrementado debido a la tensión creciente y a la 
violencia resultante de los conflictos de la guerra. Por ello parece necesario encontrar un 
método sencillo y económico que sirva para detectar con rapidez y fiabilidad la situación 
de estrés de los individuos, con objeto de poder prevenir o tratar convenientemente el 
deterioro de su salud mental. Este es el principal objetivo de este trabajo de tesis doctoral.   
Desde 2003, se ha observado un incremento significativo de la incidencia de 
trastornos psiquiátricos en la población iraquí, sin embargo, existe poca información 
fiable sobre ello. Son muy pocos los datos epidemiológicos disponibles. Por ello, otro 
objetivo general de esta tesis doctoral ha sido el estudio y evaluación de las condiciones 
psicológicas/psiquiátricas de un grupo de población representativo de la población iraquí, 
antes de la ocupación por parte del ISIS, pero en un momento de gran violencia y estrés.  
También ha sido objetivo de esta tesis doctoral analizar y evaluar la incidencia de 
efectos adversos originados por los tratamientos farmacológicos, administrados a 
pacientes con un diagnóstico psiquiátrico preciso.  
Fluoxetina fue el primer inhibidor selectivo del re captación de serotonina (SSRI) 
aprobado para el tratamiento de la depresión en seres humanos, siendo uno de los 
antidepresivos más utilizados. Se han notificado numerosos efectos adversos de tipo 
general y que afectan a la cavidad oral en particular. En concreto algunos de los efectos 
secundarios observados están relacionados con una alteración en la secreción salival y su 
composición.  
A pesar de que fluoxetina fue aprobada por la American Food and Drug 
Administración (FDA) en 1987 para el tratamiento de la depresión, y luego para el 
tratamiento de otros trastornos psiquiátricos en adultos y niños, en Irk su introducción a 
la terapéutica fue más tardía, no existiendo datos fiables sobre la incidencia de efectos 
adversos. Probablemente esto sea debido a que la mayoría de la sociedad no reconoce 
estar padeciendo de trastornos psiquiátricos y depresión.  
Para una gran mayoría de la población de Oriente Medio, por motivos de creencias 
religiosas y probablemente por miedo al rechazo social, no es aceptado el concepto de 
tratamiento farmacológico para un trastorno psiquiátrico, especialmente para la 
depresión.  
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Este estudio farmacológico clínico ha sido uno de los primeros realizados en la 
ciudad de Mosul y probablemente en Irak sobre pacientes con alteraciones 
psiquiátrico/psicológicos tratados con fluoxetina, en los que se fomenta la información 
sobre efectos adversos intentando con ello su prevención y adecuado tratamiento.  
La saliva es uno de los factores más importantes en la regulación de la salud oral. 
Su producción y composición se ven modificados durante el desarrollo de la enfermedad 
y también como consecuencia del tratamiento con fármacos SSRI. Como ya se ha 
comentado, en el caso de la terapéutica con fluoxetina, se han descrito diversos efectos 
adversos, algunos de tipo general y otros que afectan a la cavidad oral.  
Entre los objetivos específicos de este estudio figura, la evaluación de la influencia 
de las enfermedades psiquiátricas y de su tratamiento con fluoxetina sobre el flujo salival 
y sobre su composición (SAA, sodio y potasio), e igualmente la evaluación de los efectos 
adversos (generales y u orales) del tratamiento con este fármaco y su relación con la dosis 
administrada y la duración del mismo. 
 
Los objetivos específicos del estudio fueron: 
 Evaluar la utilidad de la actividad alfa amilasa salival (SAA) como un marcador 
biológico de estrés, comprobando su eficacia como prueba diagnóstica.   
 Estudiar la posibilidad de utilizar las medidas de las concentraciones de sodio y 
potasio salival como marcadores de estrés, estableciendo su relación con las 
concentraciones de SAA y volumen del flujo salival, tanto en voluntarios sanos 
como en pacientes psiquiátricos tratados o no con fluoxetina.   
 Evaluar la incidencia de las enfermedades psiquiátricas sobre el volumen de flujo 
salival y composición de la saliva (SAA, Na+, K+).  
 Estudiar la incidencia de xerostomía y su gravedad en los pacientes tratados con 
fluoxetina, empleando medidas objetivas y subjetivas mediante la aplicación de 
una escala VAS. 
 Cuantificar los efectos adversos de tipo general u oral asociados al tratamiento 
con fluoxetina, estableciendo su relación con la dosis y duración.  
 Analizar, mediante cromatografía de alta resolución (HPLC), las concentraciones 
plasmáticas de fluoxetina en los pacientes tratados, estableciendo su relación con 
las concentraciones de SAA, Na+, K+ y con la incidencia de efectos adversos. 
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Materiales y métodos:  
En el estudio han participado ochenta personas divididas en dos grandes grupos: 
1. Grupo de Estudio (Pacientes): consiste de (60) pacientes con edad entre los (15-56) 
años. Para investigar los efectos del tratamiento con fluoxetina se dividen en dos 
subgrupos: 
1.1. Grupo de pacientes agudo: integrado por 39 pacientes (23 hombres, 16 mujeres) 
diagnosticados de diferentes enfermedades psicológicas y tratados con fluoxetina después 
de dos semanas de período de lavado. En este grupo se realizó un seguimiento durante 
dos meses. El promedio de edad es de (35.4±10.7) años.  
1.2. Grupo de pacientes crónicos constituido por 21 pacientes (7 hombres, 14 mujeres), 
diagnosticados de diferentes enfermedades psicológicas y el promedio de edad es de 
(33.95±10.7) años. Estos pacientes fueron tratados con diferentes dosis de fluoxetina 
durante diferentes periodos de tiempo. 
2. Grupo de Control: incluye 20 sujetos sanos, no fumadores (10 hombres, 10 mujeres) 
con el promedio de edad es de (35.6+13.9) años. 
De cada paciente se obtuvieron muestras de saliva y sangre en cada una de las 
visitas realizadas: una visita en el grupo de pacientes crónicos y tres (pre-, post4- y post8- 
semanas de tratamiento) en el grupo de pacientes con tratamiento agudos. Además, se 
determinó el volumen de flujo salival. En las muestras de saliva se han analizado las 
concentraciones de SAA, Na+, K+. En las muestras de sangre se analizó 
cromatográficamente (HPLC) la concentración de fluoxetina.  
A partir de los informes clínicos emitidos para cada uno de los pacientes, en las 
diferentes visitas, se recogieron datos relativos a su sintomatología y a la incidencia de 
efectos adversos. También en cada visita se aplicó a los pacientes la escala VAS.  
Resultados y discusión:  
La SAA muestra valores significativamente más altos en los pacientes con 
alteraciones psiquiátricas en comparación con el grupo control (p = 0.0001). Las 
diferencias encontradas entre ambos grupos permiten estimar SAA como un parámetro de 
alta capacidad para el diagnóstico del estrés psicológico, pues sirvió para detectar la 
alteración en el 76.9% de los pacientes pre-tratados y en el 85.7% de los sujetos 
pertenecientes al grupo pacientes crónicos. Estos porcentajes podrían incrementarse si se 
utilizan también las mediciones de las concentraciones de Na+ y K+.  Los resultados 
indican una buena capacidad de detección y por tanto sitúan a SAA como un buen 
biomarcador de estrés. 
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Dependiendo de las respuestas fisiológicas al estrés, es posible explicar los 
incrementos observados en la actividad SAA. Se sabe que el estrés psicosocial provoca 
diferentes respuestas de los sistemas fisiológicos, en particular el aumento de las 
actividades en el eje hipotálamo-pituitario-adrenal (HPA) reflejada por la secreción de 
cortisol, así como en el sistema simpático- adrenomedular (SAM) reflejada por las 
concentraciones de SAA.  
Se han publicado varios estudios en los que se ha investigado la actividad salival 
después de un estrés físico o psicológico agudo (Granger et al., 2006; Nater et al., 2006; 
Malamud y Rodriguez-Chávez, 2011). Granger et al., (2007) indicó que "un aumento de 
actividad SNS conduce a un incremento en la producción de SAA y por ello dicho 
aumento puede evaluarse examinando muestras de saliva". Varios estudios han analizado 
la relación entre la norepinefrina y SAA ya que ambos están relacionados con la activación 
del SNS. Sin embargo, los resultados han sido inconsistentes (Chatterton et al., 1996; 
Nater et al., 2006).  
Allwood et al., (2011) encontraron que la SAA es más reactiva a estresores 
experimentales que el cortisol.  
Este es el primer estudio en el que se evalúa la actividad SAA en pacientes 
psiquiátricos en fase aguda y crónica, y sometidos a diferentes situaciones psicológicas, 
estableciendo su relación con las concentraciones de electrolitos salivales y con los efectos 
adversos identificados en los pacientes. El tamaño de muestra es pequeño para que pueda 
representar a la población en general, pero puede dar una idea acerca de los cambios que 
ocurren en la saliva como consecuencia del estrés y otras condiciones psicológicas. Por 
ello consideramos que sería necesario realizar nuevas investigaciones, con un mayor 
número de pacientes, para confirmar los resultados obtenidos.  
Los cambios observados en este estudio se detallan a continuación. 
En el grupo pre-tratado (enfermos) se ha percibido un aumento significativo de 
SAA y de la concentración de Na+, y una reducción en las concentraciones de K+, en 
comparación con el grupo control de voluntarios sanos (p<0.05). También se ha observado 
una reducción significativa del volumen de flujo salival (FR) y un incremento en los 
valores de VAS en comparación con el grupo control (p<0.05). En el grupo de pacientes 
pre-tratados se detectó un elevado nivel de nerviosismo, dolor de cabeza, insomnio, 
modificación en el apetito, xerostomía y dysgeusia. Las diferencias en la incidencia de 
efectos adversos respecto al grupo de voluntarios sanos fueron estadísticamente 
significativas (p < 0.05). 
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Como se ha comentado anteriormente, la liberación de SAA está regulada por el 
sistema nervioso autónomo (Bagan-Sabastain, 2004) por lo que su incremento puede 
relacionarse con un incremento en la actividad simpática (Granger et al., 2006; 2007). La 
actividad SAA aumenta, como parte de la respuesta normal del organismo al estrés, 
mediada por el sistema simpático adrenomedular. Por ello algunos autores consideran 
SAA como un buen biomarcador para evaluar dicha actividad simpática (Friedlander y 
Mahler, 2001). 
Por otra parte, en los enfermos psiquiátricos, se ha percibido un incremento 
significativo (p < 0.05) en las concentraciones salivales de Na+ y una reducción también 
significativa de las concentraciones de K+, en comparación con el grupo control.  Esto 
podría ser debido a que la mayoría de los pacientes pre-tratados ya sufren de depresión y 
probablemente de otros trastornos psiquiátricos relacionados. Es conocido que la 
depresión puede asociarse a un incremento en la producción de aldosterona lo que 
incrementa la reabsorción de Na+ y el intercambio de K+. Esto podría explicar el mayor 
aumento en las concentraciones salivales de Na+ y en la disminución en las 
concentraciones de K+ en los enfermos psiquiátricos cuando se compara con individuos 
sanos (Zanatta et al., 2001). 
En el grupo de pacientes crónicos, el tratamiento con fluoxetina indujo una 
disminución significativa (p < 0.05) en los valores de SAA, respecto al grupo de pacientes 
pre-tratados. Por el contrario, las concentraciones de Na+ fueron significativamente 
menores y las de K+ mayores, respecto al mismo grupo de pacientes (pre-tratados). 
También se observaron modificaciones significativas en el volumen de flujo salival y en 
los valores de VAS respecto al grupo correspondiente a los enfermos antes del 
tratamiento. 
En el grupo de los pacientes agudos o de pacientes con seguimiento en el 
tratamiento con fluoxetina durante dos meses, se han observado diferencias significativas 
en los valores de SAA entre las distintas lecturas (pre, post1, post2). Aunque SAA 
disminuye con el tratamiento, se mantiene en valores más elevados que en el grupo control 
de voluntarios sanos.  
Por tanto, se observa que la concentración de SAA es significativamente mayor en 
enfermos (representados por los grupos de agudos y crónicos) que en los individuos sanos 
integrados en el grupo control. La medida de la actividad SAA fue significativamente 
mayor en el grupo pre-tratado (19.87 u/min) que en el post1 (12.86 u/min) y post2 (11,43 
Resumen 
 
 
 
u/min), lo que puede indicar la eficacia del tratamiento con fluoxetina para reducir el estrés 
psicológico. 
Estos resultados están en consonancia con lo publicado por Noto et al., (2005) que 
propone como indicador útil para detectar estrés psicológico, la medida de SAA. 
Las modificaciones en los niveles de SAA observados podrían estar relacionados 
con la activación del sistema beta-adrenérgico y en base a ello con el estrés psicológico y 
otros desórdenes psiquiátricos. Apoyando esta hipótesis, Kivlighan y Granger, (2006) e 
Inagaki et al., (2010) indican el papel predominante del sistema nervioso simpático en la 
secreción de SAA bajo condiciones de estrés psicológico y la no influencia del sistema 
parasimpático.   
La respuesta de los pacientes al tratamiento con fluoxetina, debida al incremento 
de las concentraciones de 5-HT, induce una mejoría en la enfermedad depresiva y otras 
alteraciones psicológicas, reduce el estrés psicológico y mejora en general, el estado de 
ánimo de los pacientes. Por tanto, la disminución en la secreción de SAA observada en los 
pacientes podría reflejar una disminución en la actividad simpática. 
En cuanto a las concentraciones de Na+, también se observaron cambios 
significativos (p < 0.05) entre los pacientes pre- y post-tratados con fluoxetina. Por el 
contrario, no se observaron cambios estadísticamente significativos en las concentraciones 
de K+.  Los cambios observados fueron una disminución en las concentraciones de Na+ y 
un incremento en las de K+ en los pacientes tratados con fluoxetina. 
Los estudios publicados no ofrecen una explicación científica para las 
modificaciones observadas en las concentraciones de estos iones en la saliva de los 
pacientes psiquiátricos tratados con fluoxetina. Investigaciones realizadas en enfermos no 
psiquiátricos sí podrían justificar en parte nuestros resultados. Se ha observado que un 
incremento del volumen de flujo salival está relacionado con incrementos en las 
concentraciones de proteína total, Na+, calcio, cloruros y bicarbonato, así como en el pH 
(Edgar, 1992; Tenovuo et al., 1994). La disminución en el volumen del flujo salival 
ocasionado por el tratamiento con fluoxetina, ampliamente documentado, podría explicar 
la disminución de las concentraciones de Na+ observadas en los pacientes tratados, 
alcanzando en el grupo post2 de tratamiento niveles similares a los encontrados en la saliva 
de los voluntarios sanos. Estos resultados están de acuerdo con los encontrados por Höld 
et al., (1999) al proponer una relación directa entre la secreción de Na+ y el incremento 
del flujo salival e indirecta respecto a las concentraciones de K+. También pudiera deberse 
a una modulación de tipo hormonal que incidiría de manera directa sobre la reabsorción 
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de Na+ y la secreción de K+ (Wotman et al., 1973; Kakmoto et al., 1988); o bien al efecto 
de la fluoxetine como inductor de la actividad ATPase Na-K (27% respecto al control) lo 
que provocaría igualmente un incremento en la reabsorción de Na+ y en la secreción de 
K+ (Zanatta et al., 2001). 
Conforme a lo anterior, las importantes diferencias encontradas en este trabajo en 
las concentraciones de Na+ y K+ respecto a las mencionadas en otras investigaciones, 
podrían ser indicadoras del estrés grave y continuado al que está sometido la población 
iraquí.  Este interesante hallazgo podría dar lugar al inicio de nuevos estudios dirigidos a 
investigar el efecto del estrés agudo y continuo en el rendimiento y bienestar de la 
población, y su efecto sobre las funciones cognitivas y la memoria. También podrían ser 
el punto de partida para avanzar en el abordaje de su control y tratamiento.  
En cuanto a la evaluación de la seguridad y tolerabilidad de los tratamientos, 16 
pacientes (41.02%) del grupo de tratamiento agudo, tuvieron que abandonar el estudio. 8 
pacientes (20.51%) debido a efectos adversos como trastornos gastrointestinales (GIT), 
insomnio, disfunción sexual y problemas de la articulación temporomandibular (TMJ); y 
8 pacientes (20.51%) debido a la falta de eficacia y no cumplimiento terapéutico. Los 
principales efectos adversos causados por la terapia con fluoxetina fueron dificultades 
respiratorias, sueños anormales, somnolencia, insomnio, dolor de cabeza, pérdida de 
peso, cambios en el apetito, temblor, mialgias, anorexia, náuseas, diarrea, ansiedad, 
cambio en el sentido del gusto (disgeusia), xerostomía y problemas de la TMJ. 
La influencia del género sobre los parámetros estudiados solo se evidenció en 
cuanto a los valores de concentración de Na+, significativamente más elevados en mujeres 
que en hombres en el grupo de enfermos crónicos. Mientras que los efectos adversos de 
tipo general como ansiedad, dolor de cabeza y nerviosismo fueron significativamente 
mayores en hombres que en mujeres en el mismo grupo de pacientes. En el grupo de 
pacientes con tratamiento agudo la incidencia de ansiedad, estreñimiento y palpitaciones 
fue significativamente mayor en varones que en hembras.  
En cuanto a las manifestaciones que afectan a la cavidad oral, solo en el caso de 
la disgeusia, la incidencia ha sido significativamente mayor en hombres que en mujeres 
en el grupo crónico, mientras que en el grupo de pacientes con tratamiento agudo han sido 
los trastornos de la articulación temporomandibular los que se han manifestado en un 
mayor número de casos también en hombres que en mujeres. 
En relación a la influencia de la dosis administrada de fluoxetina, se ha observado 
que las concentraciones de Na+ en saliva y la incidencia de nerviosismo han mostrado un 
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aumento significativo con la dosis de 40 mg/d en el grupo de pacientes crónicos (p = 0,04 
y p = 0.034 respectivamente). En el grupo de pacientes agudos, sólo se observó un 
incremento significativo en la incidencia de ansiedad cuando la dosis administrada fue de 
60 mg/d (p = 0,035).  
La duración del tratamiento también influyó en los parámetros analizados en este 
trabajo de investigación. El flujo salival (FR) disminuyó con la duración del tratamiento 
mientras que los valores subjetivos obtenidos mediante la escala VAS fueron mayores en 
caso de tratamientos prolongados. En cuanto a la aparición de efectos adversos, los 
tratamientos de mayor duración se asociaron a una significativa mayor incidencia de 
pérdida de peso, mialgia, estreñimiento, palpitaciones, dificultad respiratoria, 
nerviosismo, ansiedad, insomnio, nausea, disgeusia, xerostomía, trastornos de la 
articulación temporomandibular y lengua negra vellosa (p < 0.05). 
En los pacientes tratados con antidepresivos siempre se debería realizar un 
seguimiento médico con objeto de poder detectar un posible empeoramiento clínico, 
tendencias suicidas o cambios inusuales en el comportamiento, especialmente durante los 
primeros meses de tratamiento, o cuando se procede a modificar el mismo, aumentando 
o disminuyendo la dosis. Por ello, en este trabajo se procedió a cuantificar las 
concentraciones plasmáticas del fármaco (fluoxetina) durante las diferentes visitas de los 
pacientes, empleando métodos cromatográficos (HPLC). 
Son varios los factores que pueden influir en las concentraciones plasmáticas de 
los fármacos, entre ellos modificaciones en la absorción, distribución y aclaramiento de 
los mismos, que pueden verse afectados por aspectos genéticos y por diferencias 
interindividuales. Los resultados obtenidos, aunque variables, se encuentran dentro de los 
márgenes terapéuticos estimados para fluoxetina.  
En general, las concentraciones medias fueron más elevadas en mujeres que en 
hombres en los dos grupos de tratamiento (agudo y crónico). Estos resultados están en 
consonancia con los obtenidos en trabajos previos, en los cuales se demostró que, a igual 
dosis, las concentraciones plasmáticas de fluoxetina y norfluoxetina son más bajas en 
hombres (Amsterdam et al., 1997; Ferguson, 2006; Blazquez et al., 2014). Por el 
contrario, Pato et al., (1991) indica que el sexo y la edad de los pacientes no influyen en 
la concentración plasmática ni en el metabolismo de la fluoxetina. En este estudio, no se 
observó una relación clara entre la concentración plasmática y el abandono del estudio 
por algunos pacientes, sin embargo, en éstos se encontraron concentraciones plasmáticas 
del fármaco más elevadas en comparación con otros pacientes.  Por otra parte, Amsterdam 
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et al., (1997) indicaron que la respuesta clínica disminuía cuando las concentraciones 
plasmáticas eran más elevadas y Altamura et al., (1994) que cuando estas concentraciones 
plasmáticas de fluoxetina y norfluoxetine eran superiores a 500 mg/L se obtenía peor 
respuesta clínica que a concentraciones más bajas.  
En este estudio, no se ha encontrado ninguna relación significativa entre la 
concentración plasmática de fluoxetina y la aparición de efectos adversos de tipo general. 
Estos resultados están de acuerdo con los obtenidos por Beasley en el año 1990 en su 
estudio titulado “Fluoxetina: relaciones entre dosis, respuesta, efectos adversos y 
concentraciones plasmáticas, en el tratamiento de la depresión" en el cual tampoco se pudo 
encontrar una relación entre las concentraciones plasmáticas del fármaco y la incidencia 
de efectos adversos. Por el contrario, Altamura et al., (1994) observaron una mayor 
incidencia de náuseas y vómitos al incrementarse las concentraciones plasmáticas de 
fluoxetina. 
En cuanto a los efectos adversos relacionados con la cavidad oral, se ha encontrado 
una relación directa entre la concentración plasmática y la incidencia de los mismos. Se ha 
observado un mayor número de casos de xerostomía y disminución del flujo salival cuando 
las concentraciones plasmáticas son más elevadas. Este síntoma puede ser el resultado de 
una disminución en la secreción de la saliva y de una alteración en su composición (Patricia 
et al., 2012). No obstante, la sensación subjetiva de sequedad de boca puede ocurrir incluso 
cuando el flujo de saliva es normal, por tanto, no está necesariamente asociada a una 
disminución de su cantidad (Närhi, 1994). 
Los antidepresivos inhiben las señales colinérgicas en los tejidos salivales 
induciendo una disminución en la secreción de fluidos por las glándulas. Además, al incidir 
sobre las vías de señalización serotoninérgicas y dopaminérgicas, pueden modificar su 
composición (Atkinson y Baum, 2001). 
Es importante destacar que la sensación de sequedad de boca y la modificación de 
la composición de la saliva puede ocurrir también durante períodos de estrés y/o ansiedad 
aguda, frecuentes en estados depresivos, como consecuencia de la estimulación 
predominante del sistema simpático, e independientemente del uso de medicamentos 
ansiolíticos o antidepresivos (Guggenheimer y Moore, 2003). Por lo tanto, resulta difícil 
determinar si estos efectos secundarios y su intensidad son debidos a la situación de estrés 
psicológico o enfermedad que motivó el tratamiento; son debidos a la medicación prescrita 
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para resolverlos (Smith y Burtner, 1994), o lo que es más problable, sean el resultado de 
ambos (Patrícia et al., 2012). 
 
Teniendo en cuenta los resultados de este estudio y la discusión de los mismos, se 
pueden obtener las siguientes conclusiones:  
 
1. La evaluación de la cantidad y el análisis de la composición de la saliva podrían ser 
considerados como un método analítico, no invasivo y eficaz, para el estudio de los 
cambios originados en el estado de los pacientes psiquiátricos, así como en la 
evolución de su tratamiento.   
2. Se han encontrado diferencias significativas en la concentración salival de SAA, Na+ 
y K+ entre los voluntarios sanos, los pacientes con alteraciones psicológicas, y los 
pacientes tratados farmacológicamente.  
3. La medida de la concentración de alfa amilasa salival (SAA) puede considerarse un 
adecuado biomarcador para evaluar el estrés en pacientes con alteraciones 
psicológicas. También puede ser empleado para evaluar la eficacia de los tratamientos 
farmacológicos sobre el grado de estrés de los pacientes. 
4. A pesar de que el tratamiento con fluoxetina origina una disminución significativa en 
la liberación de SAA y en la concentración de Na+, no es posible establecer una clara 
correlación entre su concentración plasmática, determinada en los pacientes tratados, 
con los biomarcadores de estrés y/o con la incidencia de efectos adversos. Por ello, 
no es posible considerar la medida de la concentración plasmática de fluoxetina, como 
estimador para el seguimiento de la evolución del estado psicológico de los pacientes, 
ni para la toma de decisión en el tratamiento. 
5. Se ha observado una correlación directa entre la concentración de Na+ y la medida del 
flujo salival. 
6. Los resultados obtenidos, tras la aplicación a los pacientes de la escala analógica 
visual (VAS), ha mostrado una buena correlación con los cambios observados en el 
flujo salival. En pacientes enfermos, valores elevados en VAS están relacionados con 
una disminución en el flujo de saliva. Tras el tratamiento con fluoxetina se observan 
cambios significativos en los valores de VAS y en el flujo salival. Por ello, esta escala 
puede ser considerada una buena herramienta para la estimación subjetiva de la 
percepción de sequedad de boca. 
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7. En este estudio el porcentaje de abandono del tratamiento farmacológico se ha 
estimado en un 41.02%, de los cuales un 20.5% ha sido consecuencia de los efectos 
adversos provocados por el tratamiento, especialmente trastornos gastrointestinales, 
insomnio y alteraciones en la función sexual. El abandono del estudio como 
consecuencia de alteraciones en la articulación temporo-mandibular (TMJ) ha sido 
del 2.56%. Xerostomia y disgeusia son efectos adversos asociados al tratamiento con 
fluoxetina. 
8. El género influye significativamente tanto en el abandono del tratamiento como en la 
incidencia o percepción subjetiva de efectos adversos. Se observó un mayor número 
de abandonos en los varones. Sin embargo, en el grupo de mujeres, los valores de 
VAS fueron más elevados, por lo que parecen ser más sensibles a la percepción de 
sequedad de boca.  
9. Se constata la escasa información científica publicada acerca de los efectos adversos 
originados en la cavidad oral por los tratamientos con antidepresivos y en especial por 
inhibidores en el re captación de serotonina (SSRIs), así como sobre su posible 
prevención y tratamiento. Para mejorar ese conocimiento se proponen las siguientes 
recomendaciones: 
 En los registros del seguimiento diario de los pacientes con alteraciones 
psiquiátricas debería incluirse información sobre la higiene de la cavidad oral 
y los efectos de la medicación sobre la misma. 
 Sería conveniente alentar a los pacientes para que se preocupen por la higiene 
y salud de su cavidad bucal como parte importante de su estado saludable o 
como manifestación de algún problema psiquiátrico. También fomentar en 
ellos la comunicación de cualquier incidencia al médico.  
 Crear programas educativos dirigidos a los ciudadanos para controlar el estrés 
y para manejar convenientemente las consecuencias psíquicas y físicas del 
mismo. 
 Implementar programas de formación continua para profesionales sanitarios 
que les permita la actualización de conocimientos sobre los síntomas orales, 
tanto de los trastornos psiquiátricos como de los efectos adversos inducidos 
por los tratamientos. 
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1. INTRODUCTION 
1.1 Stress and their developed biological markers 
In the last recent decades, stress has become an inevitable part plaguing the daily 
lives. Psychological stress has a negative impact over physical, mental and social well-
being of a person. It has been suggested to play an important role in causation or 
precipitation of multitude of medical and dental problems ranging from serious heart 
diseases, cancers, gastrointestinal diseases, to common headaches, migraine, recurrent 
oral ulcerations, burning and dry mouth.  
In order to better understand the role of stress, valid and reliable measurement of 
stress is of utmost importance. Since, most of methods used for the diagnosis of stress are 
questionnaires form (subjective methods) which depends on person and there is many 
inter individual variation between subjects, thus there is increased need of biological 
stress markers to provide an objective, reliable and authentic evidence of stress. Many 
biomarkers have been used in determination of stress such as cortisol levels, 
immunoglobulins, chromogranin-A, cardiovascular parameters. Studies showed there is 
an evidence of sensitivity of SAA (salivary alpha amylase) levels in response to different 
stressful conditions, physically and psychologically. 
Salivary biomarkers are important field of research because of easy, non-invasive 
and rapid collection of samples compared to the blood and urine samples thereby 
increasing the patient compliance. The components of saliva act as a “mirror of the body 
's health”, and the widespread use and growing acceptability of saliva as a diagnostic tool 
is helping individuals, researchers, health care professionals and community health 
programs to better detect and to monitor diseases and to improve the general health of the 
public (Dodds and Johnson, 2005). Many studies showed that analysis of saliva sample 
is a convenient means for assessment of physiological conditions, evaluation the serum 
concentration of medicine and assessment of the severity of an illness (Loewit et al., 
1996; Tadasi, 2002). 
Psychosocial stress is widely known to induce various adaptational responses of 
physiologic systems with particular increasing activities in the hypothalamus-pituitary-
adrenal axis (HPA) as well as in the sympathetic-adrenal-medullary (SAM) system. 
Cortisol levels reflect the HPA activity whereas SAA is said to reflect the SAM activity. 
Many studies comparing SAA activity with stress and/or adrenergic activity had shown 
that SAA reflected the adrenergic activity and thus might be used as a reliable index of 
the SAM activity during stress. Chatterton and colleagues (Chatterton et al., 1996; 1997) 
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linked levels of SAA to sympathetic activation during physically and psychologically 
stressful conditions which found to be closely associated with changes in norepinephrine 
concentrations. Psychological stress activates both the HPA axis, as well as the SAM axis, 
which manifests as changes in cortisol and SAA output. For example, SAA has been 
found to respond to psychological stress (Bosch et al., 1996; Skosnik et al., 2000; Nater 
et al., 2005, 2006; Rohleder et al., 2006). Sympathetic stimulation causes high SAA 
release from the parotid and submandibular acinar cells, whereas parasympathetic 
stimulation causes low SAA release from the sublingual acinar cells (Kelly et al., 2010). 
Bosch, in his study in 1996, measured the salivary proteins associated with stress 
and found significant stress-mediated increase of salivary total protein concentration, 
alpha-amylase activity, amylase/protein ratio, alpha-amylase output, s-IgA concentration, 
and s-IgA output. While Chatterton et al. (1997) identified that salivary α-amylase levels 
increased in response to exercise. These authors compared levels of salivary α-amylase 
in males prior to and following exercise, a written examination or rest, and identified that 
aerobic exercise induced a three-fold mean increase in α-amylase levels. 
Nater and colleagues had done many studies about SAA.  In 2005 they set out to 
investigate human salivary alpha-amylase changes employing a reliable laboratory stress 
protocol to investigate the reactivity of salivary alpha-amylase to a brief period of 
psychosocial stress. And they report significant differences between psychosocial stress 
and the rest condition in alpha-amylase activity, cortisol levels and heart rate, with marked 
increases before and after stress. While the author said in another study published in 2006 
that salivary alpha-amylase is sensitive to psychosocial stress. Since it does not seem to 
be closely related to other biological stress markers such as catechol amines and cortisol, 
salivary alpha-amylase may be a useful additional parameter for the measurement of 
stress. 
These studies and others showed there is an evidence of sensitivity of SAA levels 
in response to different stressful conditions, physically and psychologically. Also some 
studies provide evidences about the relation of salivary sodium and potassium and the 
physical and psychological stressor. 
Changes in SAA are thought to have implications for health. And consider a 
promising role of salivary alpha amylase as a possible biological stress marker. 
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1.2 Mental health problems 
Mental health problems are a growing public health concern. A recent index of 
301 diseases found mental health problems to be one of the main causes and a major 
contributor of the overall disease burden worldwide. (Prince et al., 2007; Mark et al., 
2009; Vos et al., 2013). Costs of mental health services are high and yet there is evidence 
that the coverage of mental health care is insufficient to address current need (Rice and 
Miller, 1995; Ferrari et al., 2013). Mental health problems constitute the largest single 
source of world economic burden, with an estimated global cost of £1.6 trillion (or 
US$2.5 trillion) – greater than cardiovascular disease, chronic respiratory disease, cancer, 
and diabetes on their own (Insel, 2011). 
According to the World Health Organization (WHO, 2008), major depression is 
forecast to be the condition causing the second highest loss in disability adjusted life years 
by the year 2020. Depression has the third highest burden of all diseases global. WHO 
estimates that depression will be the number one health concern in both the developed 
and developing nations by 2030 (WHO, 2008).  
According to the 2010 Global Burden of Disease Study, mental health and 
behavioral problems (e.g. depression, anxiety and drug use) were reported to be the 
primary drivers of disability worldwide, causing over 40 million years of disability in 20 
to 29-year-olds (Lozano et al., 2012). The most predominant mental health problems 
worldwide are depression and anxiety (White ford et al., 2013).  Also they found major 
depression to be the second leading cause of disability worldwide and a major contributor 
to the burden of suicide and ischemic heart disease (Ferrari et al., 2013). Globally, up to 
90% of people diagnosed with anxiety and depression are treated in primary care. 
However, there are many individuals who are undiagnosed and therefore do not seek 
treatment (NICE, 2011). 
 
1.2.1 Depression, prevalence, historical reviews 
Depression is a broad and heterogeneous diagnosis, characterized by depressed 
mood and/or loss of pleasure in most activities. Severity of the disorder is determined by 
both the number and severity of symptoms and the degree of functional impairment. 
Because depression displays high rates of lifetime prevalence, early age of onset, 
high chronicity, and role impairment, the WHO has ranked depression as the single most 
burdensome disease in the world in terms of years lived with disability (Murray and 
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Lopez, 1996; Richards, 2011; WHO, 2012; Ferrari et al., 2013). Depression is one of the 
leading causes of disease worldwide. Historically conceived as either a disease of the 
mind or of the brain, treatment options followed this etiology. Current diagnostic 
assessment of depression is based on descriptions of symptoms, their presence and 
magnitude over time. Epidemiological studies demonstrate that depressive disorders are 
highly prevalent: displaying high rates of lifetime incidence, early age onset, high 
chronicity, and role impairment. 
Depression is one of the most commonly diagnosed mental disorders among 
adults. Our understanding of the course and nature of depression has changed 
significantly in the last twenty years. From being seen as an acute and self-limiting illness, 
to a growing clarity that for many depressions is now considered a chronic, lifelong illness 
(WHO, 2012). 
Prevalence of depression is of concern, as the cost that depression exacts is 
considerable. It is not only economically detrimental, but also engenders significant 
personal and interpersonal suffering alongside its societal impact (Johnson et al., 1992). 
In the U.S. for the year 2000 the economic burden of depression was estimated at $83.1 
billion. Thirty-one percent (31%) related to direct medical costs, 7% related to mortality 
costs, and 62% to workplace costs (Greenberg et al., 2003). In Europe for the year 2004 
the annual cost of depression was estimated at €118 billion. Direct healthcare costs 
amounted to 36% and indirect costs due to morbidity and mortality amounted to 64% 
(Sobocki et al., 2006). In 2012, depression is estimated to affect 350 million people.  The 
World Mental Health Survey conducted in 17 countries found that on average about one 
in 20 people reported having an episode of depression in the previous year (WHO, 2012). 
Historically, mood disorders usually diagnosed depending on the Diagnostic and 
Statistical Manual of Mental Disorders which put definitions and criteria for diagnosis of 
psychiatric disorders in different editions. In the Diagnostic and Statistical Manual of 
Mental Disorders-First Edition (DSM-I) mood disorders have been conceived as either 
“organic” or “reactive,” (DSM-I) (American Psychiatric Association [APA], 1952). The 
second edition of the manual (DSM-II) continues this basic distinction using the terms 
“psychotic” and “neurotic.” Mood disorders were understood as either a disease of the 
brain and organic, or neurotic and therefore a disease of the mind ((DSM-II) (American 
Psychiatric Association, 1968; Boland and Keller, 2002). Disorders of a neurotic or 
reactive variety could be cured once the cause was removed. Those of a psychotic or 
organic nature were viewed as having a less favorable outcome. Considered chronic, their 
Introduction 
 
7 
fate was institutionalization combined with somatic treatment. The third Edition (DSM-
III) (American Psychiatric Association, 1980) favored a descriptive approach, whereby 
individuals were diagnosed with a mood disorder based on whether or not they met clear 
diagnostic criteria, which was based on a constellation of symptoms and specific duration. 
The Fourth Edition (DSM-IV-TR) describes a Major Depressive Disorder (MDD) 
diagnosis based on the presence of a specified number of symptoms with a precise 
duration. Primarily symptoms of either depressed mood or loss of interest or pleasure are 
present. Additionally, the criteria of at least five items from the DSM-IV-TR (APA, 2000) 
list need to be present for a duration of two weeks and as such, represents a change from 
previous functioning. It includes depressive mood and loss of interest in most activities, 
appetite and sleep disturbance, feelings of worthlessness and guilt, suicidal thoughts and 
ideation (American Psychiatric Association, 2000). For DSM-V the criteria for diagnosis 
of these disorders remains the same as DSM-IV-TR (American Psychiatric Association, 
2000). The DSM-V proposes additional diagnostic categories such as mixed 
Anxiety/Depression and also integrates childhood and adolescent psychiatric disorders 
into relevant chapters (American Psychiatric Association, 2013). 
The World Health Organizations (WHO) International Classification for Diseases 
and Related Disorders (ICD-10) describes the criteria for a depressive episode, where at 
least four items, such as loss of interest in activities, lack of emotional reactions, sleep 
disturbance, loss of appetite, motor retardation, weight loss, loss of libido, and decreased 
energy are present for a duration of two weeks (World Health Organization WHO, 1993). 
The goal of treatment was symptom reduction or extinction if possible. However, 
treatment outcomes including continued relapse and recurrence posed challenges to 
developing adequate treatments. (Angst, 1986; Andrews et al., 2011). 
 
1.2.2 Managements 
Depression may disrupt work, family, and personal life. Many of these 
consequences, however, are avoidable. Depression is a treatable disease, yet many people 
who are depressed do not seek treatment. Depression is a disorder that can be reliably 
diagnosed and treated in primary care by general practitioners (The World Health Report, 
2001). Despite it being a common and debilitating mental disorder, depression is 
clinically under-recognized and undertreated.  30-50% of cases of depression are not 
detected in medical settings (Anderson et al., 2008). 
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Treatment often involves a combination of different therapies such as medication, 
psychological therapies, social support, and self-help techniques. An individual’s 
treatment will depend on the severity of their symptoms. And according to WHO Guide, 
preferable treatment options consist of basic psychosocial support combined with 
antidepressant medication or psychotherapy, such as cognitive behavior therapy, 
interpersonal psychotherapy or problem-solving treatment.  Antidepressant medications 
and brief, structured forms of psychotherapy are effective.  Antidepressants can be a very 
effective form of treatment for moderate-severe depression but are not the first line of 
treatment for cases of mild or sub-threshold depression (Andrews et al., 2011). 
 
1.3 Antidepressants 
Antidepressants are recommended by the National Institute for Health and Care 
Excellence (NICE) as a first-line treatment of severe depression and for the treatment of 
mild-to-moderate depression that persists after conservative measures such as cognitive 
therapy (NICE, 2009). 
The different types of antidepressants are generally categorized by which natural 
chemicals they affect in your brain to help change your mood. They can also be broken 
down into categories of older and newer drugs (Bartha, 1999; Linardatos et al., 2008; 
Canadian Mental Health Association, 2010)  
 Older 
Monoamine oxidase inhibitor (MAOIs) (the first antidepressants)  
Cyclics (or tricyclic antidepressants: TCAs) 
  
 Newer  
Selective Serotonin Reuptake Inhibitors (SSRIs)  
Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 
Norepinephrine and Dopamine Reuptake Inhibitors (NDRIs) 
 
Medications are often increased gradually to optimize their effects. The first weeks may 
be more about managing any side effects rather than real symptom relief, which can take 
a while to begin for some. (Bartha, 1999). 
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1.3.1 Monoamine oxidase inhibitors (MAOIs): MAOIs work through a chemical 
reaction with monoamine oxidase A and B, enzymes which oxidize speciﬁc monoamines. 
When an MAOI reacts with monoamine oxidase, the enzyme is permanently deactivated 
and cannot function until the protein is replaced by the body. MAOIs are no longer used 
as front-line treatment for depression (the most commonly still in use today are 
Isocarboxazid and Phenelzine) is due to the fact that MAO is responsible for breaking 
down other trace dietary amines, such as tyramine and tryptophan causing alarming issues 
such a major hypertensive crisis or serotonin syndrome which can be fatal leading to death 
attributed to dietary amine consumption. As a result of these dangers and the requirement 
of a speciﬁc, restrictive diet, MAOIs are currently only used for patients who do not 
respond to other types of antidepressants (Rang, 2003; Linardatos et al., 2008). 
 
1.3.2 Tricyclic antidepressants (TCA): TCAs are the oldest class of antidepressants and 
were used as ﬁrst-line treatment for depression since the 1950’s. They are characterized 
by three carbon rings in their molecular structure. Amitriptyline is the most commonly 
prescribed TCA and is the most effective for treating depression. TCAs act as ligands for 
the transporters and prevent them from bonding to anything else. They have a very high 
affinity for serotonin and norepinephrine but not dopamine. They also have a high affinity 
for H1 and H2 histamine receptors, and for the muscarinic acetylcholine receptor which 
results in TCAs also acting as effective antihistamines and anticholinergics. These 
affinities create undesirable side effects such as lethargy, ataxia, dry mouth, increased 
body temperature, tachycardia, and in severe cases delirium. These unpleasant and in 
some cases severe side effects are a reason TCAs have been supplanted by newer drugs 
for the treatment of depression. The primary reason TCAs are no longer used as ﬁrst-line 
treatment is due to their high potential toxicity and consequently their potential to cause 
a fatal overdose. They are rapidly absorbed into the bloodstream as onset of overdose 
symptoms occurs quickly. Death is most commonly caused by the cardiac effects of 
acetylcholine antagonism. TCAs have been attributed to as many as 33% of all fatal 
poisonings, and 95% of deaths related to antidepressants alone. These dangers are 
signiﬁcant and thus TCAs are only administered to patients who do not respond to other 
antidepressant medications. TCAs have been largely supplanted by SSRIs for ﬁrst line 
treatment (Rang, 2003). 
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1.3.3 Selective serotonin reuptake inhibitors (SSRIs): SSRIs (fluoxetine, fluvoxamine, 
sertraline, paroxetine, citalopram, escitalopram) are a newer class of antidepressants 
which are the most widely prescribed antidepressant. They are almost exclusively used 
as ﬁrst-line treatment for major depressive disorder. SSRIs’ mode of action is to inhibit 
the re-uptake of serotonin into the presynaptic cell by bonding to serotonin transporter. 
This is different from the TCA drugs because SSRIs have high bonding affinity only for 
serotonin transporter and very minimal affinity to other monoamine transporters. This 
means that SSRIs have much more limited side effects and do not have any of the 
anticholinergic or antihistamine effects that TCAs do (Anderson, 2000)  
SSRIs are therefore much less toxic than TCAs and are very difficult to achieve a 
dangerous reaction to an overdose. The most severe complication arising from overdose 
is serotonin syndrome, an excess of serotonin in the brain which can, in very severe cases, 
lead to seizures, coma, and death. SSRIs do have some minor side effects mostly related 
to depression itself. The most common reason for discontinuation due to side effects is 
sexual dysfunction. This is thought to be caused by SSRIs creating chemical imbalances 
in the brain in the dopamine pathways which directly inﬂuence sexual arousal and 
function. 
SSRIs were the ﬁrst type of psychoactive drug to be rationally designed; as 
opposed to the trial-and-error used up to that point. This involves creating a molecule that 
has speciﬁc binding properties based on hypothetic beneﬁts. In the case of SSRIs, the goal 
was to create a molecule that bonded to serotonin transporter. This is most commonly 
done using computer assisted tools and analysis (Rang, 2003). 
 
1.3.4 Serotonin and norepinephrine reuptake inhibitors (SNRIs): SNRIs 
(venlafaxine, milnacipram, duxoletine) are a more recent development than SSRIs, and 
are also very widely used. The most commonly prescribed is Venlafaxine and their 
metabolites. They have been shown to have slightly higher efficacy than SSRIs due to 
their dual mode of action, blocking both serotonin and norepinephrine transporter. SNRIs 
have the same sexual side eﬀects that SSRIs do, although with lower occurrence (Kajdasz 
et al., 2008). 
 
1.3.5 Norepinephrine and dopamine reuptake inhibitors (NDRIs): NDRIs act on 
norepinephrine and dopamine transporter and thus increases the amount of both 
neurotransmitters in the postsynaptic cell. This is the only class of non-serotonergic drug 
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commonly prescribed for depression. Bupropion, has been shown to be more effective 
than SSRIs on its own and is also used to augment the performance of an SSRI. It does 
not cause sexual dysfunction or weight gain and has only isolated side effects. This 
indicates that sexual dysfunction is a function exclusively of serotonin reuptake 
inhibition, as drugs which do not effect it does not have sexual side effects (Costa et al., 
2002). 
 
1.3.6 Noradrenergic and speciﬁc serotonergic antidepressants (NaSSA): This class of 
atypical antidepressants is solely composed of Mirtazapine. Its mode of action is 
completely different from the reuptake inhibitors and instead is a highly potent antagonist 
of H1, a histamine receptor, the serotonin receptors 5-HT2A, 5-HT2C, 5-HT3, and the 
alpha2-adrenergic receptor. It has no affinity for any neurotransmitter transporter. The 
antidepressant effect comes primarily from the antagonism of 5-HT2C which normally 
prevents dopamine from being released in the pleasure centers of the brain. 
Mirtazapine therefore has none of the negative side effects related to increased 
amounts of serotonin, dopamine, or norepinephrine, instead making the available amount 
more effective. 
It is sometimes used in addition to another antidepressant in order to alleviate their 
side effects and improve their antidepressant effect (Timmerman et al., 1998; Linardatos 
et al., 2008). 
 
1.4 Selective serotonin reuptake inhibitors (SSRIs) 
Dysfunction of serotonergic neurotransmission is considered as one of the major 
underlying cause of mood and other neuropsychiatric disorders (Souza et al., 2004).  
The antidepressants known as selective serotonin reuptake inhibitors (SSRIs) 
have become widely used to treat major depression and many other psychiatric disorders 
(Brunton and Parker, 2008). However, the efficacy of SSRIs in depression is no greater 
and their onset of action is no more rapid than that of the MAOIs or TCAs. In addition, 
they are not completely devoid of side effects but, SSRIs are used as a first-line treatment 
for depression, in part because of their relatively benign adverse effect profile and safety 
in overdose, especially compared with the older TCAs and MAOIs (Mourilhe and Stokes, 
1998; Chantal and Mike, 2007).  
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 SSRIs are believed to increase the extracellular level of the neurotransmitter 
serotonin by inhibiting its reuptake into the presynaptic cell, increasing the level of 
serotonin in the synaptic cleft available to bind to the postsynaptic receptor. 
In the brain, messages are passed from a nerve cell to another via a chemical 
synapse, a small gap between the cells. The presynaptic cell that sends the information 
releases neurotransmitters including serotonin into that gap. The neurotransmitters are 
then recognized by receptors on the surface of the recipient postsynaptic cell, which upon 
this stimulation, in turn, relays the signal. About 10% of the neurotransmitters are lost in 
this process; the other 90% are released from the receptors and taken up again by 
monoamine transporters into the sending presynaptic cell, a process called reuptake. 
SSRIs inhibit the reuptake of serotonin. As a result, the serotonin stays in the synaptic 
gap longer than it normally would, and may repeatedly stimulate the receptors of the 
recipient cell as shown in figure (1.1).  
In the short run, this leads to an increase in signaling across synapses in which 
serotonin serves as the primary neurotransmitter. On chronic dosing, the increased 
occupancy of pre-synaptic serotonin receptors signals the pre-synaptic neuron to 
synthesize and release less serotonin. Serotonin levels within the synapse drop, then rise 
again, ultimately leading to downregulation of post-synaptic serotonin receptors 
(Goodman and Gilman's pharmacological basis of therapeutics, 2001). 
They have varying degrees of selectivity for the other monoamine transporters, 
with pure SSRIs having only weak affinity for the noradrenaline and dopamine 
transporter (Preskorn et al., 2004) . These SSRIs represent a chemically diverse class of 
agents include: Most common: Fluoxetine, Sertaline, Paroxetine, Fluvoxamine, 
Citalopram, Escitalopram (Waldinger and Oliver, 2004) and most recently Vilazodone 
(Khan et al., 2011; Mathews et al., 2015). Others: dapoxetine, indalpine (discontinued), 
zimelidine (discontinued), cericlamine (reached phase III; discontinued in 1999), 
Panuramine.  
The newer antidepressants SSRIs are easy to prescribe and take (usually as a 
single dose in the morning or at bedtime); cause fewer side effects than some of the older 
antidepressants, such as the Tricyclic antidepressants (TCAs), and do not require dietary 
restrictions, such as those required for the mono amino oxidase inhibitors (MAOIs) 
(Brunton and Parker, 2008). 
The antidepressants known as selective serotonin reuptake inhibitors (SSRIs) 
have become widely used to treat major depression and many other psychiatric disorders 
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including obsessive compulsive disorder (OCD), panic disorder, generalized anxiety 
disorder, social anxiety disorder, post-traumatic stress disorder, eating disorders (e.g., 
bulimia nervosa), and premenstrual dysphoric disorder (Brunton and Parker, 2008). 
 
 
Figure 1.1: Mechanism of action of SSRIs (inhibition of serotonin reuptake to the 
presynaptic cell). Kate Donavan (2013). Psychopathology sum-up: Types of antidepressants. 
ASHILEY F MILLER. The ORBIT; https://the-orbit.net/ashleyfmiller/tag/ssris/ 
 
 
1.5 Fluoxetine  
1.5.1 Fluoxetine discovery 
 In the early twentieth century, depression was identified as ‘melancholia’, and it 
was mainly treated with barbiturates and amphetamines. It was not until the 1950s when 
the first two compounds with more potent antidepressant activity were developed, named 
antidepressants. They are iproniazid, the first monoamine oxidase inhibitor (MAOI), and 
imipramine, the first tricyclic antidepressant (TCA). The emergence of these two 
antidepressant drugs revolutionized psychiatry and the pharmaceutical industry. Indeed, 
the discovery of these new treatments for major depressive disorder (MDD) led to the 
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development of new theories about the pathophysiology of the mood disorder. Ten years 
later, other TCAs were synthesized (amitriptyline, nortriptyline, desipramine and 
clomipramine), some of which are still in use to treat depression and other pathologies. 
In 1965, the monoaminergic hypothesis of depression was postulated (Schildkraut, 1965), 
which implicated noradrenergic and serotoninergic dysfunction in depression. As a result, 
some pharmaceutical companies focused their research on the search for new drugs that 
specifically target 5-HT reuptake. Thus, an SSRI was developed by Eli Lilly and 
Company, the compound numbered LY110140 (fluoxetine) was initially approved as a 
drug for medical use in Belgium in 1986, although it was not approved by the FDA until 
1987, under the name of Prozac®. Numerous clinical trials reported that the 
antidepressant efficacy of fluoxetine was as potent as the TCA but with fewer side effects 
due to its selective profile (Bremner, 1984; Perez-Caballero et al., 2014). 
Fluoxetine is one of the class termed SSRIs which is a 5-hydroxy tryptamine 
(5HT) or serotonin agonists, acting to increase the amount of 5-HT within the synaptic 
cleft. (Breggin and Breggin, 1995).  
Fluoxetine is currently one of the most commonly prescribed antidepressant 
medications for children and adolescents, and its use appears to be increasing 
internationally (Zito et al., 2002; Murray et al., 2004; Aras et al., 2006). It is approved 
for treatment of depression and obsessive compulsive disorders of both child and 
adolescents in 2003. Despite this, there has been ongoing speculation regarding safety 
and efficacy in this younger populations (Garland, 2004; Cohen, 2007). 
Whittington et al. (2004) said that in view of the evidence for efficacy and no 
increased risk of serious adverse effects, fluoxetine seems to have a favorable risk–benefit 
profile for treatment of children and young people than other SSRIs.  
 
1.5.2 Chemical structure and chemical formula 
Fluoxetine hydrochloride is a psychotropic drug for oral administration. It is 
designated (±)–N–methyl–3–phenyl–3–[(α,α,α–trifluoro–ptolyl)oxy] propylamine 
hydrochloride and has the empirical formula of C17H18F3NO•HCl.  Its molecular weight 
is 345, and its structural formula (Brunton and Parker, 2008) is shown in figure (1.2). 
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            Figure 1.2: Chemical structure of fluoxetine hydrochloride  
 
1.5.3 Biochemistry 
Fluoxetine (3-(p-trifluoromethylphenoxy)-Nmethyl-3-phenylpropylamine) is an SSRI 
that exists as a racemic molecule, with the R (-) and S (+) enantiomers showing equal 
potency as inhibitors of 5-hydroxytryptamine (5-HT) uptake in both in vitro and in vivo 
uptake assays (Robertson et al.,1988). Moreover, fluoxetine is metabolized by N-
demethylation to norfluoxetine, which is an active metabolite which also acts as an SSRI 
but with a stronger potency than the parental compound (Hyttel et al.,1994). This active 
metabolite also exists in an enantiomeric form, but unlike fluoxetine enantiomers, S-
norfluoxetine is over 20-fold more potent in inhibiting 5-HT uptake than the (R)-
enantiomer (Wong et al., 1993; Perez-Caballero et al., 2014). 
 
1.5.4 Mechanism of action 
Fluoxetine is a prototype of SSRIs which act on the neurotransmitter serotonin. 
Serotonin is normally released into the synapse between the nerve cells and is either 
destroyed or reabsorbed back into the cell that released it.  SSRIs block this reuptake 
causing more serotonin to accumulate in the synapse, thus the concentration of serotonin 
in the cleft is heightened and neuronal activity is enhanced (Brunton and Parker, 2008), 
as can be seen in figure (1.3). Specific Transporters are involved in the neuronal reuptake 
of neurotransmitters and the regulation of their levels in the synaptic cleft as seen in figure 
(1.1), the serotonin transporter (SERT) is a glycoprotein with 12 trans membrane regions 
embedded in the axon terminal and cell body membranes of serotonergic neurons. These 
SERT plays a role in the reuptake and clearance of serotonin in the brain (Joseph et al., 
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2003). 
Membrane transporters are the targets of many drugs, thus SERT is the specific 
target of the SSRIs (e.g. fluoxetine and paroxetine) and one of several targets of TCAs 
antidepressants (e.g. amitriptyline), SSRIs allosterically inhibit the SERT transporter by 
binding the receptor at a site other than active binding site for serotonin. At therapeutic 
doses, about 80% of the activity of the transporter is inhibited (De Battista, 2009). 
 
 
    Figure 1.3: Mechanism of action of Fluoxetine.  
      Drug time (2017). Antidepressants. Fluoxetine. Sertraline. Paroxetine. Citalopram. Fluvoxamine.  
       https://www.drugtimes.org/antidepressants/fluoxetine-sertraline-paroxetine-citalopram-fluvoxamine.html#          
 
A new theory of the mechanism of action of fluoxetine has been postulated using 
a unique and relatively simple cell–based fluorescent assay. Berkeley (2011) have 
identified a means by which fluoxetine, suppresses the activity of the TREK1 potassium 
channel, which is accompanied by an unbinding of the protein's C–terminal domain from 
the membrane. This is the first observation of the mechanism by which TREK1 might be 
regulated by antidepressant drugs. TREK1 activity has been implicated in mood 
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regulation and could be an important target for fluoxetine and other antidepressant 
(Berkeley, 2011).  
 The way through which fluoxetine produced his action in the short and long term 
therapy (acute and chronic administration) have been discussed in many studies and there 
is a lot of controversy and there is still a need for more studies to get rid of ambiguity. 
 
Acute fluoxetine administration enhances extracellular 5-HT levels, in 
conjunction with a decrease in both the synthesis and turnover of 5-HT in the raphe nuclei 
(Bel and Artigas, 1996) and unlike other SSRI, fluoxetine increases dopamine and 
noradrenaline concentrations in the prefrontal cortex (Bymaster et al., 2002). The increase 
in 5-HT has been reported in the raphe nuclei and other brain regions, such as the frontal 
cortex, striatum, diencephalon or hippocampus (Bel and Artigas, 1996). This large 
increase in 5-HT that have been noted in the raphe nuclei, may negatively control cell 
firing and 5-HT release into terminal areas including the frontal cortex by the activation 
of somatodendritic 5-HT1A auto receptors and this may explain why the 5-HT increase 
in the frontal cortex by acute fluoxetine treatment is smaller than that in the raphe nuclei 
(Perez-Caballero et al., 2014). 
 
 
     Figure 1.4: Affinity of fluoxetine to different receptors 
     Stahl S M. Essential psychopharmacology. Neurosientific basis and practical applications. 4th ed. New York. 
       Cambrigde University Press,2013     
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It has been demonstrated that fluoxetine acts as a 5-HT2C receptor antagonist due 
to its relative affinity for this receptor as can be notice in figure (1.4) (This receptor 
subtype exerts inhibitory control on both ventral tegmental dopaminergic and locus 
coeruleus noradrenergic neurons) (Palvimaki et al., 1996), this is because unlike other 
SSRI, fluoxetine increases dopamine and noradrenaline concentrations in the prefrontal 
cortex, as measured by micro dialysis. 
It was suggested that this effect might reflect an interaction with the 5-HT2C 
receptor, and indeed, it has been demonstrated that fluoxetine acts as a 5-HT2C receptor 
antagonist. Thus, the ability of fluoxetine to block 5-HT2C receptor is the most plausible 
explanation for the cortical increase in catechol amines (Bymaster et al., 2002). 
 
Chronic fluoxetine administration induces a persistent increase in 5-HT levels 
in several brain regions, such as the diencephalon, striatum, hippocampus and frontal 
cortex, without altering those of cortical noradrenaline and dopamine. Initially, the simple 
accumulation of higher plasma levels result from chronic fluoxetine administration and 
its metabolite, caused the sustained 5-HT enhancement due to their long half-life. 
However, this would appear to be unlikely given that residual drug was still present and 
the enhanced extracellular 5-HT levels were promptly restored after acute treatment. 
Thus, several adaptive mechanisms associated with 5-HT neurotransmission have been 
proposed to explain the persistent changes of extracellular 5-HT after chronic fluoxetine 
treatment (Perez-Caballero et al., 2014). 
Hensler in his study in 2002 has been suggested that the desensitization of 5-
HT1A auto receptors may be due to alterations in their signal transduction, which 
involves G-protein. Other studies suggested that fluoxetine negatively regulate the release 
of 5-HT in terminal areas by desensitization of raphe somatodendritic 5-HT1A auto 
receptors (Sharp et al., 1989; Le Poul et al., 2000). Furthermore, electrophysiology and 
micro dialysis assays demonstrated that the persistent increase in extracellular 5-HT 
induced by chronic fluoxetine administration might be explained by the desensitization 
of terminal 5-HT1B auto receptors, whose activation exerts a feedback inhibition of 5-
HT release (Blier et al., 1988; Newman et al., 2004). 
There is some controversy regarding the role of 5-HT transporters in the adaptive 
changes following chronic fluoxetine administration (Le Poul et al., 2000). For example, 
Gobbi et al. in his study in 1997 said that long-term treatment with fluoxetine does not 
lead to robust alterations in 5-HT receptors (5-HT2 or 5-HT3). While Vidal et al. (2009) 
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proved that long-term treatment with fluoxetine produced functional desensitization 
involving the adenylate cyclase system and downregulates the density of 5-HT4 
receptors.  
Recently, Covington et al. (2011) in his study has been described that fluoxetine 
induces epigenetic modifications that may contribute to the therapeutic action of this 
antidepressant. In this way, modifications in levels of acetylated histones as well as 
altering the expression of some microRNAs (miRNAs) in several brain areas have been 
related to depressive pathology. Thus, chronic fluoxetine treatment is able to reverse some 
of these changes and interestingly, these miRNAs alterations are also reversed by the non-
pharmacological electroconvulsive therapy (O’Connor et al., 2013). Even more, other 
new mechanisms have been proposed for this antidepressant, for example a recent study 
involves a chromatin remodeling factor in the antidepressant effect of fluoxetine (Oh et 
al., 2013; Perez-Caballero et al., 2014).  
1.5.5 Pharmacokinetics 
Fluoxetine is well absorbed from the gastrointestinal tract, 80–95% absorbed 
following oral administration. Peak plasma concentrations of fluoxetine from 15–55 ng 
/ml were observed after 6 to 8 hours following a single oral 40 mg dose. Harvey and 
Preskorn (2001) reported pharmacokinetics parameters of fluoxetine administration of 20 
mg orally. 
Fluoxetine may be administered with or without food. The systemic 
bioavailability of fluoxetine does not appear to be affected by food, although it may 
inconsequentially delay its absorption (Thrasher, 2010).  Maximal cerebral effect reported 
between 8–10 hours. Fluoxetine has a high lipophilic profile, and it appears to bind 
strongly to plasma protein, which means it is widely distributed. Thus, high 
concentrations of fluoxetine and its metabolite norfluoxetine reach the brain (Perez-
Caballero et al., 2014). It is highly bound to plasma proteins, mostly albumin. Altamura 
et al., (1994) found in experimental with animals, that fluoxetine is widely distributed in 
body tissues with the highest concentration in lung and liver (NTP–CERHR, 2004).  
 Fluoxetine excreted through urine and feces (Siddiqui, 2011), and it undergoes 
hepatic metabolism and CYP2D6 isoenzyme convert fluoxetine to pharmacologically 
active metabolite norfluoxetine by demethylation, which is also serotonin reuptake 
blocker (Wong et al., 2005).  Fluoxetine has along t1/2 of 1–3 days after a single dose or 
2–7 days after repeated administration, while norfluoxetine has a t1/2 of approximately 7–
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15 days. Thus, fluoxetine can be a good choice for a patient who frequently misses 
medication doses, but, may be problematic for patient with comorbid medical conditions 
and on multiple medications (Hansaen, 2004). 
 The elimination half–life of norfluoxetine is about three times longer than 
fluoxetine as a result fluoxetine has to be discontinued 4 weeks or longer before MAOI 
can be administered to mitigate the risk of serotonin syndrome (De Battista, 2009).  
Because of its long half-life, some doctors switch patients from short agents to fluoxetine 
to create a more gradual withdrawal experience, although success rates utilizing this 
technique are unknown (Haddad and Anderson, 2007). Also fluoxetine may be a better 
agent to use in patients with poor compliance as a long half-life (Adams, 2001). 
Fluoxetine is converted metabolically to norfluoxetine and other metabolites 
(Bergstrom et al., 1988), and CYP isozymes play an essential role in the clearance of both 
fluoxetine and norfluoxetine. Furthermore, both compounds inhibited CYP2D6 isozymes 
in vitro and in vivo. The (S)-enantiomers of fluoxetine and norfluoxetine are six times 
more potent than both (R)-enantiomers, and therefore, both compounds can compete with 
other drugs for their metabolism by CYP2D6, which would explain their potential to 
participate in pharmacokinetic drug interactions (Stevens et al., 1993; Perez-Caballero et 
al., 2014).  
 
1.5.6 Determination of fluoxetine concentrations in serum by high performance 
liquid chromatography HPLC 
HPLC is currently the most widely used method of quantitative analysis in the 
pharmaceutical industry and in pharmaceutical analysis laboratories (Reddy, 2007). 
Chromatography is an analytical technique based on the separation of molecules due to 
differences in their structure and/or composition (Simpson, 1976; Pungor, 1995; Moffat 
et al., 2004). 
Clinical analysis of fluoxetine is useful for monitoring patients' blood levels, 
especially during co administration with other drugs because of the long half-life of 
fluoxetine and its metabolite which may increases risk of drug-drug interactions. The long 
half-lives of fluoxetine (2-3 days) and norfluoxetine (7-9 days) can, however, lead to 
pharmacological interactions with other drugs administered to the patients because 
plasma levels can remain high even weeks after discontinuation of the therapy (Benfield 
et al., 1986; Risley et al., 1990). Reliable and very sensitive analytical methods are needed 
for this purpose, because plasma concentrations are usually very low (Raggi et al., 1999; 
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Reddy et al., 2007).  
Several methods have been published for the determination of fluoxetine in 
human plasma; most of these are chromatographic methods with UV or fluorescence 
detection including HPLC assays with liquid-liquid extraction or, more recently, solid-
phase extraction (SPE) for the pretreatment of biological samples (Risley et al., 1990; 
Raggi et al., 1999; Reddy et al., 2007). 
In 1999, Raggi and his group developed an HPLC method with fluorescence 
detection for the determination of fluoxetine and its main metabolite norfluoxetine in 
human plasma. It seems to be a useful tool for clinical monitoring, because it requires 
small plasma samples and is highly sensitive and highly selective. It is HPLC method 
with fluorimetric detection for the determination of fluoxetine and norfluoxetine in 
human plasma, using a 15 mm x 6 mm i.d., 5 gm ResElut C8 reversed phase column with 
a 50:50 (v/v) mixture of pH 1.9 tetra methyl ammonium perchlorate and acetonitrile, flow 
rate 1 mL min -1, as the mobile phase, with fluorimetric detection (230nm, 290 nm). 
Many researchers try to developed methods simple, fast, more sensitives, low cost 
and can be used to assess fluoxetine levels in human plasma in pharmacokinetic studies, 
in clinical monitoring as well as and in overdose cases such as (Gleiter et al., 1994; Eap 
et al., 1996; Gevirtz et al., 1999; Kristoffersen, et al., 1999; Frahnert et al., 2003; 
Thompson et al., 2004; Vlase et al., 2005; Unceta et al., 2007). Also Tuchilă et al. (2015) 
which develop HPLC method with fluorescence detection for the quantification of 
fluoxetine in human plasma. The method was fully validated and all validation parameters 
are within acceptable limits according to bioanalytical method validation guidelines: the 
method is linear, accurate and precise on the domain of concentration 0.1-1.0 μg/mL, 
appropriate to therapeutic plasmatic concentration of fluoxetine (0.05-0.48 μg/mL). This 
makes the method useful for monitoring the patients under treatment. The method is 
simple, fast (3 minute time of analysis) and the applicability was checked using plasma 
samples spiked with fluoxetine, extracted using a solid phase extraction technique. It can 
be considered that the method developed can be used in pharmacokinetics studies and in 
therapeutic drug monitoring for patients under treatment with fluoxetine. 
 
1.5.7 Pharmacodynamics profile 
1.5.7.1 Inhibition of monoamine uptake: In vitro uptake studies confirmed the strong 
capacity of fluoxetine to inhibit 5-HT uptake, greater than its affinity for other 
monoamines (Owens et al., 1997). In vivo uptake studies into rat brain synaptosomes also 
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demonstrated that acute fluoxetine administration produced a significant reduction in 5-
HT uptake (57%) compared with controls but not that of noradrenaline or dopamine 
(Wong et al., 1975). The brain regions with the most pronounced reduction in 5-HT 
uptake were the cerebral cortex and brainstem, whereas fluoxetine administration failed 
to inhibit uptake into synaptosomes in cerebellum. In vivo studies were carried out to 
evaluate the duration of the effects of fluoxetine on 5-HT uptake inhibition, 
demonstrating that maximal inhibition occurred after 4 h and that uptake was restored to 
normal levels 48 h after administration of fluoxetine. However, throughout this time 
course, the uptake of noradrenaline was unaltered by fluoxetine administration (Wong et 
al., 1975). The effect of fluoxetine was long lasting compared with the time course of 
other antidepressants, which could reflect the extremely long half-life of both fluoxetine 
and its active metabolite, norfluoxetine. Overall, these data suggest that the metabolite 
plays an important role for the therapeutic effect of fluoxetine (Perez-Caballero et al., 
2014). 
 
1.5.7.2 Transporters and receptors binding: Several competitive binding assays with 
monoamine transporters showed that fluoxetine presents a strong affinity for the 5-HT 
transporter and only a weak or no affinity for the noradrenaline and dopamine 
transporters, respectively (Owens et al., 1997; Bymaster et al., 2002; Wood et al., 1986). 
Therefore, these data confirmed the 5-HT selective profile of this compound as in figure 
(1.4). Furthermore, fluoxetine showed relatively weak affinity for 5-HT receptors, as 
measured by radio ligand binding to the 5-HT1 (A, B, C and D), 5-HT2 and 5-HT3 
subtypes, although the strongest affinity was found for 5-HT2 receptors (Hyttel, 1994; 
Owens et al., 1997; Koch et al., 2002). Additional studies were carried out to evaluate the 
interaction of fluoxetine with other neurotransmitters receptors, with radio ligand-binding 
assays showing that fluoxetine has low affinity for D1 and D2 dopaminergic, alfa and 
beta-adrenergic, muscarinic cholinergic and histamine H1 receptors (Hyttel, 1994; Perez-
Caballero et al., 2014).  
1.5.8 Indications and usage 
Although fluoxetine and SSRIs can immediately change extracellular levels of 
serotonin in the central nervous system. Therapeutic effects of these drugs usually require 
weeks of treatments (Stahl, 1998). In this way, to accelerate the clinical action of 
fluoxetine and even to improve its antidepressant efficacy, preclinical data suggest that 
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can be used strategies based on fluoxetine treatment in combination with antagonists of 
the 5-HT desensitized receptors after long-term treatment (Artigas, 1993; Zhang et al., 
2000; Vidal et al., 2009).  
The pharmacologic action and the clinical indications of fluoxetine has been 
reviewed in many studies (Wong et al., 1995; Stokes and Holtz, 1997; Grimsley and Jann, 
2001). 
  
 Depression  
          Fluoxetine was approved by FDA in December 1987, for the treatment of 
depression (ICSI, 2004).   Fluoxetine has been specifically approved for use in geriatric 
depression in October 1999, but in February 2001, the FDA approved fluoxetine for 
maintenance treatment of depression. In January 2003 FDA approved fluoxetine for 
pediatric use in depression (Cohen, 2002). 
Fluoxetine was used to treat depression in a dose equals to 20 mg/day in the morning 
in adults, may be increased to a maximum of 80 mg per day. Generally, fluoxetine may not 
the drug of first choice for patients in whom a rapid antidepressant effect is important or for 
those who are agitated, because of slow onset of action, but it may have advantages over other 
SSRIs in patients who are poorly complaint with treatment and those who have previously 
had troublesome discontinuation symptoms (Hansaen, 2004).  
Earlier investigations into the efficacy of fluoxetine for the treatment of pediatric 
and adolescent depression showed limited success (Rowse, 2010).  They showed similar 
rates of improvement across the treatment and placebo groups (Andersen and Navalta, 
2004). In contrast, some studies (Whittington et al., 2004; March et al., 2004) concluded 
that fluoxetine has a favorable risk–benefit profile. 
Many studies showed that fluoxetine have has similar efficacy in treatment of 
depression with paroxetine, citalopram and sertaline, with comparable side effects 
including nausea and vomiting (Adams, 2001). 
Fluoxetine is the only SSRIs approved for the treatment of depression in children 
8–18 years (ICSI, 2004; Kaiser, 2005; American Psychiatric Association, 2000) and the 
recommended dose was: 10–20 mg/day; lower–weight children can be started at 10 
mg/day. 
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 Major anxiety disorders  
Fluoxetine was used to treat Major anxiety disorders including post-traumatic 
stress disorder (PTSD), obsessive–compulsive disorder (OCD), social anxiety disorder, 
generalized anxiety disorder (GAD), and panic disorder and get FDA–approval in July 
2002 (Cohen, 2002). 
Fluoxetine was approved by FDA for the treatment of OCD in adults in 
Febuary1994 (Cohen, 2002). SSRIs are considered first–line treatment for PTSD and can 
benefit a number of symptoms including anxious thoughts and hyper vigilance. The 
recommended dose in PTSD is 20–40 mg/day (De Battista, 2009). 
Fluoxetine is used to treat OCD in a dose of 20–60 mg/day (adolescents and higher 
weight children, in7–17 years: 10 mg/day; may increase to 20 mg/day) (Bandelow et al., 
2008). 
 
 Premenstrual dysphoric disorder (PMDD) 
Fluoxetine received approval for treatment of PMDD in July 2000 (Cohen, 2002).  
Approximately 5% of women in the child–bearing years will have prominent mood and 
physical symptoms during the late luteal phase of almost every cycle. The SSRIs are 
known to be beneficial to many women with PMDD, and fluoxetine and sertraline have 
been approved for this indication (De Battista, 2009). Fluoxetine used to treat PMDD in 
a dose of 20 mg/day continuously, or 20 mg/day starting 14 days prior to menstruation 
and through first full day of menses (repeat with each cycle). 
The mechanism of action of fluoxetine in PMDD is unknown, but is presumed to 
be linked to its inhibition of CNS neuronal uptake of serotonin. Studies at clinically 
relevant doses in humans have demonstrated that fluoxetine blocks the uptake of 
serotonin into human platelets. Studies in animals also suggest that fluoxetine is a much 
more potent uptake inhibitor of serotonin than of norepinephrine (Medication Guide 
FDA, 2009). 
 
 Eating disorders 
In November 1996, the FDA granted fluoxetine approval for the treatment of 
bulimia nervosa in adults, it was the first drug to be approved for this condition, the dose 
recommended in eating disorders was; 60 mg/day (Cohen, 2002). Bulimia nervosa and 
anorexia nervosa are potentially devastating disorders. Anorexia is often chronic and may 
be fatal in 10% or more cases (Potter and Hollister, 2007). 
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 Premature ejaculation 
Antidepressants are commonly associated with inducing sexual adverse effects, 
some of these effects may prove useful for some sexual disorders. For example, SSRIs 
are known to delay orgasm in some patients, for this reason, it is sometimes used to treat 
premature ejaculation (De Battista, 2009). 
 
1.5.9 Adverse reactions 
Although the selective serotonin reuptake inhibitors (SSRIs) were used as a first 
line treatment for depression, they were not devoid of side effects. Most short-term 
treatment-related side effects of SSRIs are transient and disappear after a few days or 
weeks. However, following long-term treatment with the SSRIs some adverse events may 
occur. They are often difficult to recognize since they often resemble residual symptoms 
of the depression (Moret and Isaac, 2007). The most troubling adverse events seen during 
long-term SSRI therapy are Sexual dysfunction, weight gain and sleep disturbance 
(Ferguson, 2001; Moret and Isaac, 2007). 
Since, SSRIs apparent pharmacological activity is the inhibition of the reuptake 
of serotonin. Most of side effects result from an over-stimulation of various serotonin 
receptors in both the brain and the periphery (Lieberman, 2003). The most common side 
effects associated with SSRIs such as nausea and headache, nervousness, insomnia and 
sexual dysfunction (Kelsey, 2001), all this symptom are related to the stimulation of 5-
HT2 and 5-HT3 receptors.  
Many of the side effects of SSRIs are transient and subside over time, and can be 
minimized by having patients take the drug with meals and starting treatment with low 
doses followed by a slow titration to recommended doses (Kelsey, 2001). 
Fluoxetine adverse effect like other SSRIs is mostly dose dependent, appear in up 
to 75% of patients on normal doses (Kauffman, 2009). It appears similar in children to 
those in adults, consisting most commonly in headache, nausea, diarrhea, insomnia, 
nervousness, anxiety and somnolence (Lilly Sarafem Labeling, 2002; Lilly Prozac 
labeling, 2003).  
 
 
 
 
Introduction 
 
26 
1.5.9.1 General adverse reactions 
 Gastrointestinal adverse effects 
Nausea (occur in 21% as recorded incidence in many studies), anorexia (9%), 
diarrhea, dry mouth, insomnia (15% and it sufficient to result in stopping the medication), 
dyspepsia (6%), stomatitis and upper gastrointestinal bleeding (reviewed suggestion 
decreased platelets aggregation in response to serotonin reuptake inhibition (NTP–
CERHR, 2004; ICSI, 2004).  
Jing Zhao (2010) found that fluoxetine caused nausea more than paroxetine, but 
less than sertaline and venflaxine. Also he found that diarrhea incidence was higher with 
fluoxetine, rather than paroxetine and venflaxine. 
 
 Nervous system adverse effects 
Headache, nervousness, insomnia, drowsiness, tremor, akathisia, fatigue, sleep 
abnormalities, dyskinesia, worsening of Parkinson disease, and cognitive dysfunction, 
extrapyramidal symptoms (EPS). All are adverse effects have been reported in FDA 
patient information sheet (2006). 
A variety of EPS have been reported to be associated with the SSRIs, ranging 
from tremor to dystonic reactions (Goldberg, 1998). Meltzer et al. (1989) reported a 
severe dystonic reaction in a 25–year old man on the fourth day of treatment with 30mg 
of fluoxetine twice daily. While Coulter and Pillans (1995), reported on the prevalence of 
EPS. There are 15 reports of EPS among 5555 patients receiving fluoxetine. 
Akathisia has been reported to occur in the first week of treatment with SSRIs and 
may occur with the first dose. Although akathisia has been reported in association with 
fluoxetine and sertraline, no cases have been reported with paroxetine (Goldberg, 1998). 
Lipinski et al. (1989) reported their estimation of incidence between 10% and 
25%. While Hamelton and Opler (1992) suggested that the mechanism of fluoxetine 
induced akathisia would be via serotonin–induced inhibition of the dopaminergic 
neurons.  
Jing Zhao (2010) found that fluoxetine caused headache and insomnia more than 
venflaxine, but less than paroxetine and sertraline.  
 
 Psychiatric adverse effects 
It has been reported suicidal ideation, mania, hypomania, agitation and 
depersonalization syndrome. In May 1990, the U.S. FDA required the manufacturer of 
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prozac, Eli Lilly and Company, to add "suicidal ideation "and "violent behaviors" to the 
post introduction reports sections of its label (Breggin, 2003). 
Mania and psychosis is the extreme end of a stimulant continuum that often begins 
with lesser degrees of insomnia, nervousness, anxiety, hyperactivity and then progress 
toward more severe agitation, aggression, and varying degrees of mania (Breggin, 1992).  
Mania has been reported with fluoxetine, but occurs with low incidence (about 1%) and 
less than TCA (Goldstein and Goodnick, 1998). 
 
 Genitourinary adverse effects  
Sexual dysfunction includes male and female anorgasmia, decreased libido, 
ejaculatory dysfunction and impotence. Increasing serotonergic tone at the level of the 
spinal cord and above is associated with diminished sexual function and interest. As a 
result, at least 30–40% of patients treated with SSRIs report loss of libido and delayed 
orgasm. The sexual effects often persist as long as the patient remains on the 
antidepressant but may diminish with time (De Battista, 2009). 
In experimental animals, altered estrous behavior, altered sexual receptivity and 
reduced sexual motivation were observed (NTP–CERHR, 2004). 
 
 Hematologic adverse effects 
Fluoxetine interfere with platelets function may cause petechiae, increased 
bleeding time and gastrointestinal hemorrhage (FDA Guide, 2009). More than 99% of 
whole body serotonin is stored in platelet and under normal circumstances platelets 
release serotonin at the site of vascular tears, leading to platelets aggregation and 
vasodilatation (allowing for clotting without thrombosis). Since fluoxetine as SSRIs 
block serotonin uptake into platelets, it may be expected to potentially impair aggregation 
and increase bleeding time (Celada et al., 1992). Aranth and Lindberg (1992) reported a 
case of a 40-year-old woman receiving 60 mg/d of fluoxetine who developed heavy 
menstrual flow, spontaneous ecchymosis, and splenomegaly, which led to discontinuation 
of fluoxetine. 
The ecchymosis faded and the spleen size decreased about 4 days after 
discontinuation fluoxetine treatment. Fisher et al. (1995) have reported on the incidence 
of adverse effects in patients receiving either sertraline or fluoxetine. Four patients 
reported bleeding as an adverse effect from a total 2786 patients. 
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 Endocrine adverse effects 
Fluoxetine causes syndrome of inappropriate antidiuretic hormone (SIADH) 
particularly in elderly patients (Medication Guide, 2009). The SIADH is characterized by 
a reduced ability to excrete water, resulting in extra-cellular dilution with resulting 
hyponatremia. 
Cases of SIADH associated with SSRIs have been described in conjunction with 
fluoxetine, paroxetine, or sertraline treatment. It is not known how the SSRIs induce 
SIADH. It has been suggested that the SSRIs cause the release of ADH. Another possible 
explanation is that the SSRIs increase renal responsiveness to ADH (Goldberg, 1998). 
 
 Other adverse effects 
         Fluoxetine does not cause weight gain that may occur with TCA 
(De Battista, 2009). Fluoxetine is more likely to produce appetite suppression and weight 
loss is reviewed by Goldstein and Goodnick (1998) leading to off label use of this 
medication in obesity, which also have been reviewed by Stokes and Holtz (1997). 
Weight loss due to the anorexic effects of fluoxetine, have been demonstrated in a study 
of 20 non depressed obese women receiving 60 mg fluoxetine a day, indicated that 
fluoxetine increased resting energy expenditure and basal body temperature which can 
limit food consumption (Lilly Prozac Labeling, 2003; Medication Guide, 2009).  Rash 
(4%), pruritus (2%) and other allergic reaction have been reported with fluoxetine (Lilly 
Annual Report 2001; Clinical pharmacology and biopharmaceutics, 2002). 
 
1.5.9.2 Oral adverse reactions 
The oral side effects which have been reported may include xerostomia (affecting 
approximately 18% of patients), dysgeusia (altered taste sensations), stomatitis and 
glossitis. 
Fluoxetine and SSRIs produce no significant changes in salivation (Hunter and 
Wilson, 1995a) but dry mouth may still be seen (Ellingrod and Perry, 1994; Ravindran et 
al., 1997; Trindade et al., 1998). Patients receiving fluoxetine may develop a movement 
disorder that includes clenching, grinding of the teeth (bruxism) or both, further 
worsening the periodontal condition. This may occur, because these medication increases 
extra pyramidal levels of serotonin, thereby inhibiting dopaminergic pathways that 
control movements (Friedlander, 2001; Guggenhiemer, 2003). 
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1.6 Xerostomia  
Xerostomia is defined as a subjective complaint of dry mouth that may result from 
a decrease in the production of saliva (Sreebny, 1989; Navazesh et al., 1992; Thomson et 
al., 2001; Guggenheimer et al., 2003). Studies have found the condition in17–29% of 
sampled   populations based on self–reports or measurements of salivary flow rates 
(Sreebny and Valdini, 1987; Nederfors et al., 1997).  Complaints of dry mouth generally 
are more prevalent in women (Neville et al., 2002; Guggenhiemer, 2003).  
Xerostomia generally accompanied by salivary gland hypo function and adverse 
reduction in the secretion of unstimulated whole saliva (Sreebny, 1989), but it is not 
necessarily reflected in the actually measured flow rate (Nederfors et al., 1997).   
A visual analogue scale (VAS) can be used to assess the severity at the initial visit 
and to evaluate the patient’s response to the recommended therapy at subsequent visits. 
VAS is commonly used in the assessment of pain, but also can be used to assess salivary-
related complaints. Dentists or designated staff members ask patients a series of questions 
and instruct them to mark their responses to each question by placing vertical lines on a 
100-millimeter horizontal scale. The scale is labeled at both ends. One end represents the 
maximum intensity or frequency of the presenting condition, and the other end represents 
the absence of the condition. For example, if a patient is asked to rate dryness of the 
mouth, the scale is labeled “not dry at all” at one end and “very dry” at the other end. The 
practitioner then compares future scores with this baseline score to determine if the 
patient’s condition is improving or worsening (Navazesh, 2003). This questionnaire has 
previously been tested for validity and reproducibility and was found to have high test–
retest correlations, high internal consistency, and sensitivity for changes in dryness 
(Wewers and Lowe, 1990; Eisbruch et al., 2001; Jabbari et al., 2005; Meirovitz et al., 
2006). 
 
1.7 Saliva   
Saliva represents an increasingly useful auxiliary means of diagnosis. Sialometry 
and sialochemistry are used to diagnose systemic illnesses, monitoring general health, 
and as an indicator of risk for diseases creating a close relation between oral and systemic 
health.  
The primary constituents of saliva are water, proteins and electrolytes. These 
components enhance taste, speech, and swallowing and facilitate irrigation, lubrication, 
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and protection of the mucous membranes in the upper digestive tract. Additional 
physiological functions of saliva provide antimicrobial and buffering activities that 
protect the teeth from dental caries (Guggenheimer, 2003). 
The combined secretions from the various salivary glands are termed "whole 
saliva". Whole saliva contains components in addition to salivary secretions including 
gingival crevicular fluid, leukocytes, epithelial cells and microorganisms, as well as, 
possibly, food debris, blood and viruses.  
The amount of saliva in the mouth is not constant and varies within a person over time 
and between individuals (Ship et al., 1991). 
 
1.7.1 Salivary flow rate 
At rest, without exogenous or pharmacological stimulation, there is a small, 
continuous salivary flow denominated basal unstimulated secretion, present in the form 
of a film that covers, moisturizes, and lubricates the oral tissues. Whereas, stimulated 
saliva is produced in the face of some mechanical, gustatory, olfactory, or 
pharmacological stimulus, contributing to around 80%-90% of daily salivary production 
(Edgar, 1992; Axelsson, 2000). The salivary flow is categorized as unstimulated or 
resting (Guggenheimer, 2003) on which, the parotid, submandibular, sublingual and 
minor mucous glands contribute about 25%, 60%, 7–8%, and 7–8% respectively to whole 
saliva and to stimulated on which the parotid glands contribution increases by at least 
10% (Dawes, 2008). 
The salivary flow rate is influenced by a large number of factors, including the 
degree of hydration, body position, exposure to light, previous stimulation, circadian and 
circannual rhythm, gland size and drug use (Edgar et al., 2004; Dawes, 2008). 
Daily salivary output is estimated to be approximately one liter per day, and flow 
rate fluctuated by as much as 50 percent with diurnal rhythms. The unstimulated flow rate 
average 0.3–0.4ml per minute, but the range is wide (Enberg et al., 2001; Dawes, 2008). 
Salivary gland secretion is mainly under autonomic nervous control, 
Parasympathetic stimulation produces copious saliva of low protein concentration, while 
sympathetic stimulation produces little saliva, but of high protein concentration and may 
thus give a sensation of dryness (Carlson, 2000). 
The salivary flow index (SF) is a parameter allowing stimulated and unstimulated 
saliva flow to be classified as normal, low, or very low (hypo salivation) (Tenovue et 
al.,1994; Malamud, 2006). In adults, normal total stimulated SF ranges from (1–3) ml/ 
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min, low ranges from (0.7–1.0) ml /min, while hypo salivation is characterized by a SF 
of less than (0.7) ml /min.  
The normal unstimulated SF ranges from 0.25–0.35 ml/min, low ranges from (0.1–
0.25) ml /min, while hypo salivation is characterized by a SF of less than (0.1) ml/min 
(Axelsson, 2000; Malamud, 2006). However, the values denominated “normal” for 
stimulated and unstimulated SF exhibit a large biological variation (Edgar et al., 2004). 
It has become apparent that many systemic diseases affect salivary gland function 
and salivary composition. Studies of the effects of systemic diseases on salivary variables 
have been valuable in understanding the pathogenesis of the diseases, but their use as 
diagnostic markers have been limited (Edgar et al., 2004). 
 
1.7.2 Salivary α -amylase (SAA) 
It is a major secretory protein found in saliva and aids in the initial digestion of 
starch (Turner and Sugiya, 2002). This enzyme is considered to be a good indicator of 
properly functioning salivary glands (Enberg et al., 2001). The greater part of this enzyme 
(80%) is synthesized in the parotids and the remainder in the submandibular glands. SAA 
is an enzyme that is produced by the acinar cells of the salivary gland. SAA levels follow 
a diurnal pattern, with low levels in the morning and a steady increase in levels throughout 
the day. Its release is regulated by autonomic innervation (Turner and Sugiya, 2002; 
Granger et al., 2007). 
SAA were shown to be flow-rate independent (Rohleder et al., 2006; Wolf et al., 
2008). Chatterton and colleagues (Chatterton et al., 1996, 1997) linked levels of SAA to 
sympathetic activation during physically and psychologically stressful conditions which 
found to be closely associated with changes in norepinephrine concentrations. 
Psychological stress activates both the HPA axis, as well as the SAM axis, which 
manifests as changes in cortisol and SAA output. For example, SAA has been found to 
respond to psychological stress (Bosch et al., 1996; Skosnik et al., 2000; Nater et al., 
2005, 2006; Rohleder et al., 2006). Sympathetic stimulation causes high SAA release 
from the parotid and submandibular acinar cells, whereas parasympathetic stimulation 
causes low SAA release from the sublingual acinar cells (Kelly et al., 2010). 
SAA measurement presents a noninvasive and a highly reliable indicator of SAM 
activity and also used as a biomarker for stress, as shown in many studies which showed 
a marked increase in SAA concentration in response to stressful tasks of procedures, such 
as (Busch et al., 1996; 1998; Chatterton et al., 1996; Skosnik et al.,  2000; Nater et al., 
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2004; Labudda et al., 2007). Changes in SAA is thought to have implications for health. 
Two studies by Granger et al. (2006; 2007a) who suggested a link between SAA and 
disease. Levels of SAA also rise in temperature extremes, and academic examinations 
response to stressful conditions, including exercise (Chatterton, 1996; 1997; Skosnik et 
al., 2000).  
 
1.7.3 Salivary sodium (Na+) and potassium (K+) 
These two ions are very important for different physiological activities. Na+ is the 
major extracellular cation and plays a central role in the maintenance of normal 
distribution of water and osmotic pressure. While K+ is the major intracellular cation 
(Burtis and Ashwood, 1994). 
Na+, K+ with chloride in saliva are the most important ions for maintaining the 
ionic strength of saliva. Studies on the structural element of enamel revealed that Na+ is 
present in the enamel of human teeth, in an increasing concentration gradient from the 
surface to the dentin (Thylstrup and Fejerskov, 1996). The Na+ and K+ concentrations of 
saliva are markedly affected by corticosteroids, especially aldosterone. The Na+ / K+ ratio 
of stimulated whole saliva can be used in diagnosing and monitoring Cushing’s syndrome 
and Addison’s disease. Investigators have also demonstrated the diagnostic value of Na+ 
/ K+ ratio in primary aldosteronism (Wotman et al., 1969). 
 
1.8 Saliva and oral health 
Saliva is one of the most important factors in regulating oral health (Katie et al., 
2008), with flow rate and composition changing throughout development and during 
disease and treatment with different type of medications (Dodds and Johnson, 2005). 
Salivary fluid is an exocrine secretion (Edgar, 1992; Humphrey and Willimson, 2001) 
consisting of approximately 99% water, containing a variety of electrolytes (sodium, 
potassium, calcium, chloride, magnesium, bicarbonate, phosphate) and proteins 
represented by enzymes, immunoglobulins and other antimicrobial factors, mucosal 
glycoproteins, traces of albumin and some polypeptides and oligopeptides of importance 
to oral health. 
Saliva is critical for preserving and maintaining the health of oral tissues and has 
been used as a source of non-invasive investigation of metabolism and the elimination of 
many drugs. However, it receives little attention until its quantity diminishes or its quality 
becomes altered (Katie et al., 2008.) 
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Many researchers have made use of sialometry and sialochemistry to diagnose 
systemic illnesses, monitoring general health, and as an indicator of risk for diseases 
creating a close relation between oral and systemic health. With advances in 
microbiology, immunology and biochemistry, salivary testing in clinical and research 
settings is rapidly proving to be a practical and reliable means of recognizing oral signs 
of systemic illness and exposure to risk factors. The components of saliva act as a “mirror 
of the body 's health”, and the widespread use and growing acceptability of saliva as a 
diagnostic tool is helping individuals, researchers, health care professionals and 
community health programs to better detect and to monitor diseases and to improve the 
general health of the public (Dodds and Johnson, 2005). Many studies showed that 
analysis of saliva sample is a convenient means for assessment of physiological 
conditions, evaluation the serum concentration of medicine and assessment of the severity 
of an illness (Loewit et al., 1996; Tadasi, 2002). 
Saliva is a good indicator of the plasma levels of various substances such as 
hormones and drugs and can therefore be used as a non-invasive method for monitoring 
plasma concentrations of medicines or other substances (Dodds and Johnson, 2005). 
 
1.9 Oral health as an integral and critical part of general health of a psychiatry 
Drug use is associated with significant detrimental, psychological, nutritional, and 
social changes, any of which can affect the general and oral health (Guzeldemir et al., 
2009). Although oral health problems are rarely serious, they may have significant social, 
economic and psychological consequences for patients (Nikias, 1985). 
Saliva is one of the most important factors in regulating oral health, with flow rate 
and composition changing throughout development and during disease and treatment with 
different type of medications like SSRIs.  In view of the shortage of data, health care must 
be judged increasingly on “how well it keeps people healthy” as opposed to “how well it 
cures diseases (Jones et al., 2006). This concept includes oral health care, in which 
maintenance of optimal functioning and well-being is an important goal (Guzeldemir et 
al., 2009). 
Although oral health problems are rarely serious, they may have significant social, 
economic and psychological consequences for patients, including quality of life. It is 
important, however, to distinguish between clinical oral conditions and patients’ 
perceptions of how oral conditions affect functioning and wellbeing patients. The effect 
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of oral conditions on physical health may vary with age, sociodemographic and 
psychological status, and history of significant illnesses (Guzeldemir, 2009). 
More knowledge is needed regarding what works to prevent oral health problems 
and reduce disparities in oral health status experienced by disadvantaged groups. For 
those with mental illness, the illness-and xerostomia-associated pharmacological 
management, puts individuals at greater risk for tooth decay, periodontal diseases, and 
increased requirements for periodontal treatment, dental restorations, and dental 
execrations (Allomania, 2009). 
A volition in individuals with severe mental illness may affect their ability and 
desire to perform preventive oral hygiene procedures (Friedlander and Mohler, 2001). 
Furthermore, increased the use of candy, chewing gum, and carbonated beverages to 
combat xerostomia can further promote tooth decay (Allomania, 2009). 
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2. AIMS OF STUDY 
2.1 General objectives and benefit of the study 
It’s very difficult to describe the situation in IRAQ. Some American which are 
not veteran and visit IRAQ for different purposes said that “War was followed them 
home”.  I thought when read that “What about peoples, war is their only home!”.  
In Iraq since 2003 there is no accurate statistics in all fields especially in health 
sector which has been affected thoroughly by the war and the number of subjects need 
psychological health care has been increased due to the increased stress, violence due to 
the post war conflicts. For these reasons it is necessary to find simple and economical 
method to detect subjects under stress to help in the prevention of deterioration of their 
mental state and progress to a more serious condition. This will be the prime objective of 
this study. 
In view of the shortage of data in IRAQ especially from 2003 and with increased 
susceptible of people to violence and stress and increase susceptibility to psychiatric 
disorders and increase need for drug treatments, this study was to record type of 
psychiatric disorders in sample of different patients as an example that may reflect the 
population, adverse effects of most widely used fluoxetine therapy in our population as a 
goal to reach maintenance of optimal functioning and well-being and as try to achieve 
“keep people healthy” as opposed to “how well it cures diseases and the consequence of 
adverse drug therapy”, as a part, encourage the patients to concern with oral hygiene and 
maintain their oral health as a part of the general health and to report any dental problems 
including adverse effects of drugs to the psychiatrist. 
Drug use is associated with significant detrimental, psychological, nutritional, and 
social changes, any of which can affect the general and oral health. Fluoxetine was the 
first SSRIs approved to treat depression in humans and is one of the most widely 
prescribed antidepressant drugs. Many general and oral adverse effects have been 
reported with fluoxetine therapy. Some of its observed secondary effects are related to an 
alteration in the salivary secretion and composition. Despite that fluoxetine was approved 
by the United States Food and Drug Administration's (FDA) in 1987 for the treatment of 
depression and then for the treatment of a number of psychiatric disorders in adults and 
children, it was used in the psychiatric treatment in IRAQ in the ultimate years and there 
is shortage of data that record efficacy, adverse effects and other about drug due to the 
non-recognition of the psychiatric disorders and mainly depression by the majority of the 
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society. Most of the people in the Middle East does not accept the concept of 
(pharmacological treatment) for the psychiatric disorders especially depression because 
of some religious believes and social aspects. This study was the first pharmacological 
study done in Mosul and Iraq on the psychological patients to see the effects of the drug 
(fluoxetine) on the patients and encourage both the psychiatrist and the patients to detects 
the adverse effects of the drug and try to avoid it as possible. 
Salivary biomarkers are important field of research because of easy, non-invasive 
and rapid collection of samples compared to the blood and urine samples thereby 
increasing the patient compliance. There is increased need of biological stress markers to 
provide an objective, reliable and authentic evidence of stress such as salivary alpha 
amylase. In this we try to evaluate the usefulness of SAA as a biomarker of stress and if 
there is a relation between salivary SAA and sodium and potassium levels. 
 
2.2 Specific objectives of the study 
The specific aims of the study were to investigate: 
1. The usefulness of salivary alpha amylase (SAA) as a good biological marker of 
stress in psychological patients and check the possibility to use it to detect person 
on stress like a psychological patient. 
2. Salivary sodium and potassium, as a markers of stress. And check the possibility 
to use them to detect person on stress in conjunction to SAA to detect patients. 
3. The biochemical changes in saliva including sodium, potassium and salivary 
alpha amylase concentrations, and changes in salivary flow rate associated with 
fluoxetine therapy in psychiatric patients. 
4. The effects of psychiatric diseases on the composition of saliva (salivary alpha 
amylase, sodium and potassium) and salivary flow rate. 
5. Objective and subjective measurement of xerostomia and determination of its 
grades as a result of disease process and fluoxetine therapy. 
6. The adverse effects associated with fluoxetine therapy in our population including 
both general adverse effects on the body at whole and oral adverse effects and 
their relation with dose and duration of therapy. 
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7. Fluoxetine concentrations in serum by high performance liquid chromatography 
(HPLC) and their relation to SAA, Na+ and K+ concentrations and adverse effects 
due to administration of fluoxetine. 
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3. MATERIALS AND METHOD  
3.1 Subject groups 
The study carried out on total number of (80) subjects with an average age 
between (15-59) years. 
This case control study was conducted at the psychiatric departments in Ibn Sina 
and AL Salam Teaching Hospitals in Mosul, and in some private clinic in Mosul during 
2014. 
Permission to examine the subjects and to perform the research were obtained 
from the concerned authorities in the Directorate of General Health in Ninava and 
ministry of health/IRAQ. 
The study was done in two major groups: Study group (patients), and Control 
healthy subjects. 
 
3.1.1 The study group (patients) 
Patients were eligible to participate in the study, if they had been diagnosed by 
their doctors, with a different psychiatric disorders that required treatment with 
fluoxetine. 
The study group was divided into two subgroups according to the duration of 
fluoxetine therapy. 
 
A.  Acute (follow up) group: included patients who had been diagnosed by the 
psychiatric doctors and prescribed to have fluoxetine therapy for the first time. The design 
of the study was an 8-weeks open trial. All patients had been provided with fluoxetine 
capsules starting by (20mg/ day) dose. Then increasing the dose according to their clinical 
response from (20-60 mg/day). This group consisted of a total of (39) patients (23 M, 16 
F), their average age was (35.4±10.7) years. 
Three readings (biochemical and clinical parameters) taking from the 
patients were recorded for this group. The first pre-treatment parameters before 
they started the administration of fluoxetine, considered as a base line to be  
B. Chronic group: Included patients were already on fluoxetine 
therapy for different doses and durations (more than 8 weeks of therapy). 
In this group, (21) patients (7 M, 14 F) accepted to participate in this study, their average 
age was (33.95) years. 
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One reading (biochemical and clinical parameters) taking from the patients were 
recorded for this group.   
   
3.1.2 Control group  
This group included (20) nonsmoker healthy subjects (10 M, 10 F) with an average 
age (35.6) range (17–59years). None of these subjects had a history of any systemic 
diseases, and the females were not pregnant or lactating.  
 
3.2 Subjects groups assessments 
A standard questionnaire form was used containing detailed information about 
each patient (appendix 1). It included the following information: 
I-   Case history: Name, age, sex, address, marital state. 
II- Medical history: The information was taken from their medical records in the 
psychiatric department in the hospital which include the diagnosis, family history, 
treatments (drug types, doses, duration of treatment and side effects) and the past medical 
or surgical history. 
III- Visual analog scale (VAS) for the determination of the grade and severity of 
xerostomia. 
For chronic and control groups screening by medical history, physical 
examination and sample collection (saliva and blood) was done at one visit, while the 
screening for follow-up group was done three times, the 1st assessment at base line 
(pretreatment) visit before the first dose of the fluoxetine, the 2nd assessment was done 
at (4 weeks) during treatment and 3rd data were collected at the end of trial period (8 
weeks). 
 
3.2.1 Evaluation and assessment of xerostomia 
Oral dryness feeling or xerostomia is a subjective sensation, and does not reflect 
a dry mouth in up to one third of cases. It is associated with an unpleasant feeling in the 
mouth and throat (Nederfors, 2000). In this study the evaluation of xerostomia was done 
by two methods which are:  
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 3.2.1.1 Visual analogue scale (subjective assessments) 
As xerostomia is primarily a symptom, patient self-reporting may be meaningful 
in assessing its severity. For this reason, a type of xerostomia questionnaire (XQ) was 
used which called as the visual analogue scale (VAS). The patient self-reported XQ 
instrument is detailed in table (3.1).  
 
Table (3.1):  Xerostomia self-reported questionnaire (XQ) 
*(Navazesh, 2003; Jabbari et al., 2005; Meirovitz et al., 2006). 
 
The questions are equally divided into four items asking about dryness while 
eating or chewing (2, 3, 5, y 7), and four items about dryness while not eating (1, 4, 6 y 
8). Subjects rated each symptom on scale from 0 to 10, with higher scores indicating 
greater dryness or discomfort because of dryness.  Each item score was added, and the 
sum was transformed linearly to produce the final summary score, with higher scores 
denotes worse xerostomia (Wewers and Lowe, 1990; Eisbruch et al., 2001; Jabbari et al., 
2005; Meirovitz et al., 2006). 
 
3.2.1.2 Salivary flow rate method (objective Assessment):  
  This is usually done after the collection of each saliva samples. The salivary flow 
rate (FR) was calculated as the volume in (ml) of the sample collected divided by the time 
in (minute) required for collection. 
 
𝐒𝐚𝐥𝐢𝐯𝐚𝐫𝐲 𝐟𝐥𝐨𝐰 𝐫𝐚𝐭𝐞 (𝐦𝐥/𝐦𝐢𝐧) =
𝐒𝐚𝐥𝐢𝐯𝐚𝐫𝐲 𝐯𝐨𝐥𝐮𝐦𝐞(𝐦𝐥)
𝐓𝐢𝐦𝐞(𝐦𝐢𝐧)
  
No Questions Score 
( 0-10) 
1.  Rate your difficulty in talking due to dryness  
2.  Rate your difficulty in chewing due to dryness  
3.  Rate your difficulty in swallowing solid food due to dryness  
4.  Rate the frequency of your sleeping problems due to dryness  
5.  Rate your mouth or throat dryness when eating food  
6.  Rate your mouth or throat dryness while not eating  
7.  Rate the frequency of sipping liquids to aid swallowing food  
8.  Rate the frequency of sipping liquids for oral comfort when not eating  
 Total scores  
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The grade of xerostomia was divided according to the amount of saliva produced 
in one minute as shown in Table (3.2). 
 
 Table (3.2):  Objective grading system for xerostomia  
Grade Salivary flow rate (ml/min) 
1                             Flow rate ≥ 0.2               ml/min 
2                             Flow rate 0.1–0.2          ml/min 
3                             Flow rate ≤ 0.1             ml/min 
    *Whole-mouth, un stimulated flow rates. ** Navazesh, 2003; Nederfors, 2000 
3.2.2 Safety and tolerability assessment 
Assessment of drug safety was carried out during the treatment period by 
recording the incidence and intensity of adverse effects reported by the psychiatrist in the 
patient record. 
Safety and tolerability were assessed at the baseline (pre-treatment) visit, fourth 
week during treatment and at the end of trial period (8 weeks) or at the time of withdrawal, 
the cause and the time of withdrawal were also recorded. 
  
3.3 Methods 
3.3.1 Collection of saliva samples 
Whole unstimulated saliva samples were collected with the subject setting quietly 
using spitting method for 5 minutes (Dittmer, 1991; Kashmoola, 2000; Khudir, 2008).    
The samples were usually collected about 2 hours after breakfast, usually between 
(9 to 12 pm). The subject was asked to rinse his mouth many times with water to remove 
all food debris from the mouth. Sterile graduated plane tube and a glass funnel was given 
to each subject for spitting the collected saliva.  The volume of the saliva sample collected 
was recorded. Top of the tubes were closed to prevent any contamination of salivary 
samples. The sample were kept cold in ice container and freeze (-20ºC) within 30 min of 
collection because many analytes are usually not stable at room temperature (Navazesh, 
1993; Nater et al., 2005). 
The salivary sample treated on the day when the samples to be assayed by 
complete thawing of the samples, vortex, and then centrifuge for 15 minutes at 
approximately 3.000 RPM (1500 x g). Freezing saliva samples will precipitate the 
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mucins, which can make accurate pipetting difficult (Navazesh, 1993; Nater et al., 2005; 
Khudir, 2008). Assays were performed using only clear saliva, avoiding any sediment 
present in the bottom of the tube. Tubes were re-centrifuged following each freeze-thaw 
cycle as additional precipitates that may be developed upon re freezing. 
 
3.3.2 Blood samples 
Patients’ blood samples were drawn in red-top Vacutainer blood-collection tubes 
(16 x 100 mm, 10-mL, no. 6530; Becton Dickinson, Rutherford, NJ). Specimens were 
allowed to clot and then centrifuged. Serum was removed from cells, aliquoted, and stored 
at -20 until analysis. 
 
3.4 Materials 
3.4.1 Chemical materials and kits  
The general laboratory chemicals used in this study were of analaR-grades. In 
addition, standard kit was used to measure SAA parameter suggested in this study. Tests 
were performed and interpreted following instructions outlined in each kit. Specific 
chemicals used in this study with their suppliers are listed in table (3.3).  
 
 Table (3.3): Kits and chemicals used in this study. 
Materials Supplier 
Sodium chloride Fluka, AG, Switzerland 
Salivary alpha amylase assay ELISA kit  SALIMETRICS –USA, catalog 
no.1-1902 
  *ELISA: Enzyme-Linked Immuno-Sorbent Assay 
 
 
3.4.2 Equipment and instruments 
1. ELISA reader (Beijing Prolong New Technology. CO. LTD- Japan) as shown in 
Figure (3.1). 
2. ELITE ion selective electrode reader (Elektra Medical Corporation-USA) as 
shown in Figure (3.5). 
3. Electronic sensitive balance (AND GX-200-Japan) 
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4. Centrifuge (Remi motors, China). 
5. Water bath (Haak, WB22-Germany). 
6. Micropipette (5 - 200 µl) (Rainin, USA). 
7. Multichannel micropipette (100 µl) (Japan). 
8. Sterile graduated plane tubes for saliva and serum samples collection. 
9.  Disposable micropipette tips. 
10.  Graduated plane tubes for saliva and blood samples collection. 
11.  Eppendorff tubes (1.5 ml) for deep freeze sample storage.  
12.  Glass funnel for the collection of saliva. 
13.  Schematzu HPLC reader. 
 
 
    Figure 3.1: ELISA reader (Beijing Prolong New Technology. CO. LTD- Japan). 
    
     * The photo taken by the researcher during testing of samples in the college of veterinary   
       medicine/University of Mosul. 
  
 
3.5 Biochemical assays of saliva 
3.5.1 Measurement of alpha amylase in saliva 
3.5.1.1 Measurement of alpha amylase concentration in saliva 
Determination of SAA concentrations was estimated using ELISA kinetic SAA 
assay kit from Salimetrics (USA) as in figure (3.2). 
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Principle: The Salimetrics© SAA assay kit is a simple kinetic enzyme 
assay that measures the concentration of AA in a saliva sample by observing its 
action on a color-producing substrate over time (Wallenfels et al., 1978), the 
AA substrate consists of 2-chloro-p-nitrophenol (CNP) attached to a linear 
chain of three glucose molecules (maltotriose). AA cleaves the bond between 
the CNP and the maltotriose, releasing free CNP, which has a yellow color that 
can be measured in a spectrophotometer. 
  
 
    Figure 3.2: Salivary Alpha Amylase kit (SALIMETRICS) 
    *The photo was taken by the researcher during testing of samples. 
 
The amount of yellow color formed is directly proportional to the 
amount of AA activity present in the sample (Figure 3.3).  
The optical density (OD) of the CNP formed is first measured at 1 min after addition 
of the substrate, followed by a second measurement at the 3 min time point. The change 
in OD over the 2-minute measurement period is then used to determine the amount of AA 
activity present in the sample. The optical density data are easily converted by a formula 
into a result expressed in units/mL, where 1 unit equals 1 μmol of product formed per 
minute. 
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         Figure 3.3: Yellow color formed in AA ELISA micro-titration. 
*The intensity of the yellow color directly proportional to the amount of AA activity present in    the   
sample.    **The photo taken by the researcher during testing of samples.  
 
Reagents   
1. AA Substrate: 45 mL of a ready-to-use liquid preparation of 2-chloro-p- nitrophenol 
linked with maltotriose. Sodium azide, at 0.01%, is added as a preservative. 
2. AA Controls: One vial containing 100 μL of a high level of SAA activity and one 
vial containing 100 μL of a low level of SAA activity in a saliva-like matrix. 
Controls come pre-diluted.  
3. AA Diluent: 30 mL of a phosphate buffered solution containing a non-mercury 
preservative. 
Preparation of Saliva Sample: 
Saliva samples had to be diluted with the AA diluent provided. Prepare a 1:10 
dilution of the saliva by pipetting 10 μL of saliva into 90 μL AA diluents. Mix well. 
Further dilute by pipeting 10 μL of the 1:10 dilution into 190 μL AA diluent (1:20). Final 
dilution is 1:200. 
 
Procedures: 
1. All reagent was thoroughly warmed and mixed before use. (A minimum warm-up 
time of 20 minutes, from room temperature, was recommended). 
2. 8 μL of controls (prediluted) and/or diluted saliva samples were added to individual 
wells.  
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3. 320 μL of preheated (37ºC) AA substrate solution was added to each well 
simultaneously using a multichannel pipette. 
4. Reading the result in 37ºC plate reader was conducted by doing the following steps: 
 The timer was started   immediately and mix (500-600 RPM)  
 The OD at exactly 1 minute had been read and the plate was    
         returned to mixing at 37ºC.    
 1st minute OD readings were saved. 
 Then the OD at exactly 3 minute had been read. 
 3rd minute OD readings were saved also. 
5.  Subtraction of the one minute readings from the three-minute reading were done, and 
the results of this subtraction were multiplied by the conversion.  Excel spread sheet 
was used to subtract the ODs and multiply as shown in figure (3.4). Results were 
expressed in U/ml. 
 
          Figure 3.4: Excel spread sheet of SAA calculation 
 
 
Calculations: 
                 = U/ml of SAA activity in saliva  
 
1. Where: ΔAbs./min = Absorbance difference per minute. 
2. TV = Total assay volume (0.328 mL). 
∆Abs. /min× TV × DF    
MMA× SV × LP     
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3. DF = Dilution factor (1:200).  
4. MMA = Millimolar absorptivity of 2-chloro-p-nitrophenol (12.9). 
5. SV = Sample volume (0.008 mL). 
6.  LP = Light path = 0.97(specific to plate received with kit). 
 
                                = Δ Abs. x 328 = U/mL AA concentration 
 
 
 
3.5.1.2 Determination of SAA output in saliva  
Many analytes was found to be affected by the salivary flow rate, such as SAA 
and secretary immunoglobulin A (SIgA) and others, thus its necessary to correct their 
concentrations with the salivary flow and obtained their salivary output of such analytes 
in u/min by multiplying it with the flow rate (Nederfor, 2000; Kaite et al., 2008) and as 
follows:  
       SAA Conc. (U/ml) × SF (ml/min) = SAA output (u/min)  
 
3.5.2 Measurement of Na+ and K+ concentration in saliva 
Na+ and K+ ions concentrations in saliva had been measured by the use of ELITE 
ion selective electrode (ISE) reader (ELEKTRA MEDICAL CORPORATION-USA) in 
the college of dentistry/University of Mosul as shown in (Figure 3.5). 
 
Principle: 
An ion selective electrode (ISE) generates a difference in electrical potential 
between itself and a reference electrode. The output potential is proportional to the 
amount or concentration of the selected ion in solution where the concentration means 
the measurement of the number of ions in a specific volume. 
ELITE ISE is a microprocessor based instrument which was programmed with 
direct concentration modes of operation. Calibration and sample measurement are carried 
out automatically. Thus the traditional drawing of calibration graphs is no longer 
necessary. 
Sample preparation: 
According to ELITE reference manual, it is recommending to operate the general 
implications for serum, plasma, whole blood.  
∆Abs. /2× 0.328 × 
200  
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The range of performance of ELITE for the Na+ and K+ as analyte is out of the 
predicted concentration in our samples(saliva), thus our samples were prepared in a 
manner make its measurements by the ELITE ISE reader possible and reliable. A new 
method was created based on the basic principles of biochemistry that make the 
measurements of the salivary minerals (Na+ and K+ in saliva) is possible. This method 
was standardizing with flame photometry the traditional method of measuring Na+ and 
K+ concentrations for decade and accuracy was improved. 
 
 
 
Figure 3.5: ELITE ion selective electrode (ISE) reader (ELEKTRA MEDICAL 
CORPORATION-USA) 
 
3.5.2.1 Measurement of K+ in saliva sample 
As mentioned above, the range of performance of ELITE for the K+ as analyte is 
(4-10mmole/liter), which is out of the predicted concentration in our samples (predicted 
to be 8-40 mmole/L according to many research like (Ritschel and Thombson,1983; Höld 
et al., 1999), the dilution method which is a known chemical method was used in the 
analytical procedures to make the measurement more reliable. 
Sample Preparation: 0.5 ml of saliva sample diluted by 0.5ml of double deionized water 
and mix well. The sample then read by ELITE ion selective electrode reader and if the 
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concentration is too high, a second dilution (or third dilution, if needed) and good mixing 
after each dilution was ensured. 
 
Calculations of K+ Concentration:  The concentration of K+ was calculated as follows: 
            Concentration K+ (mmole/ L) = reading mmole/ L × Dilution factor 
 
3.5.2.2 Measurement of Na+ in Saliva Sample 
The range of performance of ELITE for the sodium ions as analyte was (60-
200mmole/liter) which is also out of the predicted concentration in our samples (predicted 
to be 5-100 or even 150 mmole/liter) according to many researchs like (Ritschel and 
Thombson, 1983; Höld et al., 1999).  
                                               
Sample Preparation: The addition subtraction method was done by adding a known 
concentration of a standard solution of Na+ to the samples which is then subtracted from 
the ELITE reading was completed and as follows: 
0.5ml of a standard Na+ solution of (80 mmole/L) was added to 0.5 ml of saliva 
sample and well mixing was done and then measured.  
 
Calculations: For sodium ion measurement, the concentration of sodium ion was 
calculated as follow: 
Concentration of Na+ (mmole/L) = (The reading of the ELITE in mmole/L -  40) 
× 2 (Dilution factor) 
 
3.6 Determination of fluoxetine in serum by high performance liquid 
chromatography (HPLC) 
3.6.1 Materials pure samples 
Fluoxetine HCl was obtained from (Sigma Aldrich®), The purity given as % purity ± SD 
was found to be 100.65 ± 0.71.  
 
3.6.2 Chemical and reagents 
 For HPLC work double distilled water was prepared in laboratory. Acetonitrile 
(Merck®), triethylamine (Sigma ChemicalCo., St. Louis, MO), phosphoric acid (Baker, 
Materials and method 
 
55 
Phillipsburg, NJ), Methanol for chromatographic use (Merck®), chloroform, n-hexane 
and isopropanol were of HPLC grade from (Merck,Sharp & Dohme, West Point, PA). 
Ammonium chloride and 4-dimethylaminobenzaldehyde were  
3.6.3 Specimen collection 
Patients’ blood samples were drawn in red-top Vacutainer blood-collection tubes (16 x 
100 mm, 10-mL, no. 6530; Becton Dickinson, Rutherford, NJ). Specimens were allowed 
to clot and then centrifuged. Serum was removed from cells, aliquoted, and stored at -20 
until analysis. 
3.6.4 Instrumentation and chromatography 
The HPLC system was a Shimadzu system comprising of a pump PU-2080 and a UV-
2070 detector. Chromatography was conducted on a 5p.m (particle size), 15 cm x 4.6 mm 
LC-8-DB reversed-phase column. The mobile phase: 10mM triethylamine buffer pH 6.0 
w/phosphoric acid/tetrahydrofuran/Methanol (for chromatographic use) (60: 30: 10) and 
acetonitrile, 65:35 (by volume), was filtered through a 0.45 p.m (pore size) nylon filter 
(Sigma Aldrich®) and degassed before use, operating at ambient temperature. Shimadzu 
AY 120 (max 120 g d = 0.1 mg) analytical balance was used for weighing, PCi 
Ultrasonicator, Laboratory centrifuge Remi R- 8C was used for centrifugation.  
The therapeutical plasma concentrations of fluoxetine are very low (at a level < 
1µg/mL). Therefore, a sensitive and selective method for the assay of fluoxetine is 
needed. 
The chromatographic conditions were as follow: the flow rate was set at 1.5 
ml/min, detection wavelength at 227 nm, injection volume was 10 µL and temperature 
was 22 C, analysis time: 3 minutes. Calibrators and stock standards were prepared and 
stored at -20ºC until use and were stable for at least 6 months under these conditions.  
Standard solution was prepared: Fluoxetine HCl-110µg/mL in mobile phase 
(fluoxetine stock solution: 10 mg of fluoxetine hydrochloride were quantitatively 
transferred into a 10 mL volumetric flask, dissolved in (solvent) and diluted to volume 
with the same solvent. Fluoxetine working solution (10µg/mL) was prepared by dilution 
with mobile phase, from the stock solution). 
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Peaks were detected at 227 nm on a Shiniadzu SPD-6AV ultraviolet spectrophotometric 
detector set to a sensitivity of 0.02 absorbance unit (full scale) with normal response time. 
The amount of drug was quantified by the peak height ratio of analyte to standard. 
 
3.7 Statistical analysis 
Statistical analysis of data was conducted using SPSS 17 for windows software. A p-
value of < 0.05 was considered statistically significant. The following statistical methods 
were used for the analysis of data (Runyon, 1977; Howitt and Cramer, 1999): 
- The results for age, sex, dose, duration, and biochemical parameters in saliva were 
expressed as mean ± standard deviation (SD). 
- The results of clinical indications, general and oral adverse effects were expressed 
as the number of observations. 
- The t test was used to analyze normally distributed data for the demographic and 
biochemical characteristics of the study population. 
- Non-Parametric test assumptions were conducted for comparisons of these groups 
by means of the Mann-Whitney U test and Kruskal-Wallis test. The results of 
nonparametric tests were expressed as the number of observations and means ± 
standard deviation.  Spearman rank correlation coefficient was used to evaluate 
correlations between non parametric variables and Pearson correlations between 
parametric variables.  
In this study, first of all, a comparison was made between the pretreated level (base 
line level) of follow up group with the control group, any deviation from normal condition 
clearly indicated the effect of the disease (depression, OCD, anxiety, panic disorders, and 
postpartum depression) on the patients. 
A second comparison was done between the chronic group and the pretreated (base 
line level) of follow up group and the control group, and this will have explained the 
effect of fluoxetine therapy on the patients (long term therapy). 
A third comparison was done in the follow up group parameters, between pretreated 
base line level and the post 1 and post 2 parameters, after 4weeks and 8weeks of treatment 
with fluoxetine in the acute group. This indicated the pure effects of the fluoxetine therapy 
on the patients.   
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4. RESULTS 
4.1 Patients characteristics 
4.1.1 The demographic distribution of patients age and gender between the groups 
The number of individuals enrolled in this study was  80, their average age was (35.25 ± 
12.16) years, consisted of (40 M) and (40 F), their average age was (35.88± 12.75) and 
(34.63± 11.57) years  respectively as shown in Table (4.1). The eighty individuals were 
distributed in two major groups: 
 1. Patients group (Acute  and Chronic groups)  
 2. Control group 
Table 4.1. Demographic distribution of (age and gender) between groups in the study. 
Groups Gender N Age(years)  mean± SD 
Acute 
M 23 35.2±11.7 
F 16 35.8±9.6 
Total 39 35.4±10.7 
Chronic 
M 7 36.4±12.5 
F 14 32.7±10.0 
Total 21 33.95±10.7 
Control 
M 10 36.0±14.0 
F 10 35.3±14.5 
Total 20 35.6±13.9 
Total no.  
 
M 40 35.8±12.7 
F 40 34.6±11.5 
 
       1. Patients group: 
A total of (60) patients (30 M and 30 F) suffering from different psychiatric  conditions 
were selected to participate in the study. Their age  between (15-56) years. The age 
distribution was shown in figure (4.1) 
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Figure 4.1: Frequency distribution of age in the study group.  
 
A. Acute group:   
           Thirty nine patients were selected to receive fluoxetine capsules  in a dose ranging 
from (20 to 60 mg/day). Their sex distribution and age were shown in table (4.1).  The 
dose adjustment (increased or decreased) in each visit was based on the safety and 
toleralability of the drug on the patients as shown in table (4.2). 
 
Table 4.2 : The number and percentage of patients in the acute and chronic group with 
the doses of fluoxetine administered: 
Dose 
(mg/day) 
Acute 
Chronic 
Pre Post 1 Post2 
20 
39(100%) 32(100%) 13(54.2%) 8(38%) 
40 
0(0%) 0(0%) 7(29.2%) 13(61.9%) 
60 0(0%) 0(0%) 4 (16.6%) 0(0%) 
Total No 39(100%) 32(100%) 24(100%) 21(100%) 
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B. Chronic group: 
    Twenty one  patients were investigated including (7 M) , (average age 36.43±12.5 
years) and (14 F) (average age 32.71±10.0 years) as mentioned in table (4.1). Single 
reading was taken in this group. Table (4.2) showed different dosage regimes used by 
patients of this group. 
 
2. Control group : 
   Twenty  healthy subjects were asked to enrolled in this study ( average age 35.65±13.9 
years)  consisted of (10 M) and (10 F) with their average age (36.0±14.0) and 
(35.30±14.5) years respectively as shown in table (4.1). The same parameters were 
collected from each subject.  
 
4.1.2 Clinical indications of fluoxetine 
    Fluoxetine had been prescribed for different psychatric disorders in this study 
including: 
1. Depression (mild, moderate, severe, and chronic depression). 
2. Anxiety disorders . 
3. Obssesive compulsive disorders (OCD) . 
4. Panic disprders and  
5. Post partum depression. 
    The total number of patients and number of M and F (and their  percentages) which 
had been daignosed in each clinical indications were shown in Table (4.3). 
 
Table 4.3: Clinical indications of fluoxetine in the study. 
Total 
No. (%) 
Postpartum 
depression 
No. (%) 
Panic 
disorder 
No. (%) 
OCD 
No. (%) 
Anxiety 
No. (%) 
Depression 
No. (%) 
Gender 
30(50%) 1 (1.7%) 1 (1.7%) 0 (0%) 2 (3.3%) 26 (43.3%) Female 
30(50%) 0 (0%) 1 (1.7%) 2 (3.3%) 8 (13.3%) 19 (31.6%) Male 
60(100%) 1 (1.7%) 2 (3.4%) 2 (3.3%) 10 (16.6%) 45 (74.9%) Total 
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      Many life factors may contribute in the psychological disorders or the continuation of 
the disease and may make the subject suffer from stress leading to depression and other 
psychological disorders such as age, gender, marital state, person occupation or no, 
studying or no, getting the good marks in exams, getting the appropriate work, family and 
children and many other think that important for human life. As can be seen in Figure 4.2. 
      Fifty percent of the sample population was male and the rest was female. 
      Eight percent of the patients is teenager while the large percent was adults 59% (27% 
under age 30 and 32% under 40) and only 10% in the age of retirement. 
     Forty-one percent of the patients was under the stress of working and have different 
types of work and thirty seven percent was under the stress of disemployment and trying 
to find a work to live.  
    Seventen percent of the patients was students under stress of studying and examination. 
A small percent of only (5%) was retired persons.  
    Forty-seven percent of the patients was married, 30% single and 27% was divorce. 
In the control group, we try to get person on the same conditions of the patients (age, sex, 
marital state, occupation) as possible as to make the comparison rasonable. As try to get 
persons in the same life style of the patients. And this very clear in Figure (4.2). 
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Figure 4.2: Percentage of gender, age, occupation, marital state in the study group (patients) and control group  
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4.2 Salivary alpha amylase concentrations as a possible biological marker of stress 
in psychological patients 
The SAA conc.(U/ml) was measured in the three groups as seen in Table (4.4) 
Table 4.4:  The salivary alpha amylase obtained from all groups 
Groups SAA conc. 
(U/ml) 
SAA output 
(U/min) 
 
Acute 
pre 40.31±26.6 19.87±14.9 
Post1 41.57±29 12.86±16.7 
Post2 54.07±29.9 11.43±17.8 
Chronic 70.99±52.8 20.46±23.2 
Control 12.27±3.5 10.97±6.9 
 
 
4.2.1 Comparison of SAA activity (concentration and out put) between groups 
      Significant difference reported between the three groups at p <0.05. The chronic 
group concentration (70.99±52.8)U/ml was significantly higher  than the pre level 
(40.31± 26.6)U/ml and the control group (12.27±3.5) U/ml as shown in table (4.5). 
 
Table 4.5: Comparison of SAA between Groups 
Salivary 
parameters 
Acute (Pre) 
n=39 
chronic 
n=21 
control 
n=20 
P= value 
SAA Conc. 
(U/ml) 
40.31±26.6 
a 
70.99±52.8        
b 
12.27±3.5            
c 
0.0001 
SAA Output 
(U/min) 
19.87±14.9           
a 
20.46±23.2       
b 
10.97±6.9           
c 
0.000 
*Data represened as mean ±SD. 
**Different letters (a, b, c) horizontaly means significant differences at p<0.05. 
 
The significant differences founded between SAA level in the chronic and healthy state 
may indicate that it can be used as a biomarker of stress in the chronic conditions. The 
comparison between the three groups in their SAA concentrations showed increased level 
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of SAA in disease condition (representing here by the chronic group and the pretreated 
level) than the control healthy subject in the control group. 
    The concentration of SAA in the chronic group show increments (478.5%) than the 
control level and only (76.1%) than the pre treated level. While, the pre level increment 
than the control level was (228.5%).  
     SAA output showed Significant difference  between all groups at p<0.05 as shown in 
Table (4.5). The chronic group showed significantly higher SAA output (20.46± 
23.2)U/min than the control group (10.97±6.9)U/min while it was slightly higher than the 
pre treated level (19.87±14.9) U/min. 
    SAA output as SAA conc. was higher in disease condition (representing by the chronic 
and pre level of acute group ) than in the healthy condition 
    The percentage of increment of SAA out put in the chronic group was (86.5%) than the 
control group  and it was only (2.9%) than the pre level. While the pre level increment 
than the control level was (81.1%). 
 
4.2.2 Comparison of SAA activity (concentration and out put) between pre, post 1 
and post 2 readings in the acute group    
     Although there were no significant differences P>0.05 between the three readings of 
SAA conc. in this group as shown in Table (4.6). But, the concentration of SAA in post2 
(54.07±29.9)U/ml was higher than post1 (41.57±29.0)U/ml and the lowest concentration 
reported in pretreated base line level (40.31±26.6)U/ml in this group as can be seen in 
Table (4.4). 
The percentage of increment of post 2  SAA conc. over the pre treated level was (34.1%) 
and (30%) over the post 1 which increased over the pre level by only (3.1%). 
Table 4.6 : N-Pair test of SAA concentration and output for the acute group: 
Post 1- post 2 
P value 
Pre-post2 
P value 
Pre-post1 
P value 
Salivary 
parameter 
NS NS NS SAA conc. 
(U/ml) 
0.040 0.048 NS SAA  output 
(U/min) 
*NS means no significant differences at p<0.05. 
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     Significant difference had been shown between the reading of patients (after fluoxetine 
therapy) and pre treated level at p value<0.05 in SAA output as shown in table (4.6). The 
SAA output baseline pre treated level (19.87±14.9)U/min was significantly higher than 
post2 level (11.43±17.8)U/min. Also post2 level was significantly lower than post1 level. 
The SAA output appeared to decrease with fluoxetine therapy duration as shown in   the 
decline in SAA output in post2 (after 8weeks of fluoxetine therapy)than in post1(4 weeks 
of therapy). The percentage of post 2 level decline was (42.4%) than pre treated level and 
only (11.1%)  than the post 1level which decline from the pre level by only (25.2%) . 
    From all these comparison, we can notice that SAA was higher in the stress condition 
(in patient’s group; acute and chronic) than in the control healthy subjects which make it 
a good indicator of stress as it clear notice in Figure (4.3). 
           
 
 Figure 4.3: Salivary alpha amylase concentrations in groups. 
 
     Since we have indicated that SAA could be used as a biological marker of stress, let 
us study its efficiency to detect psychological patients under stress, and since there is no 
one universal normal salivary alpha amylase level published and accepted all over the 
world and thus we try made a comparison considering the measurements in the healthy 
subjects (the control group) as the distinct or cutoff value between healthy and disease 
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condition, especially that all living under the same conditions. Considering the levels in 
the healthy control subjects as a normal value at rest in our sample of population. For 
example, concerning the pretreated patients, it was noticed that 30 of 39 patients have 
SAA level higher than the highest SAA level in the healthy control group. This mean that 
76.9% of the psychological patients under stress can be detected by this simple  SAA test. 
Table (4.7) shows the detection percentage of stress in psychological patients in groups 
by using SAA concentration. It can be seen that percentage of detection of stress is high 
and thus we beleive that it’s a good percent of detection which ensure that SAA is a good 
biomarker of stress in psychological patients. 
 
Table (4.7): Percentage of detection of stress in psychological patients in groups by using 
SAA concentration 
Groups No. of patients Percentage of patients under 
stress(higher SAA level than 
control healthy condition) 
 
Acute 
pre 30 76.9% 
Post1 26 81.2% 
Post2 22 91.6% 
Chronic 18 85.7% 
 
 
4.3 Na+ and K+ concentrations in saliva in acute and chronic groups 
4.3.1 Comparison of  sodium and potassium ion concentrations between groups 
    Significant difference was shown in the concentration of Na+ between the pre treated 
level and control group while the chronic group showed no significant differences with 
both the pre level and control group. The concentration of Na+ in the chronic group 
(51.33±8.7)mmol/l was higher than the control group (48.30±7.6)mmol/l but it was less 
than pre treated concentration (54.76±7.3)mmol/l .  
    Generally Na+  concentration was higher in the diseased state than in the healthy state. 
Also significant differnce was shown in K+ concentration  between the three groups at p< 
0.05 as shown in Table (4.8). The pretreated level (28.31± 20.4) mmol/l was significantly 
lower than both the chronic and control levels (40.85±21.0 and 46.43± 24.8) mmol/l 
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respectively. Although no significant differences between control and chronic groups, but 
the concentration of  K+ was higher in the control group than in the chronic group as can 
be seen in table (4.8). 
 
  Table (4.8): Comparison of  sodium and potassium ion concentrations between groups. 
Salivary 
parameters 
Acute(Pre) 
n=39 
Chronic 
n=21 
Control 
n=20 
P value 
Na+ 
(mmol/l) 
54.76±7.3           
a 
51.33±8.7         
a b 
48.30±7.6           
ь 
0.01 
K+ 
(mmol/l) 
28.31± 20.4          
a 
40.85±21.0           
ь 
46.43± 24.8       
ь 0.007 
*Data represened as mean ±SD. 
**Different letters (a,b) horizontaly means significant differences at p<0.05. 
 
4.3.2 Comparison of Na+ concentration(mmol/l) between pre, post 1 and post 2 
readings in acute group 
    The pretreated level of Na+ (54.77±7.3) mmol/l was higher than post1 and post2 
concentration (49.92± 5.4  and 47.88±7.5) mmol/l respectively as shown in table (4.9). 
 
Table 4.9 : Changes of sodium concentration  in the acute group. 
Salivary parameters 
Pre 
n=39 
Post1 
n=37 
Post2 
n=24 
Na+(mmol/l) 
54.77±7.3 49.92± 5.4 47.88±7.5 
K+ 
(mmol/l) 
28.32±20.4 33.83±26.1 38.27±36.5 
   *Data represened as mean ±SD.   **Significant at p value ≤0.05. 
 
    Although no significant difference was reported between these two readings (post1 and 
post2) but, the concentration in post2 (two  month duration of therapy) was lower than 
post1. There was a (12.5%) decline in the concentration of Na+ in post 2 than the 
pretreated level and (4.0%) than post 1 level while post 1 decline than the pretreated level 
by  only (8.8%).  
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     K+ concentration  showed no significant difference in in this group at p< 0.05. But the 
concentration was higher in the post 2 readings (38.27±36.5) than both post1 and the pre 
treated level (33.83±26.1) and (28.32±20.4) respectively. We can notice that the lowest 
level was reported in the pre treated reading. K+ concentration showed increment with 
increased duration of fluoxetine therapy 
    Making the same procedure of comparison made on SAA activity concerning the Na+ 
and K+ concentration measurements and comparing it with the healthy levels, we have 
notice that there is a difference in the concentration between healthy and disease state but 
this differences is not sufficient to make a clear distinction between healthy and disease 
state. The percentage of detection of stress in our sample population using salivary 
sodium and potassium conc. was low. Thus we think that salivary Na+ and K+ 
measurements cannot be used solely as biomarkers and it might need more studies. This 
can be deduced from Figures (4.4), and (4.5). 
    Sodium show increment in the acute disease condition (sodium conc. in the pretreated 
level was higher than the control level) and decreased gradually with treatment while 
show different pattern of response in the chronic state. While potassium conc. show 
decrease in the disease state, the pretreated level was lower than the healthy state and this 
concentration increased with treatment as can be seen in Figure (4.5). Post1 and post 2 
levels was higher than the pretreated level before administration of fluoxetine therapy.  
Using the Na+ concentration measurement, only 4 pretreatment patients are detected by 
the comparison of their Na+ concentration with the healthy subjects, whilst using the K+ 
concentration measurement only 3 pretreatment patients (diagnosed psychological 
patients before using fluoxetine therapy) are detected.  
    And by using the SAA, Na+ and K+ concentration measurements together to detect 
psychological patients, the number of pretreated patients that has been detected increases 
from 30 to 32 from the original 39 patients, 82.05% of the total patients can be detected 
which consider a good high percent of detection and might consider them as a good 
possible biomarkers of stress. 
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Figure 4.4: Salivary sodium concentrations in groups. 
 
 
Figure 4.5: Salivary potassium concentrations in groups. 
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4.4 Assessments of the effects of fluoxetine therapy on the salivary parameters 
obtained from the participants 
    The comparison was done for all the biochemical  and clinical parametres collected 
from patients Table (4.10).  
Table 4.10:  The salivary parametres obtained from all groups 
Groups SAA conc. 
(U/ml) 
SAA output 
(U/min) 
Na+ conc. 
(mmol/l( 
K+ conc. 
(mmol/l) 
FR 
(ml/min) 
VAS 
  
  
  
  
  
  
A
cu
te
 
 
pre 
 
40.31±26.6 
 
19.87±14.9 
 
54.77±7.3 
 
28.32±20.4 
 
0.46±0.2 
 
17.51±12.5 
Post
1 
 
41.57±29 
 
12.86±16.7 
 
49.92±5.4 
 
33.83±26.1 
 
0.36±0.17 
 
24.91±10.0 
Post
2 
5 
4.07±29.9 
 
11.43±17.8 
 
47.88±7.5 
 
38.27±36.5 
 
0.32±0.14 
 
29.05±10.3 
 
Chronic 
 
70.99±52.8 
 
20.46±23.2 
 
51.33±8.7 
 
40.85±21 
 
0.32±0.22 
 
29.05±9.2 
 
Control 
 
12.27±3.5             
 
10.97±6.9 
 
48.3±7.6 
 
46.43±24.8 
 
0.56±0.17 
 
8.65±2.7 
  *Data represened as mean±SD 
 
    First, the comparism was done between the three groups (control, chronic and the 
pretreated level of the acute group). This comparism show the differences in the disease 
condition (treated and untreated) and the healthy condition and explain the effects of 
psychiatric disease on general health of the patient. 
 
4.4.1 Comparison of  salivary parameters between the three groups (chronic and 
pretreated level and control group) 
4.4.1.1 Comparison of salivary biochemical parameters (SAA, Na+, K+ 
concentrations) between  the three groups  
     Comparison of SAA concentration (U/ml) between groups: Significant difference 
reported between the three groups at p<0.05. The chronic group concentration 
(70.99±52.8) was significantly higher  than the pre level (40.31± 26.6) and the control 
group (12.27±3.5) as shown in table (4.5), menthioned above. 
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    Comparison of SAA output (U/min) between groups: SAA output showed Significant 
difference  between all groups at p<0.05 as shown in Table (4.5). The chronic group 
showed significantly higher SAA output (20.46± 23.2) than the control group (10.97±6.9) 
while it was slightly higher than the pre treated level (19.87±14.9). SAA output as SAA 
conc. was higher in disease condition (representing by the chronic and pre level of acute 
group ) than in the healthy condition.  
    The percentage of increment of SAA output with fluoxetine administration  in the 
chronic group was (86.5%) than the control group  and it was only (2.9%) than the pre 
level. While the pre level increment than the control level was (81.1%). 
    Comparison of Na+ concentration (mmol/l) between groups: Significant difference 
was shown in this study between groups in concentration of Na+ in saliva at p value <0.05 
as shown in Table (4.11). 
 
   Table 4.11: Comparison of Na+ concentrations between groups. 
Salivary 
parameters 
Acute(Pre) 
n=39 
Chronic 
n=21 
Control 
n=20 
P value 
Na+ 
(mmol/l) 
54.76±7.3           
a 
51.33±8.7         
a b 
48.30±7.6           
ь 
0.01 
    *Data represened as mean ±SD. 
    **Different letters (a,b) horizontaly means significant differences at p<0.05. 
 
    Significant difference was shown in the concentration of Na+ between the pre treated 
level and control group while the chronic group showed no significant differences with 
both the pre level and control group. The concentration of Na+ in the chronic group 
(51.33±8.7) mmol/l was higher than the control group (48.30±7.6) mmol/l but it was less 
than pre treated concentration (54.76±7.3) mmol/l . It is clear that the concentration of 
Na+ was decline with the treatment as shown from the concentration of the chronic group 
which was less than the pre treated level in disease condition, but it was still higher than 
the control group.  
   The pretreated level was increased than the control level in (12.4%) while, the chronic 
level decline with fluoxetine treatment by (6.6%) than the pretreated level, but still higher 
than the control level by (6.2%). Generally Na+  concentration was higher in the diseased 
state than in the healthy state. 
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   Comparison of K+ concentration (mmol/l) between groups: Significant differnce was 
shown in K+ concentration  between the three groups at p< 0.05 as shown in Table (4.12). 
The pretreated level (28.31± 20.4) mmol/l was significantly lower than both the chronic 
and control levels (40.85±21.0 and 46.43± 24.8) mmol/l respectively. Although no 
significant differences between them, but the concentration of  K+ was higher in the 
control group than in the chronic group. 
 
Table 4.12: Comparison of potassium ion concentrations between groups. 
Salivary 
parameters 
Acute(Pre) 
n=39 
Chronic 
n=21 
Control 
n=20 
P value 
K+ 
(mmol/l) 
28.31± 20.4          
a 
40.85±21.0           
ь 
46.43± 24.8       
ь 
 
0.007 
    *Data represened as mean ±SD.      
    **Different letters(a,b) horizontaly means significant differences at p<0.05. 
 
   Concentration of K+ showed increment with fluoxetine treatment as can be shown from 
the concentration of chronic group which was higher than the pre level in the disease 
condition by (44.1%) but this concentration was still less than the control level by (12%). 
The disease level represented by pre level was (39%)  less than control level. Generally 
K+  concentration was less in the diseased state than in the healthy state.      
                  
4.4.1.2 Comparison of the salivary flow rate and visual analoug scale between the 
three groups  
   Significant difference was shown between the three groups in the salivary flow rate 
(FR) and visual analogue scale (VAS) at p< 0.05 as shown in table (4.13). 
   The FR was higher in the healthy subjects than in patients, while VAS showed higher 
scores in patients rather than control healthy subjects. 
   A good correlation can be noticed betwen salivary flow and VAS which gave a good 
patient express of mouth dryness, make VAS a good scale for mouth dryness. 
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Table 4.13: Comparison of Flow Rate and Visual Analog Scale between the three groups: 
 
Salivary 
parameters 
Acute  (Pre) 
n=39 
Chronic 
n=21 
Control 
n=20 
P value 
FR 
(ml/min) 
0.46± 0.20 
a 
0.32±0.22 
ь 
0.56± 0.17 
a 
0.002 
VAS 
17.51± 12.5 
a 
29.05±9.2 
ь 
8.65± 2.7 
c 
0.000 
     *Data represened as mean ±SD. 
     * *Different letters (a,b,c) horizontaly means significant differences at p<0.05. 
 
   Comparison of salivary flow rate between the three groups: As mentioned in table 
(4.13), the chronic group showed significant difference from both the control and 
pretreated level while no significant difference reported between these two levels at 
p<0.05. The disease condition represented by (the chronic level and the pre treated level) 
had showed lower flow rate (0.32±0.22) and (0.46±0.20) ml/min respectively than the 
healthy condition (control level)(0.56± 0.17)ml/min which was the higher reported level. 
   Comparison of Visual Analog Scale between the three groups: As can be seen in table 
(4.13), significant difference was reported between the three groups at p<0.05. The 
chronic group showed significantly higher score (29.05±9.2) than both the pre treated 
level (17.51± 12.5) and the control group (8.65± 2.7) which reported the lower score 
between the three groups. This may indicate increase patient sensation of mouth dryness 
in the disease condition and also the sensation of dryness increased with time with the 
fluoxetine therapy as clear in the chronic group score. 
 
4.4.2 Changes in the salivary parameters in the acute group (pre, post1, post 2 
readings) 
    The comparism have been done between the three readings of the acute group, before 
starting fluoxetine  therapy, post 4 weeks and 8 weeks of fluoxetine administration which 
might demonstrate the effects of fluoxetine therapy on the patients. 
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4.4.2.1 Changes in the salivary biochemical parameters (SAA, Na+, K+ 
concentrations)  in the acute group  
    Comparison of SAA concentration(U/ml) between pre, post 1 and post 2 readings: 
There were no significant differencesp>0.05 between the three readings of SAA conc. in 
this group as shown in table (4.14). 
 
Table 4.14: N-Pair test of SAA concentration and output for the acute group : 
Post 1- post 2 
P value 
Pre-post2 
P value 
Pre-post1 
P value 
Salivary 
parameter 
NS NS NS SAA conc. 
(U/ml) 
0.040 0.048 NS SAA  output 
(U/min) 
NS means no significant differeces between data.         
 **Significant at p value ≤0.05. 
 
    The concentration of SAA in post 2 (54.07±29.9) was higher than post1 (41.57±29.0) 
and the lowest concentration reported in pretreated base line level (40.31±26.6) in this 
group as can be seen in Table (4.15). 
    The percentage of increment of post 2  SAA conc. over the pre treated level was 
(34.1%) and (30%) over the post 1 conc. which increased over the pre level by only 
(3.1%). 
 
Table 4.15 : Changes of SAA in the acute group. 
Salivary parameters 
Pre 
n=39 
Post1 
n=37 
Post2 
n=24 
SAA Conc. 
(U/ml) 
40.31±26.6 41.57±29.0 54.07±29.9 
SAA Output 
(U/min) 
19.87± 14.9 12.86±16.7 11.43±17.8 
    * Data represened as mean ±SD.     **Significant at p value ≤0.05. 
 
    Comparison of SAA output (U/min) between pre, post 1 and post 2 readings: 
Significant difference had been shown between the reading of patients (after fluoxetine 
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therapy) and pre treated level at p value<0.05 as shown in table (4.14). The baseline pre 
treated level (19.87± 14.9) was significantly higher than post2 level (11.43±17.8). Also 
post2 level was significantly lower than post1 level. 
    The SAA output appeared to decrease with fluoxetine therapy duration as shown in  the 
decline in SAA output in post2 (after 8 weeks of fluoxetine therapy) than in post1(4 weeks 
of therapy). The percentage of post 2 level decline was (42.4%) than pre treated level and 
only (11.1%)  than the post 1level which decline from the pre level by only (25.2%) . 
 
    Comparison of Na+ concentration(mmol/l) between pre, post 1 and post 2 readings:  
The pretreated level (54.77±7.3) mmol/l was higher than post1 and post2 concentration 
(49.92± 5.4  and 47.88±7.5) mmol/l respectively as shown in table (4.16). 
 
Table 4.16 : Changes of sodium concentration  in the Acute Group:   
Salivary parameters 
Pre 
n=39 
Post1 
n=37 
Post2 
n=24 
Na+(mmol/l) 
54.77±7.3 49.92± 5.4 47.88±7.5 
   *Data represened as mean ±SD.   **Significant at p value ≤0.05. 
 
    Although no significant difference was reported between these two readings (post1 and 
post2) but, the concentration in post2 (two  month duration of therapy) was lower than 
post1. There was a (12.5%) decline in the concentration of Na+ in post 2 than the 
pretreated level and (4.0%) than post 1 level while post 1 decline than the pretreated level 
by  only (8.8%). Significant difference was reported  in the concentration of Na+ ion 
between  the pre treated level and post1 and post 2 at p < 0.05 as shown in table (4.17). 
 
Table 4.17: N-Pair test of Na+, K+ concentrations for the Acute Group            
Post 1- post 2 
P value 
Pre-post2 
P value 
Pre-post1 
P value 
Salivary 
parameters 
NS 0.000 0.000 )l(mmol/+Na 
NS NS NS )l(mmol/+K 
*NS means no significant differeces between data.         
 **Significant at p value ≤0.05. 
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   Comparison of potassium  concentration (mmol/l) between pre, post 1and  post 2 
readings: No significant difference in K+ concentration in this group at p< 0.05 as shown 
in table (4.15). But the concentration was higher in the post 2 readings (38.27±36.5) than 
both post1 and the pre treated level (33.83±26.1) and (28.32±20.4) respectively. As 
shown in table (4.18). 
 
  Table 4.18: Changes of K+ concentrations  in the Acute Group. 
Salivary 
parameters 
Pre 
n=39 
Post1 
n=37 
Post2 
n=24 
K+ 
(mmol/l) 
28.32±20.4 33.83±26.1 38.27±36.5 
   *Data represened as mean ±SD.  **Significant at p value ≤0.05. 
  
   We can notice that the lowest level was reported in the pre treated reading. K+ 
concentration showed increment with increased duration of fluoxetine therapy, (35.1%) 
increment in post 2 level than the pretreated level and  (13.3%)  than post 1 K+ 
concentration. While post 1 level increased by (19.4%) than the pre treated level.   
  
4.4.2.2 Changes of the salivary flow rate and visual analoug scale between 
pretreated, post 1 and post 2 readings of the acute  group 
 
    Comparison of salivary flow rate between pretreated, post 1 and  post 2 readings of 
the acute group: The FR decreased with fluoxetine therapy and this decrease can be 
shown in the higher FR reported before starting fluoxetine administration and lower FR 
reported after two months of therapy as can be seen in table (4.19). 
 
 Table 4.19 : Changes of salivary FR and VAS in the acute  group. 
Salivary parameters 
Pre 
n=39 
Post1 
n=37 
Post2 
n=24 
FR (ml/min)      0.46±0.20 0.36±0.17 0.32± 0.14 
VAS 17.51±12.5 24.91±10.0 29.05±10.3 
    *Data represened as mean ±SD.   
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   The FR was significantly high in the pretreated baseline level (0.46±0.20) than both 
post1 and post2 levels which were (0.36±0.17) and (0.32± 0.14) respectively. No 
significant difference reported between post1 and post2 which reported the lowest 
salivary FR in this group as can be seen in table (4.20). 
 
Table 4.20: N-Pair test of SFR and VAS for the acute group : 
Post 1- post 2 
P value 
Pre-post2 
P value 
Pre-post1 
P value 
Salivary parameters 
NS 0.006 0.01 FR(ml/min) 
NS 0.000 0.000 VAS 
  
    Comparison of visual analouge scale  between Pretreated, Post 1 and Post 2 readings 
of the acute group:  In  this group, the VAS showed significant difference at p < 0.05 
between untreated (pre level) and treated levels (post1 and post2) as shown in table (4.20).  
The VAS score which was significantly lower in the pre treated base line level 
(17.51±12.5) than both post treatment readings  (24.91±10.0)  in post1 and (29.05±10.3) 
in post 2 . 
    Although no significant difference was reported between the two acute visits. But, the 
VAS score show increment with the increased duration of treatment as shown in the post 
2 score and as mentioned in table (4.20), which may demonstrate the increase sensation 
of dryness of mouth with the increase in the duration of fluoxetin therapy and is 
propotional to the decreased in salivary flow recorded with fluoxetine therapy. 
 
4.4.3 Determination of xerostomia grades according to salivary  flow rate 
    The salivary flow rate considered as an objective measure of mouth dryness and 
according to FR the patients arranged in to 3 grade of xerostomia were (0.1 ml/min) 
considered the cut off limits for hyposalivation. And as mentioned in Table (3.2), 
salivaryflow rate ≥ 0.2 (ml/min) is a grade 1 xerostomia, betwen (0.1– 0.2 ml/min) is 
grade 2 while the mas severe grade 3 in patients having salivary flow rate ≤ 0.1 (ml/min). 
   The numbers of patients suffer from xerostomia was recorded in each group and 
according to their flow rate, the grade was determined as shown in Figure (4.6). This 
figure clearly demonstrate that xerostomia is one of the oral adverse effects that might be 
caused by fluoxetine and this could be deduce from the higher numbers of observations 
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of diffent xerostomia grades in post1, post2 and also in the chronic patients on fluoxetin 
therapy. 
          
 
  Figure 4.6: Distribution of patients according to xerostomia grades in each group.  
  
   In the pretreated level, (82%) of patients was of grade 1 xerostomia while only (18%) 
of grade 2. In the post 1 level, (62.5%) of the patients sufered grade 1 xerostomia with 
only (37.5%)o f grade 2. 
   In the post 2 level (50%) of the patients were included on grade 1,(29.1%) on grade 2 
and (20.9%) on grade 3.  
   (47.6%) of the patients in the chronic group were included at grade 1 xerostomia while 
(52.4%) at grade 2.  
 
4.4.4 The relation between different salivary parameters (SAA, Na+, K+ 
concentrations, FR and VAS) 
    Generally the relation between salivary parameters in all patients was studied to find 
the relations between them. 
 
4.4.4.1 The relations betweeen different salivary parameters in the chronic group 
    Pearson correlation was done to determine the relation between salivary parameter in 
the chronic group. There were positive correlations as shown in table (4.21).  
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   A significant positive correlation between SAA and K+ concentrarion in the chronic 
group (r=0.751) and (p=0.000). 
   SAA also showed positive correlation with Na+ concentration and with VAS at p>0.01, 
while negative correlation with FR was found at p> 0.01. 
    Na+ concentration show positive correlation with SAA and K+ concentration and with       
VAS score at p>0.01, while a negative correlation with FR . K+ concentration showed 
negative correlation with FR at p>0.01.  
   Salivary FR showed significant negative correlation with VAS (r= -0.868) and 
(p=0.000). 
  
 Table 4.21 : The corelation between salivary parameters in the chronic group : 
Salivary parameters 
SAA 
Conc. 
(U/ml) 
Na+ 
(mmol/l) 
K+ 
(mmol/l) 
FR 
(ml/min) 
VAS 
SAA Conc. 
(U/ml) 
Correlation 1.000     
Sig. .     
Na+ 
(mmol/l) 
Correlation 0.190 1.000    
Sig. 0.409 .    
K+ 
(mmol/l) 
Correlation 0.751** 0.021 1.000   
Sig. 0.000 0.929 .   
FR (ml/min) 
Correlation -0.136 -0.095 -0.145 1.000  
Sig. 0.556 0.684 0.531 .  
VAS 
Correlation 0.109 0.003 0.066 -0.868 1.000 
Sig. 0.637 0.991 0.777 0.000** . 
         ** corelation is significant at the 0.01 level (2- tailed) 
 
4.4.4.2 The relation between salivary parameters in the acute group 
    The relation between salivary parameters in the pretreated level: Pearson correlation 
was done between different parameters and there was a significant negative correlation 
between the FR and VAS (r= -0.562)(p=0.000).  
    Also, a negative but not significant correlation was found between FR and K+ 
concentration. 
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     SAA showed positive correlation with all parameters at p> 0.01,  but K+ concentrations 
showed negative correlation with FR and Na+ concentrations at p>0.01as shown in table 
(4.22). 
 
Table 4.22: The corelation between salivary parameters in the pretreated level  of the      
acute  group 
Salivary parameters 
SAA 
Conc. 
(U/ml) 
Na+ 
(mmol/l) 
K+ 
(mmol/l) 
FR 
(ml/min) 
VAS 
SAA Conc. 
(U/ml) 
Correlation 1.000     
Sig. .     
Na+ 
(mmol/l) 
Correlation 0.229 1.000    
Sig. 0.160 .    
K+ 
(mmol/l) 
Correlation 0.081 -0.112 1.000   
Sig. 0.632 0.498 .   
FR (ml/min) 
Correlation 0.120 0.106 -0.219 1.000  
Sig. 0.465 0.522 0.181 .  
VAS 
Correlation 0.043 0.017 0.287 -0.562** 1.000 
Sig. 0.796 0.917 0.076 0.000 . 
        ** corelation is significant at the 0.01 level (2- tailed). 
 
      The relation between salivary parameters after 4 weeks of fluoxetine therapy in the 
post1 level: Pearson correlation showed significant negative correlation between FR and 
VAS (r= -0.602)(p=0.000). Also, significant negative correlation with K + concentration 
(r= -0.499) (p=0.004) was found at the post 1 level.  
    VAS showed a significant positive correlation with K+ concentration (r= 0.610) 
(p=0.000). SAA showed a negative correlation with VAS and positive correlation with 
the other parameters at p>0.01. Na + concentration showed negative correlation with K+ 
concentration and with VAS at p>0.01. As shown in table (4.23). 
 
     The relation between salivary parameters after 8 weeks of fluoxetine therapy in the 
post2 level: As shown in table (4.24), Pearson correlation between salivary parameters 
and the  FR showed a significant negative correlation with VAS (r= -0.595)(p=0.002) and 
also, negative correlation with SAA, Na+ and K+ concentrarions at p>0.01. A significant 
positive correlation was found between VAS and K+ concentration (r=0.547) (p=0.006). 
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SAA showed only positive correlation with Na+ concentrarion and negative correlation 
with other parameters at p>0.01. A negative correlation was found between Na+ 
concentration and FR,VAS and K+ concentration at p>0.01. 
Table 4.23: The corelation between salivary parameters in the post 1 level  of the acute 
group :  
Salivary parameters 
SAA 
Conc. 
(U/ml) 
Na+ 
(mmol/l) 
K+ 
(mmol/l) 
FR 
(ml/min) 
VAS 
SAA Conc. 
(U/ml) 
Correlation 1.000     
Sig. .     
Na+ 
(mmol/l) 
Correlation 0.110 1.000    
Sig. 0.555 .    
K+ 
(mmol/l) 
Correlation -0.223 -0.161 1.000   
Sig. 0.227 0.387 .   
FR (ml/min) 
Correlation 0.072 0.134 -0.499** 1.000  
Sig. 0.701 0.472 0.004 .  
VAS 
Correlation -0.140 -0.009 0.610** -0.692** 1.000 
Sig. 0.453 0.961 0.000 0.000 . 
         ** corelation is significant at the 0.01 level (2- tailed) 
 
Table 4.24 : The corelation between salivary parameters in the post 2 level   of the acute  
group  
Salivary parameters 
SAA 
Conc. 
(U/ml) 
Na+ 
(mmol/l) 
K+ 
(mmol/l) 
FR 
(ml/min) 
VAS 
SAA Conc. 
(U/ml) 
Correlation 1.000     
Sig. .     
Na+ 
(mmol/l) 
Correlation 0.136 1.000    
Sig. 0.525 .    
K+ 
(mmol/l) 
Correlation -0.250 -0.119 1.000   
Sig. 0.239 0.581 .   
FR (ml/min) 
Correlation -0.021 -0.100 -0.335 1.000  
Sig. 0.924 0.643 0.109 .  
VAS 
Correlation -0.178 -0.194 0.547** -0.595** 1.000 
Sig. 0.406 0.363 0.006 0.002 . 
      ** corelation is significant at the 0.01 level (2- tailed) 
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     Some of studies stated that there is a relation between SAA and salivary flow rate and 
that SAA activity propotional to the rate of salivary flow. Meanwhile other studies stated 
the contrary. Our study shows that there is no general tendency between them and this 
can be seen clearly in Figure 4.8.  
     Figure (4.8) shown that there is a negative correlation between SAA activity and FR 
in the chronic group and in the post 2 readings in the acute group following 8 weeks of 
fluoxetine administration. 
     Low positive correlation  have been found between salivary alpha amylase activity 
and the salivary flow in the control group, also in pretreated and post 1 readings.  
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Correlation between 
salivary alpha amylase concentration (U/ml) 
and 
salivary flow rate (ml/min) 
 
 
  
 
Figure 4.7: Correlation of salivary alpha amylase activity and salivary flow rate in all groups 
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4.5 Assesment of safety and tolerability of fluoxetine 
4.5.1 Patients withdrawal  
    A total of (39) psychatric patients used fluoxetine in a dose ranged from (20 to 60) 
mg/day for a duration up to two months enrolled in this study. 
    Thirty nine patients were selected in follow group to be followed up to two months, 
from those only (23) patients complete the full acute of the study, while (16) patients 
(41.02%) of the total patients were withdrawn from the study due to different causes. As 
shown in figure (4.8). Eight  patients (25.51%) withdrawn from the study due to different 
adverse effects caused by fluoxetine. One patientwithdrawn early within the first two 
weeks of the treatment due to severe TMJ problems (bruxism) which thought to be due 
to increased exrtrapyramidal level of serotonin caused by fluoxetine, thereby inhibiting 
dopamenergic pathways that control movements, also two patients (5.1%) withdrawn 
within the first 4 weeks of treatment due to nausea and to less extent anorexia. One patient 
(2.5%) claimed that he did not show any improvement of its clinical condition on 
fluoxetine therapy and thus he decided to stop taking drug. Four patients (10.2%) were 
not complaint patients (well known by the psychatric doctors that they allways not take 
their medications and they change it, and went from a doctor to another thinking that they 
might get some progress by another types of drugs). 
     During the next 4 weeks of the study 3 patients (7.6%) withdrawn due to moderate to 
severe insomnia (these patients said that they did not sleep for at least 3 to 4 continous 
days and even if they sleep, they  would be late at 4 to 5 a.m). Another 2 men (5.1%) 
withdrawn from the study due to sexual adverse effects. Two patients (5.1%) were not 
complaint patients and they stop to have their medication after the first acute  visit while 
another patient stop to take the drug because the drug had a low efficacy and he did not 
see any improvements. All these shown in table (4.25). 
Table 4.25: Patients withdrawal from the study, causes and percentage. 
Causes of withdrawal % 
No. of  patients withdrawn 
from the study 
Adverse effects of fluoxetine 20.51% 8 
Lack of efficacy 5.12% 2 
Non complaint patients 15.38% 6 
total 41.02% 16 
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        Figure (4.8):  Patients withdrawal from the study. N is the numbers of subjects  
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     Eight patients (20.51% ) of the total withdrawal cases were because of adverse effects 
of therapy, GIT adverse effects (severe nausea and to lower extent anorexia) and TMJ 
problems (bruxism) occur early within the first 4 weeks of the study. While insomnia and 
sexual adverse effects occured within the last 4 weeks of therapy leading to 
discontinuation of the drug. The main adverse effects of fluoxetine that led to 
discontinuation of drug were shown in table (4.26). 
 
Table 4.26: Types of adverse efffects of fluoxetine that cause withdrawal  of patients from 
the study. 
% No. of patients  Adverse effects  
5.12% 2 G.I.T (Nausea and anorexia) 
7.69% 3 insomnia 
5.12% 2 Sexual adverse effects 
2.56% 1 TMJ (bruxism) 
20.51% 8 Total no. and % 
 
4.5.2 General adverse effects of fluoxetine 
     The adverse effects of fluoxetine mainly appeared in CNS system, suicidal thoughts 
of the patients, GIT system and on the whole body. The CNS adverse effects include: 
nervousness, drowsness, headache, anxiety, insomnia, tremer, abnormal dreams. GIT 
adverse effects include:  diarrhea, constipation, nausea, anorexia, vomitting, decreased 
appetite. 
    While, the adverse effects of fluoxetine to the whole body may include: myalgia, 
weight loss, tachycardia, palpitation, breathing difficulties.  
    The incidence of many adverse effects was significantly higher in the chronic group at 
p<0.05 when compared with the control group and with the pretreated base line level of  
acute group. The observations on the CNS system represented the higher percentage than 
the GIT adverse effects, and on the body at whole as shown in figure (4.9). 
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Figure 4.9: The type of adverse effects with their percentage that reported with chronic 
fluoxetine therapy 
 
 
           
Figure 4.10: The type symptoms with their percentage that reported in the disease 
conditions (in the pretreated level before starting fluoxetine adminstration). 
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       Some of these adverse effects reported higher incidence in the disease condition in 
the pretreated base line level before starting fluoxetine administration (might represent a 
symptom of the psychological condition of the patients rather than adverse effects of 
therapy) such as the CNS symptoms as shown in figure (4.10). 
 
      The CNS symptoms (54%) in the pretreated level, while it showed lower incidence in 
the chronic condition only (46%) (as an effects of improvement –due to drug therapy), 
while the patients compliance of GIT adverse effects were higher in the chronic condition 
(23%) than (16%)  only in the pretreated level. 
 
4.5.2.1 Adverse effects of fluoxetine in the chronic group 
     The incidence of: breathing difficulties(p=0.00), abnormal dreams (p=0.005), 
drowsness(p=0.001), insomnia(p=0.00), headache(p=0.001), anxiety(p=0.00), weight 
loss(p=0.00), decreased appetite(p=0.00), tremor(p=0.039), myalgia(p=0.004), 
nausea(p=0.00), anorexia(p=0.023), tachycardia(p=0.016) were significantly higher in 
the chronic group than in the pretreated level at p<0.05 .  These adverse effects were mild 
to moderate in severity. 
       While the incidence of nervousness, constipation, palpitation were higher in the base 
line pretreated level before starting administration of fluoxetine as an effect of disease 
process.  
      The patients complaint of many adverse effects in the chronic group can be seen in 
the figure (4.11). 
 
4.5.2.2 Adverse effects of fluoxetine in the acute group 
     Anxiety (p=0.00), insomnia (p=0.017), nervousness(p=0.00), breathing difficulties 
(p=0.005) all were significantly higher in the pre treated level. While, headache (p=0.032) 
were higher in post 1than in post2. 
    The percentge of GIT adverse effects increased with fluoxetine therapy from (34%) in 
post1 to (40%) in post2. While, CNS adverse effects decline from (40%) in post1to (35%) 
in post2 and as shown in figure (4.12). 
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Figure 4.11: General adverse effects of fluoxetine reported in the chronic group with 
the number of observations.(n=21) 
 
              
  
Figure 4.12: The type and percentage of  adverse effects reported  between post 1 and 
post 2 of the acute group.  
9
11
9
16
14
15
4
12
6 6
7
3
11
13
0
7
12
4 4
N
u
m
b
e
r 
o
f 
o
b
se
rv
at
io
n
s
General adverse effects of fluoxetine
chronic group 
34%
20%
6%
40%40%
21%
4%
35%
GIT WHOLE BODY SUICIDAL 
THOUGHTS
CNS
P
ER
C
EN
TA
G
E 
O
F 
A
D
V
ER
SE
 E
FF
EC
TS
POST 1
POST 2
Results 
 
91 
     Suicidal thoughts reported only in one patient (4.16%) of total (24) patients after 8 
weeks of starting fluoxetine administrations. 
     CNS symptoms were decreased with therapy in acute group, only anxiety show 
number of observations in post 2 higher than post 1. 
   While, the patients complaints of GIT adverse effects were increased with fluoxetine 
therapy, as can be seen with the increased number of observations in the acute visits 
(post1 and 2) in group1 in this study. 
    Fluoxetine therapy lead to decreased patients complaints of breathing difficulties, 
tremer, myalgia, palpitation as improvement of the psychological condition of the pateints 
as effect of therapy, while it was lead to  increase weight loss and myalgia and as shown 
in figure (4.13). 
 
  
 Figure 4.13 : Whole body adverse effects reported in the acute group 
  
4.5.3 Oral adverse effects 
4.5.3.1 Incidence of oral adverse effects in the chronic group 
    Significant higher incidence of oral adverse effects such as TMJ problems(p=0.013), 
glossitis(p=0.011), dysgeusia(p=0.001), xerostomia (p=0.000) were reported in the 
chronic group.   
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    Patients in this group compliant  mainly from xerostomia, dysguasia which   appeared 
in 71.4%, 52.3% of the patient respectively. As shown in figure (4.14) which reported the 
main adverse effects caused by fluoxetine in chronic  psychiatric patients. 
 
  
        Figure 4.14 : Oral adverse effects reported in the chronic group   
 
4.5.3.2 Oral adverse effects in the acute  group  
    Only dysgeusia (P=0.003) and xerostomia (P=0.001) showed  significant difference in 
this group at p value<0.05. Most of orofacial adverse effects reported increment with 
duration of therapy as shown in figure (4.15).  
       Even the increment of orofacial adverse effects reported is not significant; but, all 
were high in the post 2 compared with the post1 and the pretreated base line readings, 
while  oral infections and sore throat were higher in the pre treated level than in the treated 
level (post 1 and 2). 
     (70.8%) of the patients complained of xerostomia or dry mouth in the second month 
followed fluoxetine therapy compared with only (43.7%) in the first month. While only 
(37.5%) of the patients complained from dysgeusia in the first month, this percentage 
rised to (54.1%) in the second month of therapy. 
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           Figure 4.15: Orofacial adverse effects of fluoxetine reported in acute group  
 
     Xerostomia and dysgeusia represented the major complaint of the patients in this study 
as an effects of the disease process and their incedence showed increment with fluoxetine 
therapy in the studied groups (acute and chronic group) as an adverse effects of fluoxetine 
therapy, as can be shown in the following table (4.27). 
 
Table 4.27: The incidence of major oral adverse effects in acute group and chronic group.  
Dysgeusia 
% 
Xerostomia 
% 
Nº of patients 
Groups 
20.6 25.6 39 Pre 
37.5 43.7 32 Post1 
54.1 70.8 24 Post2 
52.3 71.4 21 Chronic 
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 4.6 Effects of gender on the biochemical changes and clinical  adverse effects     
caused by fluoxetine therapy 
 4.6.1 Patients characteristics 
      Thirty one (51.7%) females and 29(48.3%) males were agreed to participate in this 
study and they distributed between groups as shown in table (4.28). 
      Males and females usually taking fluoxetine as a treatment of many clinical conditions 
and the different clinical indications of fluoxetine. In this study, the prevalance of 
depression was higher in females 26(43%) than males 19(31.6%).  
     Controversy, the prevalance of anxiety and OCD in males 8(13.3%) and 2 (3.3%) 
respectively were higher than females 2(3.3%) and 0(0%). 
     Equal prevalance of panic disorders 1(1.7%) was found between males and females in 
this study. 
 
Table 4.28:The distribution of males and females between treatment groups and their 
percentages 
Total  no.(%) 
Chronic group 
no.(%) 
Acute group no.(%) Gender 
29 (48.3%) 7 (11.7%) 22(36.7%) Male 
31 (51.7%) 14(23.3%) 17(28.3%) Female 
60 (100%) 21 (35%) 39(65%) Total no.(%) 
 
 
4.6.2 Assesment of biochemical changes in saliva between males and females 
4.6.2.1 Control group 
    Changes in SAA: Although, no significant difference reported between M and F at p 
value <0.05. But, the concentration of salivary amylase was higher in M (21.61± 
13.33)U/ml than in F (18.92±16.57) U/ml as shown in table (4.29). 
    Changes in the Na+ concentration: Despite that Na+ concentration was higher in M 
(50.8±7.13) than in the F (45.8±7.56)  in the healthy control state. But, no significant 
differences was found between M and F at p value < 0.05 and as shown in table (4.27).  
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   Changes in the K+ concentration: No significant difference was reported between M 
and F in K+ concentration at p value <0.05.    
     Healthy M reported lower K+ ion concentration (37.84±17.24) than healthy F 
(43.86±24.84) as shown in table  (4.29). 
     Changes in FR and and Visual Analogue Scale VAS: Although no significant 
difference between M and F at p value < 0.05.  but, the FR was higher in M (0.63±0.18) 
than the F (0.5±0.14) while, the VAS score was higher in F (9.3±3.24) than M scores 
(8.0±2.16) as shown in table (4.29).  
      Generally, the highest FR reported in the healthy subject (M and F) with the lowest 
VAS score than the patients in followup and chronic group. 
 
Table 4.29: The differences in salivary biochemical parameters between males and 
females in the control group. 
Significance 
P value ≤0.05 
±Std. 
Deviation 
mean Gender Salivary parameters 
NS 
13.33 21.61 m SAAmylase  
(U/ml) 16.57 18.92 f 
NS 
7.13 50.80 m Na+ 
(mmol/l) 7.56 45.80 f 
NS 
17.24 37.84 m K+ 
(mmol/l) 24.84 43.86 f 
NS 
0.18 0.63 m FR 
(ml/min) 0.14 0.5 f 
NS 
2.16 8.0 m 
VAS 
3.24 9.30 f 
 
4.6.2.2 Chronic group 
     Changes in SAA: Also, no  significant difference was shown between M and F in this 
group at p value <0.05. but, the concentration was higher in F (56.36±33.19) than M 
(34.90±33.81), both concentration was higher than concentrations in the control group as 
shown in table (4.30). 
      Changes in the Na+ concentration: Na+ concentration  was significantly high in female 
patients (56.154+-7.33) than in male patients (48.29+-9.19) at p value<0.05. Both 
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concentrations were higher than the concentration in the control group as shown in table 
(4.30). 
      Changes in the K+ concentration: Chronic male patient as healthy males, showed K + 
ion concentration (33.82±18.20) lower than chronic females patient (34.87±21.56). Both 
concentration lower than in the control group. 
      Changes in FR and and visual analogue scale  VAS: FR in male patients was higher 
(0.34±0.21) than female patients (0.32±0.23); while the females show higher VAS score 
(29±8.87) than the males (28.29±9.30). No significant differences reported in this group 
at p value ≤0.05.   
      The salivary flow rate of males and females in this group were lower than the healthy 
males and females in the control group while VAS was controversy with this.  
 
Table 4.30: The differences in salivary parameters between males and females in the 
chronic group. 
 
Significance 
P value ≤0.05 
±Std. 
Deviation 
mean gender Salivary parameters 
NS 
 
33.812042 34.90857 m SAAmylase  
(U/ml) 33.191361 56.36114 f 
0.047 
 
9.196 48.29 m Na+ 
 (mmol/l) 7.336 56.14 f 
NS 
 
18.2002 33.829 m K+  
(mmol/l) 21.5637 34.871 f 
NS 
.214750 .34386 m FR  
(ml/min) .234582 .32143 f 
NS 
9.30 28.29 m 
VAS 
8.87 29 f 
 
4.6.2.3 Acute group 
   Changes in SAA: Also, no significant difference reported at p value < 0.05. But, as in 
the chronic group, the concentration was higher in female (57.64±60.82) than male 
(36.0±24.46), as shown in table (4.31). These concentrations were higher than the chronic 
and the control group  
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     Changes in the Na+ concentration: No significant effect of gender on Na+ 
concentration was found in this group. But generally, the concentration of males 
(50.55±7.36)  was slightly higher than females concentration (50.47±7.56), as shown in 
table (4.31). 
     Changes in the K+ concentration: Although, no significant difference reported in this 
group between male and female. But, females showed higher K+ion concentration 
(46.85±30.88) than males (33.70±20.86). Females in this group reported higher 
concentration than chronic female patients and than the healthy femalesas shown in table 
(4.31). 
    Changes in FR and in visual analogue scale  VAS: No significant difference reported 
in this group between male and female at p value ≤0.05.   FR in male patients was higher 
(0.51±0.24) than female patients (0.39±0.15) while the female show higher VAS score 
(18±8.41) than the male group (17.5±7.9). The salivary flow rate of male and female in 
this group were lower than the healthy male and female in the control group while VAS 
was contraversy with this. 
 
 Table 4.31: The differences in salivary parameters between males and females in the 
acute group. 
 
Significance 
P value ≤0.05 
±Std. 
Deviation 
 
mean 
 
gender 
Salivary 
parameters 
NS 24.46 36.00400 m Amylase 
(U/ml) 
60.82 57.64471 f 
NS 7.360 50.55 m Na
+ 
(mmol/l) 
7.567 50.47 f 
NS 20.86 33.700 m K
+ 
(mmol/l) 
30.88 46.859 f 
NS 
.2479 .50682 
m FR 
(ml/min) 
.1521 .40806 f 
NS 7.938 17.59 m VAS 
8.419 17.41 f 
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4.6.3 Effect of gender on safety and tolerability of fluoxetine 
4.6.3.1 Fluoxetine withdrawal 
      Nine males (56.25% of the total withdrawal cases) were withdrawn from this study 
for different reasons, which was higher than the females withdrawal percentage (only 7 
females withdrawn representing 43.75%). 
     Also, females was more complaint than male which show higher withdrawal rate due 
to not compliance (25%) than only (12.5%) in females as shown in table (4.30). 
The first patient withdrawn in this study was a female, early within the first two  weeks, 
due to severe nausea caused by fluoxetine, followed by a male who stop taking fluoxetine 
due to TMJ problems and orofacial pain, occur  2 weeks after starting the administration 
of fluoxetine as he claimed, this patients refused to expose to physical examination to 
diagnose his condition as shown in table (4.32). 
 
Table 4.32: Causes of withdrawal of  males and females. 
Total no 
(%) 
 
Not 
compliance 
Lack of 
efficacy 
Sexual 
adverse 
effects 
TMJ  
bruxism 
insomnia GIT 
 
Gender 
 
9 (56.25% 
4 
(25%) 
1 
(6.25%) 
2  
(12.5%) 
1 
(6.25%) 
1  
(6.25%) 
0  
(0%) 
M 
7 
(43.75%) 
2  
(12.5%) 
1 
(6.25%) 
0  
(0%) 
0  
(0%) 
2 
(12.5%) 
2 
(12.5%) 
F 
16 
(100%) 
6  
(37.5%) 
2 
(12.5%) 
2  
(12.5%) 
1 
(6.25%) 
3 
(18.75%) 
2 
(12.5%) 
total 
 
 
4.6.3.2 Assesment of general adverse effects of fluoxetine 
Chronic group: Anxiety (p=0.038), headache (p=0.04), nervousness (p=0.042) were 
significantly higher incidence in M than F at p<0.05. 
Acute group: No significant difference was shown in the pre treated level and post 1 
between M and F at p value <0.05, but in post 2 group constipation (p=0.048), palpitation 
(p=0.046), anxiety (p=0.04), nervouusness (p=0.032)  were significant higher  in M than 
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F. Although the change were not significant but nausea, myalgia, insomnia were higher 
in F than M. 
 
4.6.3.3 Assesment of orofacial adverse effects of fluoxetine 
Chronic group: Only taste change (dysgeusia) was significantly higher in M than F at 
(P=0.035).  
Acute group: TMJ problems (bruxism), dysgeusia  were significantly higher in M than F 
at (p=0.04, p=0.035) respectively. 
 
4.7  Effects of different doses of fluoxetine on salivary flow and content and  on the  
incidence of general and oral  adverse effects on psychaitric patients 
     The patients were classified according to the dose  into 3 groups: 
 Group1: including patients taking fluoxetine in adose of 20mg/d. 
 Group2: including patients taking fluoxetine in adose of 40mg/d. 
 Group3: including patients taking fluoxetine in adose of 60mg/d. 
4.7.1 Chronic group 
    The patients enrolled in this group have different doses of fluoxetine and as shown in 
table (4.33). 
 
Table 4.33: The distribution of different doses of fluoxetine in the    chronic group  
No of patients Dose mg/d 
8 20 mg/d 
13 40 mg/d 
0 60 mg/d 
21 Total number 
 
     From all the biochemical parameters in saliva which have been studied in this group, 
only Na+ concentration showed significant differences with dose at p value≤0.05. Itwas 
higher in patients taking fluoxetine 40 mg/d (54.62±7.93) than in patient taking 20 mg/d 
of fluoxetine (46.0±7.5). FR and VAS showed no significant differences with different 
dose of fluoxetine, as shown in table (4.34). 
Results 
 
100 
     From general adverse effects reported with fluoxetine, only nervousness was highly 
significant in patients on dose (40 mg/d) fluoxetine than in (20 mg/d) at p =0.035.  
    Although no significant difference was shown  but,  most of the general adverse effects 
of fluoxetine showed slight increase in appearance with increased dose, such as weight 
loss, change appetite, tremer, myalgia, nausea, anorexia, suicidal thoughts, nervousness,  
anxiety and insomnia.  
     No significant difference reported in orofacial adverse effects. But, their mean rank of 
oral infection, dysgeusia and/or  xerostomia were increased with the dose increased. 
 
Table 4.34: Differences in salivary parameters in different fluoxetine doses in the chronic 
group  
significance Mean±SD NO. Dose 
(mg/d) 
Salivary parameters 
NS 
 
50.31±36.48 8 20 SAA(U/ml) 
83.72±58.53 13 40 
0.024 
 
46.00±7.56 8 20 Na+ (mmol/l) 
54.62±7.932 13 40 
NS 
 
46.60±17.31 8 20 K+(mmol/l) 
46.34±29.28 13 40 
NS 
 
0.319±0.18 8 20 FR(ml/min) 
 0.34±0.25 13 40 
NS 
 
27.75±16.03 8 20 VAS 
 29.85±13.20 13 40 
 
 
4.7.2  Acute group 
     All the (39) patients in this group took fluoxetine capsule (20 mg/d) as a starting dose, 
so all the patients in post1 was in this dose. But in post 2, the patients who completed the 
study have different doses of fluoxetine according to its medical state and response to 
fluoxetine therapy and as shown in table (4.35). 
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Table 4.35 : The distribution of different doses of fluoxetine in the acute  group 
No of patients Dose mg/d 
11 20mg/d 
9 40mg/d 
4 60 mg/d 
24 Total number 
 
     Generally, no significant difference were reported in the salivary parameters in 
relation to dose of fluoxetine as shown in table (4.36). 
     Although no significant difference was shown  but,  most of the general adverse effects 
of fluoxetine showed slight increase in appearance with increased dose, and from the 
general adverse effects caused by fluoxetine, only anxiety reported  higher significant in 
dose (60mg/d)  than other doses at (p value = 0.035).  
    While no significant oral adverse effects reported in this study in relation to dose. 
 
Table 4.36 : Differences in salivary parameters in different  fluoxetine doses in the second 
month of therapy 
 
significance 
 
Mean±SD 
 
NO. 
 
Dose (mg/d) 
 
Salivary parameters 
 
NS 
 
52.43±33.19 11 20  
Amylase 54.96±33.81 9 40 
55.84±24.46 4 60 
 
NS 
 
43.69±7.57 11 20  
Na+ 
 
45.86±9.20 9 40 
49.50±7.36 4 60 
 
NS 
 
41.77±21.56 11 20  
K+ 46.88±18.20 9 40 
49.45±20,87 4 60 
 
NS 
 
0.29±0.25 11 20  
FR 
 
0.31±0.15 9 40 
0.40±0,23 4 60 
 
NS 
21.50±8,42 11 20  
VAS 
 
30.50±7.94 9 40 
32.85±13.87 4 60 
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4.8 Effects of different durations of fluoxetine therapy on salivary flow and contents 
and on the general and oral adverse effects 
     The patients arranged into four groups according to durations of fluoxetine therapy 
and as follows in table (4.37). Although the number of patients was small, but we try to 
find the differences in the salivary parameters that might caused by fluoxetine therapy 
chronicly and which types of adverse effects that might happen in relation to duration of 
fluoxetine therapy.  
 
Table 4.37: The distribution of patients in groups according to duration of fluoxetine 
therapy  
No of patients Duration of therapy (months) Group 
28 Two months Group 1 
13 More than 2 and less than 4 Group 2 
3 More than 4 and less than 6 Group 3 
2 More than 6 month Group 4 
46  Total number 
 
  
4.8.1  Biochemical changes in saliva 
     SAA  and Na+ ion and K+ ion concentrations: One way Anova and Duncan Tests 
showed that all these salivary parameters had  no significant difference between the four 
group at p < 0.05. 
     Salivary Flow Rate: One way Anova showed significant difference between these 
groups at p=0.015. Duncan test showed that there was a significant difference between 
group 3 and the pretreated base line level at p value ≤0.05, which reported the highest FR 
(0.46 ml/min), while group 3 represent the lowest FR (0.16 ml/min).  No significant 
difference of FR of group 1 and 2 with both the pre treated level and group 3. But, group 
1 showed higher FR (0.34 ml/min) than group 2. 
     VAS: One way Anova showed significant difference between these groups at 
p=0.0001  Although group 1 and the pretreated base line level showed no significant 
difference, but group 1 showed higher VAS score (27.23±9.8) than the base line score 
(17.51±11.02). These both groups were significantly lower than group 2 (30.38±5.8) and 
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group 3 which higher VAS score than all groups (40.50±6.2) at p value ≤0.05. While no 
significance between group 2 and 3 at p≤0.05. 
 
4.8.2 Assesment of safety and tolerability of fluoxetine 
     Kruskal–wallis Test and chi-square showed some significant differences in the general 
and orofacial adverse effects in relation to duration of fluoxetine therapy. 
 
4.8.2.1 General adverse effects  
    Weight loss (p=0.041), myalgia (p=0.043), nausea (p=0.000), breathing diffculties 
(p=0.007), nervousness (p=0.000), insomnia (p=0.005), constipation (p=0,048) and 
anxiety (p=0.000); all  showed significant differences with incresed duration of fluoxetine 
therapy at p ≤0.05. 
    Weight loss, myalgia, nausea were increased with duration in group 1 and 2. While 
breathing difficulties, nervousness, insomnia and anxiety appeare to be high in the 
pretreated level (as an effect of disease) and they were decreased in the first group (due 
to the short term effect of fluoxetine therapy), and they increased with increase duration 
of therapy (high in group 2 and 3). 
 
4.8.2.2 Oral adverse effects 
      TMJ problems (p=0.002), black hairy toungue (p=0.027) were significantly high in 
group 1 and 4; dysgeusia (p=0.04) were significantly high in group 3 and 4; and 
xerostomia  (p=0.01) were  significantly high with increased duration of fluoxetine 
therapy at p≤0.05 in group 2 and 3. 
 
            4.9 Determination of serum fluoxetine level by high performance liquid 
chromatography (HPLC) and their relation to other patients’ data 
      All patients being treated with antidepressants for any indication should be monitored 
appropriately and observed closely for clinical worsening, suicidality, and unusual 
changes in behavior, especially during the initial few months of a course of drug therapy, 
or at times of dose changes, either increases or decreases. 
    Serum concentration measurement for fluoxetine was done for the sixty patients 
enrolled in this study as can be seen in figure (4.16). In general, the mean concentration 
was higher in females than males in the chronic and acute group. 
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    A wide range of fluoxetine concentration have been reported in the study in relation to 
dose.  
    No clear relation noticed between drug concentration and a patients’ withdrawal from 
the study, and between concentration and adverse effect occurred in the patient. 
    Direct relation was found between the fluoxetine concentration and oral adverse effects 
(xerostomia); the incidence of xerostomia was increased in the higher drug 
concentrations. 
     Salivary flow rate showed decrement with the higher fluoxetine concentrations. SAA 
activity show indirect relation with the concentration in some readings.  
       The concentration of Na+ ion show a pattren of declinment with the low fluoxetine 
concentration while this pattren was loosed at the higher concentration of fluoxetine 
which make it difficult to conclude the relation between them. This relation was more 
clear with potassium ion concentration which report indirect relations with lower 
fluoxetine concentrations than higher concentration.  
      The pattren of relations that have been reported between fluoxetine conc. and the 
concentrations of Na+ and K+ ions and SAA activity in the lower drug concentration and 
lower doses give an expresion the activity of fluoxetine might be better low dose than in 
high dose. 
                         
Figure 4.16: fluoxetine HPLC chromatogram with the chromatographic condition was as 
follows: retention time 3min, flow rate 1.5ml/min, injection volume 0.1ml, temperature 
22C°. 
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4.9.1 Measurements of fluoxetine levels in the chronic group 
      The relatively slow elimination of fluoxetine (elimination half-life of 1 to 3 days after 
acute administration and 4 to 6 days after chronic administration) and its active 
metabolite, nor-fluoxetine (elimination half-life of 4 to 16 days after acute and chronic 
administration), leads to significant accumulation of these active species in chronic use 
and delayed attainment of steady state, even when a fixed dose is used. 
     As mentioned previously in Table 4.31, eight of the patients in the chronic group was 
taken fluoxetine in a dose 20 mg/day and thirteen patients was taken fluoxetine 40 
mg/day. The mean serum fluoxetine concentration in patients on dose 20 mg/d fluoxetine 
therapy was (87.51±41.83) µg/L and C max. was 142.55 µg/L.The mean serum fluoxetine 
concentration in females on dose 20 mg/d fluoxetine therapy was (99.75±30.37) µg/L 
while (64.42±23.61) µg/L.  
      Although no significant changes was found between the serum fluoxetine 
concentration and salivary parameters (SAA  and Na+ ion and K+ ion concentrations) but, 
there is a slight inverse linear relation ship between SAA level and fluoxetinne 
concentration which can be notice from Figure (4.17).  
     The SAA level was low with the higher fluoxetine concentrations. Also indirect 
relation can be notice between the concentration of drug and Na+ ion and K+ ion 
concentracion.  
    The patients in general having salivary flow rate more than those taking fluoxetine 
40mg/d but no relation founded between drug concentration and FR and between drug 
concentration and VAS.  
     The mean serum fluoxetine concentration in patients on dose 40 mg/d fluoxetine 
therapy was (108.59±54.17) µg/L and C max. was 171.95 µg/L. 
     The mean serum fluoxetine concentration in females on dose 40 mg/d fluoxetine 
therapy was (108.32±34.81) µg/L while for males it was (96.36±45.35) µg/L.  
     No significant changes found between salivary parameters and drug concentration in 
patients with a dose 40 mg/d. SAA level was higher in the patients with low fluoxetine 
level and was decreased in the higher levels and there is indirect relation between them 
can be noticed clearly in figure (4.18). Also we can notice an inverse relation with Na+ 
ion and K+ ion concentrations, which might indicate the effect of the drug on the 
psychological state of the patients. 
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Relation 
 of fluoxetine concentration with 
salivary parameters in patients 
administered 20mg/day 
in 
chronic group 
 
  
Figure 4.17: The relation between fluoxetine concentration and salivary parameters in the 
chronic group at dose 20mg/day. 
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Figure 4.18: The relation between fluoxetine concentration and salivary parameters in the 
chronic group at dose 40 mg/day. 
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4.9.2 Measurements of fluoxetine levels in the acute group 
     Thirty-nine patients with different psychological disorders have been selected to 
participate in this study and have been followed for 8 weeks of fluoxetine therapy. The 
patients have been examined and diagnosed by the physician and selected to participated 
in this part of the study if they were physiologically well and without any acute illness or 
any  liver or renal problems. The study aim  to report the effects of fluoxetine on the 
patients and excluding any other factors that may interfere with the investigation.  
     Two of these patients have been detected a level of fluoxetine in blood in the first 
reading (before starting therapy) in spite of a two weeks of wash out that have been 
applied for all patients before starting fluoxetine administration, thus their reading was 
excluded. All the patient readings were within the therapeutic level of dosing 20-60 mg/d. 
 
4.9.2.1 Measurements of fluoxetine levels in the acute group, Post1 
     In this group all patients starting with a dose 20mg/d, thus all patients’ readings in 
post1(after one month of fluoxetine therapy) was in this dose. And the mean serum 
fluoxetine concentration in patients on dose 20mg/d fluoxetine therapy was 
(97.31±33.58) µg/L and C max. was 168,85 µg/L. 
     The mean serum fluoxetine concentration in females on dose 20mg/d fluoxetine 
therapy  after one month of therapy was (104.90±36.48) µg/L while it was (89.71±27.87) 
µg/L in males. Although no significant changes was found between the serum fluoxetine 
concentration and salivary parameters (SAA  and Na+ ion and K+ ion concentrations) but, 
there is a inverse linear relation ship between SAA level and fluoxetinne concentration 
which can be notice from Figure (4.19).  
     The SAA activity was low with the higher fluoxetine concentrations and was high in 
patients with low therapeutic fluoxetine concentration. Also indirect relation can be notice 
between the concentration of drug and K+ ion concentration. While no relation recorded 
with Na+ ion concentracion, FR, and VAS. 
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Figure 4.19: The relation between fluoxetine concentration and salivary parameters in the 
acute group at dose 20 mg/day, post1 after one month of therapy.  
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4.9.2.2 Measurements of fluoxetine levels in the acute group, Post2 
    In the second month of therapy, the patients were having different dose according to 
their response and their psychological situations. Thus the dose of fluoxetine was 20-60 
mg/d. 
    The mean serum fluoxetine concentration in patients on dose 20 mg/d in the second 
month of fluoxetine therapy in the acute group was (128,88± 31,81) µg/L and C max. was 
174,62 µg/L. 
     Females show a little higher fluoxetine level on dose 20 mg/d fluoxetine therapy  after 
two months of therapy (131.90±40.83) µg/L than male level which was (125.85±22.43) 
µg/L.  
    No significant changes found between salivary parameters and drug concentration in 
patients with a dose 20mg/d. 
    No clear relation found between concentration and SAA activity or with Na+ ion and 
K+ ion concentracion as can be notice in figure (4.20). 
 
    While the mean serum fluoxetine concentration in patients on dose 40 mg/d in the 
second month of fluoxetine therapy in the acute group was (172.85± 33.78) µg/L and C 
max. was 240.2 µg/L.  
    Also females show a little higher fluoxetin level on dose 40 mg/d fluoxetine therapy  
after two months of therapy (175.32±42.09) µg/L than males level which was 
(170.37±27.94) µg/L.  
     No significant changes were founded between salivary parameters and drug 
concentration in patients with a dose 40 mg/d. The salivary flow rate was minimum than 
in patients with 20 mg/d fluoxetine and decreased with the increment of drug 
concentration.  
    The VAS was higher and showed a direct relation with the concentration of fluoxetine 
measured while no clear relation was founded between concentration and SAA activity 
or with K+ ion concentracion. Na+ concentration show increment with the increased drug 
concentration as can be noticed in figure (4.21). 
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Figure 4.20: The relation between fluoxetine concentration and salivary parameters in the 
acute group at dose 20 mg/day, post2 after two months of therapy.  
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Figure 4.21: The relation between fluoxetine concentration and salivary parameters in the 
acute group at dose 40 mg/day, post2 after two months of therapy. 
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     At dose 60 mg/d of fluoxetine, the FR was low with the high fluoxetine concentration.  
A clear indirect relationship was noticed and a negative effect of fluoxetine on the salivary 
flow can be noticed clearly in figure (4.22).  
     The salivary flow rate decreased when fluoxetine dose and serum concentration 
increased. Also indirect relations was reported with VAS. 
    Direct proportional relation have been reported between drug concentration and Na+ 
and while no cler relation reported with K+ concentrations.  
   No clear relation reported in this dose with the SAA activity. However the number of 
patients was small. 
   The mean serum fluoxetine concentration in patients on dose 60 mg/d in the second 
month of fluoxetine therapy in the acute group was (283.69± 40.73) µg/L and C max. was 
(331.16 µg/L). 
    Females show a higher serum fluoxetin level on dose 20 mg/d fluoxetine therapy  after 
two months of therapy (307.39±33.61) µg/L than male level which was (259.95±40.02) 
µg/L.  
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Figure 4.22: The relation between fluoxetine concentration and salivary parameters in 
theAcute Group at dose 60 mg/day, post2 after two months of therapy. 
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5. DISCUSSION 
5.1 Patient characteristics 
The psychiatric disorder such as depression, anxiety, panic disorder and OCD 
represented a widely distributed disorders throughout the world. They may interfere with 
the patient's life and even they may affect their quality of life. Psychiatric disorders may 
affect the individual mainly in two ways:  
 
a) The disease itself may make the patient suffer from many symptoms which 
varied in their severity. Also the disease process may produce many biochemical 
changes in the patients. 
b) The drugs used to treat such conditions, such as fluoxetine may cause adverse 
effects on the patients and may cause biochemical changes on their bodies. 
 
Sixty patients were enrolled in this study; their average age were 34.95 years which 
had agreements with Alonso et al. (2004 which indicate the prevalence of psychiatric 
disorders in population.  The distribution of patients in relation to the type of psychiatric 
disorder (74.9% suffered from depression; 16.6% anxiety disorders; and 3.3% of OCD 
and panic disorders) was in agreements with Commonwealth of Australia (1999) which 
reported that the prevalence of depression was higher than other psychiatric disorders. 
Also according to According to the World Health Organization (WHO, 2010), major 
depression also carries the heaviest burden of disability among mental and behavioral 
disorders and according to (WHO, 2017), depression fact sheets which consider 
depression as  depression is a common mental disorder. Globally, more than 300 million 
people of all ages suffer from depression, and is the leading cause of disability worldwide, 
and is a major contributor to the overall global burden of disease. 
 
5.2 SAA as a biomarker of stress  
Self-reporting subjective questionnaire forms in stress evaluation and as 
psychological diagnostic mean provide highly inconsistent results according to patient’s 
mood and attitude. And this is because many individuals suffering from stress related 
problems have a tendency to either negate or exaggerate the real condition; which may 
lead to a deviation in the study and discompose the results. Thus there is a high need for 
studying the changes caused by stress in the human body to evaluate the usefulness of the 
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bio physiological indicators or biomarkers to provide a reliable objective evaluation and 
assessment of a stress and psychologically related conditions.  
Salivary biomarkers are one of most widely researched area of interest because it 
might to provide a reliable, noninvasive and objective measurements of the response of 
the body. The release of salivary alpha amylase enzyme was reported to react to 
physiological and psychological stressors. Thus it might be a biomarker of stress which 
consider very important and valuable biological markers in psychophysiological research 
and clinical practice. Salivary alpha amylase activity of the patients included in the study 
showed statistically significant higher values when compared to control healthy group at 
(p=0.0001). Also when comparing the SAA activity of the patients with the healthy levels, 
we notice that SAA had the ability to distinguish 76.9% of the patients at pretreated level 
and 85.7% of the patients in the chronic group. These percentages were increased by using 
the SAA, Na+ and K+ concentration measurements together to detect psychological 
patients. For these reasons, they might be considered as a good biomarkers of stress in 
psychological conditions. 
Depending on the physiological response to stress, we can explain the increment 
in the SAA activity. Psychosocial stress is known to induce various responses of 
physiologic systems with particular increasing activities in the hypothalamus-pituitary-
adrenal axis (HPA) reflected by cortisol secretion (Koray, 2003) as well as in the 
sympathetic-adrenal-medullary (SAM) system reflected by salivary alpha amylase level 
(Chatterton et. al, 1996). Many studies had shown that salivary alpha amylase reflected 
the adrenergic activity and thus might be used as a reliable index of the SAM (sympatho-
adrenal medullary system) activity during stress. (Nater et al., 2005; Ehrlert et al., 2006; 
Van Stegeren et al., 2006).  
Chatterton et al., in his study in 1996 suggest that alpha amylase levels reflect the 
reaction of a different stress system than HPA axis.  Ravindranath et al.  (2014) found that 
salivary alpha amylase activity increases in patients with chronic psychosocial stress and 
may be used as a biomarker of chronic stress.  
All these studies support our finding that SAA activity represent a good biomarker 
of stress and can be used in conjunction with the questionnaire form to detect 
psychological patients under stress. Our sample size was less to represent the general 
population, but it gives an idea about the salivary changes that accompanying the stress 
and psychological conditions. 
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Many studies study the salivary activity after acute stressor physical or 
psychological (Granger et al., 2006; Nater et al., 2006   Malamud and Rodriguez-Chavez, 
2011).  Granger et al. in the study done in 2007 said “An increase in SNS activity leads to 
higher levels of alpha-amylase production, which can be measured by examining saliva 
samples “In this way, multiple studies have examined the relationship between 
norepinephrine and SAA because both are associated with SNS activation. However, the 
results have been inconsistent (Chatterton et al., 1996; Nater et al., 2006). Allwood et al., 
(2011) suggesting that SAA is more reactive to laboratory stressors (performance or peer 
rejection tasks) than cortisol. This is the first study that examine the SAA activity in acute 
and chronic state and in psychological patients with different psychological situations and 
compare it with other salivary electrolytes and with the adverse effects reported in the 
patients. 
 
5.3 Evaluation of the changes in the disease condition 
The comparison between the pretreated baseline level before starting fluoxetine 
administration will clearly explain the effect of the disease process on the patients and as 
follows: 
 
5.3.1 The biochemical changes occurred in the saliva of the patients  
There are numerous studies on saliva due to their physiological importance.  
Hundreds of components help to detect systemic diseases and also provide biomarkers of 
health and disease status. It is critical for preserving and maintaining the health of oral 
tissues. However, it receives little attention until its quantity diminishes or its quality 
becomes altered. 
Salivary testing in clinical and research settings is rapidly proving to be a practical 
and reliable means of recognizing oral signs of systemic illness and exposure to risk 
factors. The components of saliva act as a “mirror of the body 's health”, and the 
widespread use and growing acceptability of saliva as a diagnostic helps individual, 
researchers, health care professionals and community health programs to detect, to monitor 
diseases and to improve the general health of the public. Some of these components were 
used in this study to detect the changes occur in the saliva due to drug therapy (fluoxetine) 
(Höld et al., 1999). 
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5.3.1.1 Changes in SAA, Na+ and K+ 
 In this study, significant changes were found between the pretreated level in a 
psychiatric patients and the healthy control individuals at p <0.05 in the concentrations 
and output of SAA which was higher in the patients than in the healthy subjects. This had 
agreement with many studies related to the increment in SAA to body response to stress 
(Rohleder et al., 2004; Takai et al., 2004; Nater et al., 2005; Nater et al, 2006; Ehlert et 
al., 2006). 
 Changes in SAA are thought to have implications for health, for example, two 
studies by Granger et al. (2006; 2007) suggested a link between SAA and disease. 
Release of SAA is regulated by autonomic innervations (Bagan-Sabastian, 2004) 
and usually higher level of SAA is produced by increased sympathetic activity (Granger et 
al., 2006; 2007).  
Stress response is regulated by two primary neuroendocrine systems: 
1. The hypothalamus pituitary–adrenocortical axis, in which cortisol consider a good 
biomarker to its activity, and sympathetic adreno-medullary system, in which SAA 
level considered as a good biomarker to its activity (Friedlander and Mahler, 
2001). 
2. The changes in SAA levels may be related to the activation of the beta-adrenergic 
system and reflects the psychological stress in depression and other psychiatric 
disorders. However, the results of Kivlighan and Granger (2006) and Inagaki et al. 
(2010) indicated a predominant role of the sympathetic nervous system in the 
secretion of SAA together with parasympathetic withdrawal, under psychosocial 
stress, which support the suggestion that psychological factors (like stress) effects 
SAA secretions and concentrations. 
Equally, significant changes were found between the pretreated level and the 
level in the control group in the concentrations of Na+ and K+. The Na+ concentration was 
significantly high, while K+ concentration was significantly low in the disease condition 
than in the healthy subjects.  
Since most of the patients in this study were depressed and even other 
psychiatric disorders might have been associated with depression, the explanation would 
depend on this to explain our finding.  Depression known to be associated with increased 
level of aldosterone which lead to increase Na+ reabsorption and exchange of K+ this will 
explain the increased level of Na+ and decreased level of K+ in the disease condition when 
compare with healthy individuals (Zanatta et al.,2001). 
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5.3.2 Changes in the salivary flow rate and VAS        
Multiple systemic disorders and medications have been reported to cause 
xerostomia and/or salivary gland hypofunction (Navazesh et al., 1996). Also, Rantonen 
(2003) considered that higher proportion of psychiatric illnesses in the hospitalized 
patients could be a factor simultaneously affecting salivary flow rate. The measurement 
of salivary flow is also important, because the concentration of various components of 
saliva like SAA is markedly affected by variation in flow rate (Kaite et al., 2008).  
           This may explain our finding that although there were no significant differences 
between the disease and the healthy conditions, but the FR in the pre level was less than 
the control healthy condition. This has an agreement with Hunter and Wilson (1995), who 
stated that depression itself contributed little to the oral dryness observed in depressed 
patients or reported by them. They also found that the patients subjective rating of oral 
dryness related well to a reduction in stimulated flow, this was in agreement of our finding 
that significant changes were reported in the disease condition which were higher  VAS 
score than the healthy condition and this also agreed with many studies (Wewers and 
Lowe, 1990; Eisbruch et al.,  2001; Jabbari et al., 2005; Meirovitz et al., 2006) which 
found that VAS or self-reported questionnaire was a good and useful indicator of mouth 
dryness. 
 
5.3.3 Evaluation of the clinical symptoms  
          Nervousness, constipation, palpitation, suicidal thoughts, headache, insomnia, 
change of appetite: all have been reported in the pre level group. Similarly, adverse 
consequence has been documented in the American Psychiatric Association which 
published the criteria for diagnosis of depression (Hirschfeld et al., 1997) and in Adams 
(2003).  
Black hairy tongue, xerostomia, dysgeusia had been reported in the pre level. 
Xerostomia have agreement with Hunter and Wilson (1995) who said that depression itself 
contribute little to the oral dryness reported by the depressed patients. 
 
5.4 Evaluation of the changes in the treated groups with fluoxetine (Chronic and 
Acute groups) 
It is suggested that (8 weeks) is sufficiently long enough to register clinically 
significant changes in the parameters studied. 
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5.4.1 The biochemical changes occurred in the saliva of the patients 
Significant differences have been reported in the chronic group and higher level than the 
non-treated (control and pretreated level). Also, significant differences have been reported 
between different readings (pre, post1, post2) of the acute group in the SAA output.  
Although the level showed decliner with the treatment, but it still higher than the 
healthy level.  In this study, it was found that the SAA output was significantly higher in 
the disease condition (represented by acute and the chronic group in this study) compared 
with the healthy control condition. This finding was approved with Chatterton et al. (1996; 
1997) which linked levels of SAA to sympathetic activation during physically and 
psychologically stressful conditions. The level of SAA was observed to increase in an 
investigation that used written examinations as a psychological stressor (Kelly et al., 
2010). 
Significant differences were found between the base line pretreated level 
(19.87u/min) which was higher than the treated post1 (12.86 u/min) and post2 (11.43 
u/min) measures which indicated the efficacy of the treatment to reduce psychological 
stress associated with the psychological conditions. This is in agreement with (Noto et al., 
2005) were they found that salivary alpha amylase is a useful indicator of psychological 
stress.  
The SAA level was higher in men than women. This agreed with Duskova et al. 
(2010) which mentioned that the biochemical marker such as SAA differ between men and 
women. 
As discussed above, the changes in SAA levels may be related to the activation of 
the beta-adrenergic system and reflects the psychological stress in depression and other 
psychiatric disorders. However, the results of Kivlighan and Granger (2006) and Inagaki 
et al. (2010) which indicated a predominant role of the sympathetic nervous system in the 
secretion of SAA together with parasympathetic withdrawal, under psychosocial stress, 
support our suggestion that psychological factors (like stress) affect SAA secretions and 
concentrations. Thus, as a result to body response to fluoxetine therapy and their efficacy 
in treating psychological disorders such as depression and improved in mood due to the 
increased 5-HT level and reduce the effect of stress on the patients. This will have appeared 
in the decliner in SAA secretion which reflect the decrease in sympathetic activity. 
 Fluoxetine act on the neurotransmitter serotonin which is normally released into 
the synapse between the nerve cells and is either destroyed or reabsorbed back into the cell 
that released it.  Fluoxetine block this reuptake causing more serotonin to accumulate in 
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the synapse, increasing the level of serotonin in the synaptic cleft available to bind to the 
postsynaptic receptor thus the concentration of serotonin in the cleft is heightened and 
neuronal activity is enhanced.   
On the other hand, in the chronic group, Na+ and K+ concentrations reported 
significant differences in related to the pre level group. The concentration of Na+ was less 
than in the disease condition at the pre level but it still higher than the healthy level. While 
K+ reported higher level than the pretreated levels, but still less than the healthy condition.  
Also, Na+ reported significant changes between pre and post treated level in the acute 
group while K+ showed no significant changes.  These findings have agreement with the 
study done by Hunter and Wilson (1995) who found that SSRIs treatment did not induce 
significant changes in Na+, and K+ concentrations and in salivary flow rate in patients 
using fluoxetine or paroxetine in a controlled clinical trials for two months duration. 
Published studies do not offer any explanations for drastic changes in K+ and Na+ 
concentrations in the psychiatric patients on fluoxetine therapy. It is interesting that many 
of patients in this study showed salivary changes such as significant changes reported 
between the disease condition (patients chronic and acute groups which was on fluoxetine 
therapy) when compared with the healthy control subjects. Based on published studies on 
non-psychiatric patients, it is attempted to supply some explanations. As the salivary flow 
rate increases, the concentrations of total protein, Na+, calcium, chloride and bicarbonate, 
as well as the pH increases to various levels (Edgar, 1992; Tenovuo et al., 1994) which 
may explain these findings that the Na+ showed a pattern of decliner with the treatment 
and it reached to the healthy control level in the post 2 level. This may be as a result of the 
decreased in salivary flow that have been reported with treatment and this was also in 
agreement with (Höld et al., 1999) which propose direct relation of Na+ secretion with the 
salivary flow rate. This also may explain the pattern of increment with treatment that have 
been reported with fluoxetine therapy which may be due to the indirect relation of K+ 
secretion with FR as mentioned by Höld et al., (1999). Another explanation to the decrease 
and increase in Na+ and K+ concentration respectively could be related to the hormonal 
modulation of the saliva composition (Wotman et al., 1973; Kakmoto et al., 1988), since 
it acts directly increasing the Na+ reabsorbtion and K+ secretion. Also this supported by 
different studies (Zanatta et al., 2001) which found that fluoxetine increases the Na-K 
ATPase activity by 27% than the control which might lead to increase Na+ reabsorption 
and K+ excretion. 
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According to all of the above, and by comparison of the concentrations of Na+ and 
K+ with the concentrations mentioned in other studies we can notice the higher 
concentrations of these parameters in our sample compared with others, which may be a 
serious or even dangerous indicator to the severe and continuous stress that our population 
live in. This exciting finding may give rise to many studies that should be done to 
investigate the effect of such acute and continuous stress on the performance and well-
being in our population and its effect on cognitive functions and memory. Also, on the 
ability to make a decision.  According to this point of view, that needs more studies to 
measure the effect of acute and chronic stress and anxiety in our population, not only to 
study it, but to try to find some solutions or methods to compensate or deal it.     
 
5.4.2 Changes in the salivary flow rate and VAS  
Related to changes in the salivary flow rest and subjective perceptions (VAS) at 
rest, without exogenous or pharmacological stimulation, there is a small, but continuous 
salivary flow, denominated basal unstimulated secretion. This secretion, in the form of a 
film, covers, moisturizes, and lubricates the oral tissues. Both flow rate and VAS results 
showed significant differences between the three groups in this study. Higher salivary 
flow rate was recorded in the healthy subjects and lower in the psychiatric patients treated 
with fluoxetine. On the contrary the VAS scores in the healthy control subject were lower 
compared to those obtained for the group of patients with psychiatric disorders.  
Significant changes had been found between the chronic groups and the pretreated 
level and the healthy control level. According to previous studies (Friedlander and Mahler, 
2001), significant differences have been reported between pre and post treatment level with 
fluoxetine as). The results obtained were also agreement with Bretz et al. (1993) which 
found that FR showed significant changes after fluoxetine therapy and with the study of 
Hunter and Wilson (1995) who found that fluoxetine therapy caused reduction in the 
salivary flow of the parotid gland but this reduction was not significant. 
 VAS was used in this study as a subjective measure of the feeling of the patients 
of xerostomia had a good correlation with the salivary flow and with the reduction in 
salivary flow. Salivary flow reduction interferes with the functions of saliva in the patients 
lead to disturbance in food digestion and mastication and may even interfere with the 
patients sleep leading to sleep disturbances.  
Significant differences were reported between the healthy and disease condition 
and also between pretreated level and post fluoxetine treatment levels. 
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The unstimulated saliva flow rate in this study was somewhat higher than reference 
values for unstimulated flow, 0.25 – 0.35 ml/min (Ericson and Mäkinen, 1986). It is 
obviously practically impossible to obtain true unstimulated saliva, since saliva flow is 
always influenced by some kind of stimulation. Even slight movements of the tongue, 
cheeks, jaws or lips should be avoided (Tenovuo and Lagerlöf, 1994). 
The range of normality is so broad that no reference values exist for the whole 
population (Ship et al., 1991).  In this study, female showed lower salivary flow rate than 
male in all groups; as in many studies which showed that females had lower salivary flow 
rates than males (Percival et al., 1994; Tarkkila et al., 2001). These differences have been 
attributed to two theories; women present smaller salivary glands in comparison with men 
(Dawes et al., 1978), and the female hormonal pattern may contribute to diminish salivary 
secretion. Tarkkila et al. (2001) and Percival et al. (1994) found that healthy, non-
medicated women presented a lower mean for total unstimulated SF and for stimulated SF 
of the parotid when compared with men. Whereas, Shern et al. (1993) reported the total 
unstimulated salivary flow was not influenced by gender. 
As mentioned before, saliva plays important role in regulating oral health and the 
physician does not have an attention unless its quantity in the mouth decline. Oral health 
is an integral and critical part of general health. Depression and other psychiatric disorders 
can affect oral health and lead to xerostomia, alterations in salivary composition and flow 
rate, and adverse effects related to drug therapy include oral infections, increased 
susceptibility of dental caries and bruxism. Although oral health problems rarely are 
serious, they may have significant social, economic and psychological consequences for 
patients, and may affect their quality of life. 
As patient management shifts from treatment to preventive models, the detection, 
recognition and prevention of salivary gland hypo function in depressed and psychiatric 
patient which is more susceptible to it as a result of both the disease condition and the drug 
therapy, will become more important. 
The selective serotonin reuptake inhibitors SSRIs (fluoxetine) exert their 
antidepressant effect by preventing presynaptic neurons from reabsorbing (reuptake) 
serotonin from the synaptic cleft for recycling. Thus, the concentration of serotonin is 
increased (Depattista, 2007). 
The increased incidence of breathing difficulties, abnormal dreams, drowsiness, 
insomnia, headache, weight loss, change in appetite, tremor, myalgia, anorexia, nausea, 
diarrhea, and anxiety that reported in the chronic group and in the post 2 (after 2 months 
Discussion 
 
126 
of treatment of fluoxetine) represented mainly the adverse effects caused by fluoxetine 
therapy. These adverse effects were mild to moderate in severity. Our observations are in 
agreement with Birmaeher et al. (2003) who studied the side effects of fluoxetine versus 
placebo; with many clinical trials introduced by the Elly Lilly company to get FDA 
approval in 1987; placebo-controlled clinical trials (March et al., 2004; Safer, 2006); and 
also with many researches (Goldstein and Goodnick, 1998; FDA patient information sheet, 
2006).  
The direction of causality cannot be determined, since, it is difficult to tease apart 
the effects of fluoxetine from the effects of the disease process itself, such as, suicidal 
ideation which has been frequently reported as a side effect of fluoxetine. However, this is 
also a common symptom of depression itself (American Psychiatric Association, 2000) 
and (Cohen, 2007) which reported increased suicidality in adolescent consuming 
fluoxetine. 
 
5.4.3 Evaluation of the clinical adverse effects reported with fluoxetine therapy 
Related to withdrawal from fluoxetine therapy (41.02%) of the selected 39 patients 
to be followed up for two months duration was withdrawn from our study for different 
causes, Only 23 patients complete the two months acute duration. This is considered a high 
withdrawal percentage in comparison with other studies. As it appears in the results section 
(pag. 85-87). 
It is relatively agreed with Birmaher et al., (2003) who studied the adverse effects 
of fluoxetine versus placebo and it agreed also with the Expert Panel Monograph in 2004 
which reported that insomnia, GIT, and sexual adverse effects might be the main causes of 
fluoxetine withdrawal. Moreover, Kauffman (2009) in a 6-week study reported a total 
dropout rates between 30% and 70% which some 30-40% are attributed to side effects and 
the rest to failure of treatments.  
The assessment of human sexual dysfunction associated with fluoxetine therapy is 
complicated, because sexual dysfunction is common problem in the general population 
and can be associated with depression. However, effects of fluoxetine therapy on sexual 
function, i.e., ability to achieve orgasm, have been observed at doses of 20 mg /day or 
higher also data from experimental animals support the observations in human (NTP-
CERHR, 2004). The finding of the current study agreed with the general finding in many 
studies such as (Grimsley and Jann, 1992; Wong et al., 1995; Stockes and Holtz, 1997; 
CERHR, 2004). Suppression of appetite and weight loss was reviewed by Goldestein and 
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Goodnick (1998). Also, this study might provide support for the 5-HT hypothesis of 
anxiety, which propose that increased level of 5-HT associated with anxiogenic effects, 
while reduction in 5-HT are associated with anxiolytic effects (Drapier et al., 2007).  
In relation to the oral adverse effects of fluoxetine, the official U.S Food and Drug 
Administration medication package inserted the orofacial adverse effects accompanying 
each of the antidepressant medication that may occur (Pysicians Desk Refrence, 2000). 
 In this study, there is an increased incidence of glossitis, taste changes (dysgeusia), 
xerostomia, and TMJ problems and this have an agreement with many studies, such as 
(Ellingrod and Perry, (1994); Davindran et al. 1997a; Trinddade et al., 1998; Bagan-
Sabastian,2004). Oral infection has showed to be significantly decreased with the treatment 
and it was higher in the pretreated level than in post fluoxetine treatment level, this finding 
was in agreement with Núñez (2010) who found that fluoxetine inhibit the C. albicans 
growth. Friedlander and Mahler (2001) reported similar orofacial adverse effects with 
fluoxetine therapy. Bostwick and Jaffee (1999) supposed that the cause of bruxism was 
due to the increase extrapyramidal levels of serotonin, there by inhibiting dopaminergic 
pathways that control movements. 
 
5.5 The Effect of gender in fluoxetine therapy 
Sex differences in response to fluoxetine have been previously documented by 
Laroche and Morgan (2007).  In our study we found that depression is more prevalent in 
female than in male (WHO, 2008), while anxiety and OCD are more prevalent in male. 
Many theories have been developed to explain such differences based on biological, 
environmental and psychological causes. Nolen-Hoeksema, (1990) and Blazer et al., 
(1994) have shown that women are roughly twice as likely as men in experience of 
depression. While only Shalini et al. (2011) reported that men suffer from depression was 
higher than women. Also a relationship between 5-HT and estrogen and mood regulation 
has been previously being described in both human and animal studies (Rubinow and Roca, 
1998). Suggesting that determinants of gender differences in common mental disorders are 
still far from being understood (Klose and Jacobi, 2004). 
 
5.5.1 Evaluation of the biochemical changes in saliva 
The pattern of changes in the salivary parameters were the same in the healthy 
subjects and the patients in our study. Salivary amylase, Na+, and FR were higher in males 
than in females, while potassium and VAS were higher in females than in males. Percival 
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et al. (1994) and Pavinum and Larmus (1981) also, found that healthy non-medicated 
women presented a lower mean for total unstimulated salivary flow rate and for stimulated 
salivary flow of the parotid when compared with men. Dawes (1996) and Jehi-Petri et al. 
(1997) were also in agreement with our findings that salivary flow rate was higher in males 
than in females. In the other hand, our finding that SAA was higher in male than in female 
is consistent with the study of Vigil et al., (2010). 
 
5.5.2 Evaluation of safety and tolerability of fluoxetine between male and female 
Nausea, change appetite, myalgia showed higher incidence in female than in male. 
While male showed higher incidence of anxiety and nervousness so as taste changes 
(dysgeusia). Sex differences in response to fluoxetine have been previously documented 
by Laroche and Morgan (2007).  
 
5.6 Evaluation of the effect of different doses on salivary flow and content and its 
relation with the adverse effect of fluoxetine 
Generally, no significant differences in salivary parameters in our patients reported 
in relation to dose, only Na+ concentrations showed an increase level in dose 40 mg/day. 
 Most of the adverse effects of fluoxetine showed slight increase in incidence 
associated with the increased in dose of fluoxetine. Only anxiety showed significant 
statistically higher incidence with the dose 60 mg/day from the general and oral adverse 
effects that have been reported in our study. Fluoxetine adverse effect like other SSRIs is 
mostly dose dependent, appear in up to 75% of patients on normal doses (Kauffman, 2009).   
 
5.7 Evaluation of the effect of different duration of fluoxetine therapy on salivary flow 
and content and its relation with the adverse effect of fluoxetine 
SAA and Na+ and k+ concentrations showed no significant differences between 
groups in relation to different duration of fluoxetine therapy. 
The FR decreased with the duration and the lowest FR reported was 0.16 ml, while 
the VAS showed high scores with long term treatment which was (40.50). 
Weight loss, myalgia and nausea significantly increased with the treatment duration 
(Ferguson, 2001). Fluoxetine is more likely to produce appetite suppression and weight 
loss is reviewed by Goldstein and Goodnick (1998) leading to off label use of this 
medication in obesity. 
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While breathing difficulties, nervousness, insomnia and anxiety appeared to be 
high in the pretreated base line period as an effect of the disease, as a symptom (Moret and 
Isaac, 2007). They showed decline in the short term therapy of fluoxetine and then show 
an increment with the long duration. This has an agreement with (Buchman  et al., 2002) 
which suggest the existence of a late-onset side-effect profile, which appears similar to 
acute side-effect symptomatology. Super sensitivity of the serotonin-related receptors may 
develop over the long-term and account for the phenomenon. And they report for the first 
time on two cases of late-onset adverse effects occurring 6 and 10 years after chronic-
fluoxetine treatment in which patients experienced symptoms of restlessness, tension, 
agitation, and sleep disturbances.  
Taste changes, oral infection, xerostomia, TMJ problems showed significant 
increased with the increased duration of therapy. This may occur, because this medication 
increase extra pyramidal levels of serotonin, thereby inhibiting dopaminergic pathways 
that control movements (Friedlander, 2001; Guggenhiemer, 2003). 
 
5.8 Implication of oral side effects of SSRIs and their managements 
Depression is regularly treated with antidepressant medication, which has been 
shown to have numerous side effects, some of which affect dental health. Xerostomia puts 
the individuals at greater risk for tooth decay, periodontal diseases, and increased 
requirements for periodontal treatment, dental restorations, and dental execrations (Kenkre 
and Spadigam, 2000; Friedlander and Marder, 2002). 
Major depressive disorders (MDD) may be associated with extensive dental 
disease, and people may seek dental treatment before becoming aware of their psychiatric 
illness. MDD frequently is associated with a disinterest in performing appropriate oral 
hygiene techniques and to follow a cariogenic diet, which diminished salivary flow, 
induces rampant dental caries and advance of periodontal diseases. 
A diminished volition in individuals with severe mental illness may affect their 
ability and desire to perform preventive oral hygiene procedures (Friedlander and 
Liberman, 1991; King, 1998; Friedlander and Mohler, 2001). Furthermore, increased use 
of candy, chewing gum, and carbonated beverages to combat xerostomia can further 
promote tooth decay (kenkre and Spadigam, 2000).  Since many oral and systemic 
conditions manifest themselves as changes in the flow and composition of saliva, the 
psychiatrist is advised to remain up-to-date with the effects of diseases and their treatments 
on saliva and on the oral health of the patients. 
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We must emphasize that dentistry, in concert with medicine, have much to offer to 
patients with psychiatric illness. Our goal is to encourage psychiatrists to recognize 
patients with occult oral health problems, make knowledgeable referrals to dental health 
practitioners for confirmation of the diagnosis and treatment, and to offer these patients 
the full range of dental treatment options.  
 
5.9 The relations of fluoxetine concentrations measured by HPLC with dose, gender, 
SAA, salivary electrolytes and with the adverse effects 
All patients being treated with antidepressants for any indication should be 
monitored appropriately and observed closely for clinical worsening, suicidality, and 
unusual changes in behavior, especially during the initial few months of a course of drug 
therapy, or at times of dose changes, either increases or decreases. For that purpose, HPLC 
is the most commonly used mean for quantitative serum measurements of a medications.  
Measurement of the drug is useful for managing co-medications, dose or 
formulation changes, and in assessing compliance. Therapy with fluoxetine is subject to 
numerous drug interactions, which is compounded by wide inter individual variability in 
fluoxetine pharmacokinetics such as a half-life and metabolism. Fluoxetine is a potent 
inhibitor of the metabolic enzyme CYP2D6, with lesser inhibitory effects on CYP2C19 
and CYP3A and due to the long half-lives of parent and metabolite (1-6 days), it may take 
several weeks for patients to reach steady-state concentrations 
Previous studies have examined the relationship between fluoxetine concentrations 
and therapeutic response.  Some studies like (Altamura et al., 1994; Fichtner et al., 1992; 
Cain, 1992) have suggested a curvilinear relationship between clinical response and 
plasma concentrations, while Norman et al., 1993 in his study “Relationship between 
antidepressant response and plasma concentrations of fluoxetine and norfluoxetine” said 
no relationship between fluoxetine concentrations and response. The same things found 
previously by Kelly et al., 1989. Thus determination of the relationship between fluoxetine 
concentrations and clinical response remains a questionable and also the relations between 
fluoxetine concentration and the adverse effects reported by patients. 
Many factors might influence the measured plasma drug concentrations, including 
variations in absorption, distribution, and metabolic clearance rates that are influenced by 
genetic and other differences among individuals. 
In this study, a wide range of fluoxetine concentration have been reported in 
relation to dose.  All was within the reported therapeutic levels (Montgomery et al., 1986).  
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In general, the mean concentration reported in this study was higher in females than 
males in the chronic and acute groups. Many studies mentioned that sex differences were 
observed in relation to dose and fluoxetine serum concentration. (Blazquez et al., 2014 and 
Ferguson, 2006). While, Pato et al., 1991 in his study said that sex and age of the patient 
did not impact metabolism and drug concentrations of fluoxetine 
Amsterdam et al., 1997 also support our finding and had found in his study that 
males had lower fluoxetine and norfluoxetine serum levels than females.  
In our study, no clear relation noticed between drug concentration and a patients’ 
withdrawal from the study but these patients reported a higher range of fluoxetine 
concentration in the previous reading comparing with other patients. Amsterdam et al. 
(1997) reported that decreased clinical response at higher plasma concentrations and 
Altamura et al. (1994) was find that concentrations of fluoxetine plus norfluoxetine above 
500 mg/L appear to be associated with a poorer clinical response than lower 
concentrations. Montgomery et al. (1986) were the first to provide evidence of a 
therapeutic window for fluoxetine. They studied the plasma concentration response 
relationship in two groups of patients. The first group was treated with fluoxetine 
60mg/daily, and the second group of patients received fluoxetine 80mg once weekly. They 
found that mean plasma concentrations ranged from 200 to 531 mg/L for fluoxetine and 
from 103 to 465 mg/L for norfluoxetine after the first week of therapy. No relationship 
was seen between plasma fluoxetine concentration and response, but a significant negative 
relationship was observed between plasma concentrations of norfluoxetine and response. 
The group of patients that responded at the end of the study had significantly lower plasma 
norfluoxetine concentrations than non-responders. 
Also no significant relation has been found between fluoxetine concentration and 
general adverse effects in this study and this is in agreement with Beasley (1990) which 
discuses “fluoxetine: relationships among dose, response, adverse events, and plasma 
concentrations in the treatment of depression” and found adverse events were not related 
to plasma concentrations. While Altamura et al. (1988) reported the increase in incidence 
of nausea and vomiting with the increase in fluoxetine dose and said that “It is unclear 
whether common adverse effects of fluoxetine, including nausea, are related to plasma 
concentrations of the drug. However, it is clear that with higher dosages of the drug, the 
incidence of nausea and vomiting increases”. Furthermore, according to Fichtner et al. 
study in 1991, which hypothesized that suicidal ideation may occur with high plasma 
fluoxetine concentrations   
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Direct relation was found between plasma concentration of fluoxetine and oral 
adverse effects (xerostomia); the incidence of xerostomia was increased at the higher drug 
concentrations in our study. Also salivary flow rate showed decrement with the higher 
fluoxetine concentrations. This symptom may be the result of both diminished salivary 
secretion and an alteration in saliva composition (Patrícia et al., 2012). The subjective dry 
mouth sensation may occur even in the presence of a normal salivary flow that is, not 
necessarily being associated with a diminution in the amount of saliva (Närhi, 1994). 
The antidepressants inhibit the cholinergic signals in the salivary tissues and thus 
diminish the excretion of fluids by the glands, and interferences in central pathways 
(serotoninergics and dopaminergics) may also alter salivary composition (Atkinson and 
Baum, 2001). 
It is important to emphasize that the dry mouth sensation and alteration in salivary 
composition may occur during periods of stress and/or acute anxiety, frequently present in 
depressive disorders, due to predominant stimulation of the sympathetic system, 
irrespective of the use of anxiolytic and/or antidepressant medication (Guggenheimer and 
Moore, 2003). Therefore, it may be difficult to determine whether these side effects and 
their intensity arise from the medical condition that led to the treatment, or from the 
medication prescribed for it (Smith and Burtner, 1994), it probably is as a result of both 
(Patrícia et al., 2012). 
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6. CONCLUSIONS 
Teniendo en cuenta los resultados de este estudio y la discusión de los mismos, se pueden 
obtener las siguientes conclusiones:  
1. La evaluación de la cantidad y análisis de la composición de la saliva podrían ser 
considerados como un método analítico, no invasivo, eficaz para el estudio de los 
cambios originados en el estado de los pacientes psiquiátricos, así como en la 
evolución de su tratamiento.   
2. Se han encontrado diferencias significativas en la concentración salivar de SAA, 
Na+ y K+ entre los voluntarios sanos, los pacientes con alteraciones psicológicas, 
y los pacientes tratados farmacológicamente.  
3. La medida de la concentración de alfa amilasa salivar (SAA) puede considerarse 
un adecuado biomarcador para evaluar el estrés en pacientes con alteraciones 
psicológicas. También puede ser empleado para evaluar la eficacia de los 
tratamientos farmacológicos sobre el grado de estrés de los pacientes. 
4. A pesar de que el tratamiento con fluoxetina origina una disminución significativa 
en la liberación de SAA y en la concentración de Na+, no es posible establecer una 
clara correlación entre su concentración plasmática, determinada en los pacientes 
tratados, con los biomarcadores de estrés y/o con la incidencia de efectos adversos. 
Por ello, no es posible su consideración como estimador para el seguimiento de la 
evolución del estado psicológico de los pacientes, ni para la toma de decisión en el 
tratamiento. 
5. Se ha observado una correlación directa entre la concentración de Na+ y la medida 
del flujo salivar. 
6. Los resultados obtenidos, tras la aplicación a los pacientes de la escala analógica 
visual (VAS), ha mostrado una buena correlación con los cambios observados en 
el flujo salivar. En pacientes enfermos, valores elevados en VAS están 
relacionados con una disminución en el flujo de saliva. Tras el tratamiento con 
fluoxetina se observan cambios significativos en los valores de VAS y en el flujo 
salivar. Por ello, esta escala puede ser considerada una buena herramienta para la 
estimación subjetiva de la percepción de sequedad de boca. 
7. En este estudio el porcentaje de abandono del tratamiento farmacológico se ha 
estimado en un 41.02%, de los cuales un 20.5% ha sido consecuencia de los los 
efectos adversos provocados por el tratamiento, especialmente trastornos 
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gastrointestinales, insomnio y alteraciones en la función sexual. El abandono del 
estudio como consecuencia de alteraciones en la articulación temporo-mandibular 
(TMJ) ha sido del 2.56%. Xerostomia y disgeusia son efectos adversos asociados 
al tratamiento con fluoxetina. 
8. El género influye significativamente tanto en el abandono del tratamiento como en 
la incidencia o percepción subjetiva de efectos adversos. Se observó un mayor 
número de abandonos en los varones. Sin embargo, en el grupo de mujeres, los 
valores de VAS fueron más elevados, por lo que parecen ser más sensibles a la 
percepción de sequedad de boca.  
9. Se constata la escasa información científica publicada acerca de los efectos 
adversos originados en la cavidad oral por los tratamientos con antidepresivos y en 
especial por inhibidores en el re captación de serotonina (SSRIs), así como sobre 
su posible prevención y tratamiento. Para mejorar ese conocimiento se proponen 
las siguientes recomendaciones: 
 En los registros del seguimiento diario de los pacientes con alteraciones 
psiquiátricas debería incluirse información sobre la higiene de la cavidad oral 
y los efectos de la medicación sobre la misma. 
 Sería conveniente alentar a los pacientes para que se preocupen por la higiene 
y salud de su cavidad bucal como parte importante de su estado saludable o 
como manifestación de algún problema psiquiátrico. Fomentar en ellos la 
importancia de comunicar cualquier incidencia al médico.  
 Crear programas educativos dirigidos a los ciudadanos para controlar el estrés 
y para manejar convenientemente las consecuencias psíquicas y físicas del 
mismo. 
 Implementar programas de formación continuada para profesionales 
sanitarios que les permita la actualización de conocimientos sobre los 
síntomas orales, tanto de los trastornos psiquiátricos como de los efectos 
adversos inducidos por los tratamientos. 
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Consideración final: 
Este estudio, a pesar ser un estudio preliminar, limitado por el tamaño de muestra, 
puede contribuir, por su diseño y resultados obtenidos, al hallazgo de nuevos 
biomarcadores que permitan establecer los niveles de estrés de la población mediante 
análisis sencillos y de alta capacidad, como es la evaluación de la composición de la 
saliva. No obstante, se hace necesaria la realización de una investigación más amplia 
mediante la cual, no solo afiancen los resultados obtenidos, sino que permita el estudio 
de los efectos adversos originados sobre la cavidad oral por los tratamientos 
farmacológicos de enfermedades como la depresión y la ansiedad, facilitando con ello su 
prevención y tratamiento. 
Se apunta la posibilidad de evaluar en el futuro la incidencia de la violencia y en 
concreto los efectos de la guerra en el mismo grupo de población, individuos residentes 
en la ciudad de Mosul (Irak), con objeto de establecer posibles diferencias relacionadas 
con estados de estrés crónico de grado máximo. 
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